1'-alkyl-modified ribose derivative and method of use

Abstract

The present invention provides linker compounds, scaffolds, and conjugates, and their use, in the delivery of nucleic acids and / or in the treatment or prevention of diseases. [Solution] This disclosure relates to a linker compound of formula (I) or (II): The disclosure provides pharmaceutically acceptable salts thereof, as well as associated scaffolds and conjugates. More specifically, it provides linker compounds of formulas (IA) and (II-A). The disclosure further relates to the use of linker compounds, scaffolds and conjugates in the delivery of nucleic acids and / or in the treatment or prevention of disease.

Description

[Technical Field]

[0001] Related applications This application claims priority and benefit to U.S. Provisional Patent Application No. 63 / 229,628, filed on August 05, 2021, the entirety of which is incorporated herein by reference. [Background technology]

[0002] Efficient in vivo delivery of genetic material such as RNA to cells requires specific targeting and protection from the extracellular environment, particularly serum proteins. One way to achieve specific targeting is to conjugate a targeting moiety to a nucleic acid (e.g., oligonucleotide). The targeting moiety helps direct the nucleic acid to the desired site. The targeting moiety can improve delivery by receptor-mediated endocytosis. This process is initiated via activation of a cell surface or membrane receptor following the binding of a specific ligand to the receptor. Many receptor-mediated endocytosis systems are known, including those that recognize sugars such as galactose, mannose, and mannose-6-phosphate, as well as peptides and proteins such as transferrin, asialoglycoprotein, vitamin B12, insulin, and epidermal growth factor (EGF). The asialoglycoprotein receptor (ASGP-R) is a high-capacity receptor and is very abundant on hepatocytes. ASGP-R shows higher affinity for N-acetyl-D-galactosylamine (GalNAc) than for D-Gal. Recently, certain carbohydrate conjugates have been shown to be valuable alternatives to liposomes for nucleic acid delivery. Furthermore, after successful delivery to cells, the stability of nucleic acids in the cellular environment is crucial for achieving desired therapeutic effects.

[0003] Therefore, there is a continued need for novel linkers and conjugates for nucleic acid delivery. This disclosure satisfies this need. [Overview of the Initiative]

[0004] In some embodiments, the disclosure provides a compound of formula (I) or (II), [Chemical formula] or a pharmaceutically acceptable salt thereof, wherein W is H, C1-C6 alkyl optionally substituted with one or more halogens, or an amino substituent, X is H, halogen, or -OR X wherein R X is H, C1-C6 alkyl, or -(C1-C6 alkyl)-(C6-C 10 aryl), and C1-C6 alkyl or -(C1-C6 alkyl)-(C6-C 10 aryl) is optionally substituted with one or more R Xa groups, each R Xa is independently halogen, C1-C6 alkyl, or -O-(C1-C6 alkyl), and C1-C6 alkyl or -O-(C1-C6 alkyl) is optionally substituted with one or more halogens, Y is H, C1-C6 alkyl optionally substituted with one or more halogens, -P(R Y )2, -P(OR Y )(N(R Y )2), -P(=O)(OR Y )R Y , -P(=S)(OR Y )R Y , -P(=O)(SR Y )R Y , -P(=S)(SR Y )R Y , -P(=O)(OR Y )2, -P(=S)(OR Y )2, -P(=O)(SR Y )2, -P(=S)(SR Y )2, or a hydroxy protecting group, each R Y is independently H, or C1-C6 alkyl optionally substituted with one or more halogens or cyano, Z is a C1-C6 alkyl group optionally substituted with H or one or more halogens, -P(R Z )2, -P(OR Z )(N(R Z )2), -P(=O)(OR Z )R Z , -P(=S)(OR Z )R Z -P(=O)(SR Z )R Z -P(=S)(SR Z )R Z , -P(=O)(OR Z )2, -P(=S)(OR Z )2, -P(=O)(SR Z )2, -P(=S)(SR Z )2, or a hydroxy protecting group, Each R Z These are independently C1-C6 alkyl groups optionally substituted with H, or one or more halogens or cyano compounds. Alternatively, Y and Z in equation (I) together become -Si(R L )2-O-Si(R L )2- forms, and each R L These are independently H or C1-C6 alkyl groups. Each R a These are independently H, a halogen, or a C1-C6 alkyl group optionally substituted with one or more halogens, or two R atoms on two adjacent carbon atoms. a It combines with two adjacent carbon atoms to form a double bond, Each R b These are independently H, halogens, or C1-C6 alkyl groups optionally substituted with one or more halogens. R 1 is a C1-C6 alkyl group optionally substituted with H, a halogen, or one or more halogens. R 2 is a C1-C6 alkyl group optionally substituted with H, a halogen, or one or more halogens. R 3 is a C1-C6 alkyl group optionally substituted with H, a halogen, or one or more halogens. R 4 is H, halogen, or C1-C6 alkyl optionally substituted with one or more halogens, each R 5 is independently H, halogen, or C1-C6 alkyl optionally substituted with one or more halogens, and n is an integer in the range of about 0 to about 10, provides a compound.

[0005] In some embodiments, the present disclosure provides a scaffold or a pharmaceutically acceptable salt thereof, and the scaffold is (i) a ligand, and (ii) a linker unit, wherein the linker unit is

Chemical formula

[0006] In some embodiments, the present disclosure provides a scaffold or a pharmaceutically acceptable salt thereof, and the scaffold is (i) one or more nucleic acid agents, and (ii) one or more linker units, each linker unit independently is[[ID=四十九]] には、[[ID=五十]] には、[[ID=五十一]]

Chemical formula

[0007] In some embodiments, the Disclosure provides a conjugate or a pharmaceutically acceptable salt thereof, the conjugate is (i) One or more nucleic acid agents, (ii) one or more ligands, and (iii) One or more linker units, each linker unit independently [ka] It includes one or more linker units, In the formula, the variable element R 1 , R 2 , R 3 , R 4 , R 5 X, Y, Z, R a , R b , and n are as described herein, # indicates binding to a ligand, and ## indicates binding to a nucleic acid agent.

[0008] In some embodiments, the present disclosure provides compounds that are isotopic derivatives of compounds disclosed herein.

[0009] In some embodiments, the present disclosure provides pharmaceutical compositions comprising compounds, scaffolds, or conjugates described herein.

[0010] In some embodiments, the present disclosure provides a method for modulating the expression of a target gene in a subject, which includes administering a conjugate described herein to the subject.

[0011] In some embodiments, the Disclosure provides a method for delivering nucleic acid agents, which includes administering them to conjugates described herein.

[0012] In some embodiments, the Disclosure provides a method for treating or preventing a disease in a subject requiring such treatment, comprising administering a therapeutically effective amount of a conjugate described herein to the subject.

[0013] In some aspects, this disclosure provides the use of the conjugates described herein in the manufacture of a pharmaceutical product for modulating the expression of a target gene in a subject.

[0014] In some aspects, this disclosure provides the use of the conjugates described herein in the manufacture of a pharmaceutical product for target delivery of nucleic acid agents.

[0015] In some embodiments, the Disclosure provides the use of the conjugates described herein in the manufacture of a pharmaceutical product for the treatment or prevention of a disease in a subject requiring such treatment or prevention.

[0016] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art to which this disclosure belongs. In this specification, singular forms include plural forms unless the context clearly indicates otherwise. Similar or equivalent methods and materials may be used in the implementation or testing of this disclosure, but preferred methods and materials are described below. All publications, patent applications, patents, and other references referenced herein are incorporated herein by reference. References cited herein are not considered prior art to the claimed invention. In case of any conflict, this specification, including definitions, shall prevail. Furthermore, materials, methods, and examples are illustrative and not intended to limit the scope. In the event of any conflict between the chemical structure and the name of a compound disclosed herein, the chemical structure shall prevail.

[0017] Other features and advantages of this disclosure will become apparent from the embodiments and claims for carrying out the invention described below. [Brief explanation of the drawing]

[0018] [Figure 1]The gene silencing activity of the siRNA duplex against target gene 2 in the liver on the 5th day after a single 0.5 mg / kg s.c. injection in CD-1 female mice, followed by administration of HDI on the 4th day (plasmid of target human gene 2, 20 μg), is shown.

[0019] [Figure 2] The gene silencing activity of the siRNA duplex against target gene 1 in the liver on the 5th day after a single 0.5 mg / kg s.c. injection in CD-1 female mice, followed by administration of HDI on the 4th day (plasmid of target human gene 1, 10 μg), is shown.

Mode for Carrying Out the Invention

[0020] The present disclosure provides the compounds, linkers, scaffolds, and conjugates described herein for nucleic acid delivery. The present disclosure also relates to the use of the compounds, linkers, scaffolds, and conjugates, for example, in the delivery of nucleic acids and / or in the treatment or prevention of diseases.

[0021] The linker compounds of the present disclosure In some embodiments, the present disclosure provides a compound of formula (I) or (II),

Chemical formula

[0022] With respect to the compounds disclosed herein, the variable elements W, X, and R X , R Xa , Y, R Y , Z, R Z , R L , R a , R b , R 1 , R 2 , R 3 , R 4 , R 5and n can each be selected from the bases described herein, where applicable, and the variable elements W, X, R X , R Xa , Y, R Y , Z, R Z , R L , R a , R b , R 1 , R 2 , R 3 , R 4 , R 5 Any base described herein for either and n, where applicable, is a variable element W, X, R X , R Xa , Y, R Y , Z, R Z , R L , R a , R b , R 1 , R 2 , R 3 , R 4 , R 5 It is understood that the remaining one or more of n can be combined with any of the groups described herein.

[0023] Variable elements W, X, R X , R Xa , Y, R Y , Z, R Z , and R L In some embodiments, W is H.

[0024] In some embodiments, W is a C1-C6 alkyl group (e.g., methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, pentyl, or hexyl) optionally substituted with one or more halogens (e.g., F, Cl, Br, or I).

[0025] In some embodiments, W is a C1-C6 alkyl group (e.g., methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, pentyl, or hexyl).

[0026] In some embodiments, W is methyl, ethyl, or propyl.

[0027] In some embodiments, W is a group suitable for amino substituents, i.e., for substituting hydrogens in the amino portion, such as an amino protecting group.

[0028] In some embodiments, W is an amino protecting group that includes, but is not limited to, fluorenylmethyloxycarbonyl (Fmoc), tert-butyloxycarbonyl (BOC), benzyloxycarbonyl (Cbz), optionally substituted acyl, trifluoroacetyl (TFA), benzyl, triphenylmethyl (Tr), 4,4'-dimethoxytrityl (DMTr), or toluenesulfonyl (Ts).

[0029] In some embodiments, W is an acyl that is optionally replaced (e.g., -C(=O)(C1~C) 30 It is alkyl, and C1~C 30 Alkyl is optionally substituted.

[0030] In some embodiments, W is a substituted acyl (for example, [ka] )

[0031] In some embodiments, W is trifluoroacetyl (TFA).

[0032] In some embodiments, W is an amino substituent, i.e., -C(=O)(C1~C 30 Alkyl), -C(=O)NH(C1~C 30 Alkyl), -C(=S)(C1~C 30 Alkyl), or -C(=S)NH(C1~C 30 It is a suitable group for substituting hydrogen atoms in the amino portion of alkyl groups, etc., C1-C 30 Alkyl is optionally substituted. In some embodiments, W is -C(=O)(C1~C25 Alkyl), -C(=O)NH(C1~C 25 Alkyl), -C(=S)(C1~C 25 Alkyl), or -C(=S)NH(C1~C 25 It is alkyl, and C1~C 25 Alkyl groups are optionally substituted.

[0033] In some embodiments, X is H.

[0034] In some embodiments, X is a halogen (e.g., F, Cl, Br, or I).

[0035] In some embodiments, X is F or Cl.

[0036] In some embodiments, X is F.

[0037] In some embodiments, X is -OR X That is the case.

[0038] In some embodiments, X is -OH.

[0039] In some embodiments, X is one or more R Xa The C1-C6 alkyl group is optionally substituted (for example, the C1-C6 alkyl group is methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, pentyl, or hexyl).

[0040] In some embodiments, X is -O-(C1-C6 alkyl) (for example, C1-C6 alkyl is methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, pentyl, or hexyl).

[0041] In some embodiments, X is -OCH3, -OCH2CH3, or -OCH2CH2OCH3.

[0042] In some embodiments, X is -OCH3 or -OCH2CH3.

[0043] In some embodiments, X is -OCH2CH2OCH3.

[0044] In some embodiments, X is -O-(C1~C6 alkyl)-O-(C1~C6 alkyl) (for example, C1~C6 alkyl is methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, pentyl, or hexyl).

[0045] In some embodiments, X is one or more R Xa -O-(C1~C6 alkyl)-(C6~C 10 It is Ariel.

[0046] In some embodiments, X is -O-(C1~C6 alkyl)-(C6~C 10 It is Ariel.

[0047] In some embodiments, X is [ka] That is the case.

[0048] In some embodiments, X is one or more R Xa Replaced by optional selection [ka] That is the case.

[0049] In some embodiments, X is optionally replaced with one or more halogens. [ka] That is the case.

[0050] In some embodiments, X is optionally substituted with one or more C1-C6 alkyl groups or -O-(C1-C6 alkyl groups). [ka] The C1-C6 alkyl or -O-(C1-C6 alkyl) is optionally substituted with one or more halogens.

[0051] In some embodiments, R X H is H.

[0052] In some embodiments, R X is one or more R Xa The C1-C6 alkyl group is optionally substituted (for example, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, pentyl, or hexyl).

[0053] In some embodiments, R X This is a C1-C6 alkyl group (e.g., methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, pentyl, or hexyl) optionally substituted with one or more halogens (e.g., F, Cl, Br, or I), or an -O-(C1-C6 alkyl) (e.g., C1-C6 alkyl is methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, pentyl, or hexyl).

[0054] In some embodiments, R X The C1-C6 alkyl group is (for example, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, pentyl, or hexyl).

[0055] In some embodiments, R X It is methyl, ethyl, or propyl.

[0056] In some embodiments, RX It is methyl.

[0057] In some embodiments, R X This is a C1-C6 alkyl group (e.g., methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, pentyl, or hexyl) substituted with one or more halogens (e.g., F, Cl, Br, or I).

[0058] In some embodiments, R X The C1-C6 alkyl group is a C1-C6 alkyl group substituted with one or more -O-(C1-C6 alkyl) groups (e.g., methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, pentyl, or hexyl) (for example, the C1-C6 alkyl group is methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, pentyl, or hexyl), and the -O-(C1-C6 alkyl) group is optionally substituted with one or more halogens.

[0059] In some embodiments, R X is one or more R Xa The following substitutions were made by choice: -(C1~C6 alkyl)-(C6~C 10 It is Ariel.

[0060] In some embodiments, R X -(C1~C6 alkyl)-(C6~C) is optionally substituted with one or more halogens (e.g., F, Cl, Br, or I). 10 The elements are aryl, C1-C6 alkyl (e.g., methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, pentyl, or hexyl), or -O-(C1-C6 alkyl) (e.g., C1-C6 alkyl is methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, pentyl, or hexyl), and the C1-C6 alkyl or -O-(C1-C6 alkyl) is optionally substituted with one or more halogens.

[0061] In some embodiments, R X -(C1~C6 alkyl)-(C6~C) is optionally substituted with one or more halogens (e.g., F, Cl, Br, or I). 10 It is Ariel.

[0062] In some embodiments, R X -(C1-C6 alkyl)-(C6-C) is optionally substituted with one or more C1-C6 alkyl groups (e.g., methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, pentyl, or hexyl). 10 The aryl group is C1-C6 alkyl, and the C1-C6 alkyl group is optionally substituted with one or more halogens.

[0063] In some embodiments, R X -(C1~C6 alkyl)-(C6~C) is a compound optionally substituted with one or more -O-(C1~C6 alkyl) groups. 10 The -O-(C1-C6 alkyl) is an aryl group (for example, the C1-C6 alkyl group is methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, pentyl, or hexyl), and the -O-(C1-C6 alkyl) is optionally substituted with one or more halogens.

[0064] In some embodiments, R X is -(C1~C6 alkyl)-(C6~C 10 It is Ariel.

[0065] In some embodiments, R X It is benzyl.

[0066] In some embodiments, at least one R Xa This is a halogen (e.g., F, Cl, Br, or I).

[0067] In some embodiments, at least one R XaThis is a C1-C6 alkyl group (e.g., methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, pentyl, or hexyl) optionally substituted with one or more halogens (e.g., F, Cl, Br, or I).

[0068] In some embodiments, at least one R Xa is an -O-(C1-C6 alkyl) optionally substituted with one or more halogens (e.g., F, Cl, Br, or I) (e.g., C1-C6 alkyl is methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, pentyl, or hexyl).

[0069] In some embodiments, Y is H.

[0070] In some embodiments, Y is a C1-C6 alkyl group (e.g., methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, pentyl, or hexyl) optionally substituted with one or more halogens (e.g., F, Cl, Br, or I).

[0071] In some embodiments, Y is a C1-C6 alkyl group (e.g., methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, pentyl, or hexyl).

[0072] In some embodiments, Y is methyl, ethyl, or propyl.

[0073] In some embodiments, Y is -P(R Y )2, -P(OR Y )(N(R Y )2), -P(=O)(OR Y )R Y , -P(=S)(OR Y )R Y -P(=O)(SR Y )R Y -P(=S)(SR Y)R Y , -P(=O)(OR Y )2, -P(=S)(OR Y )2, -P(=O)(SR Y )2, -P(=S)(SR Y )2.

[0074] In some embodiments, Y is -P(R Y )2.

[0075] In some embodiments, Y is -PH2.

[0076] In some embodiments, Y is -P(OR Y )(N(R Y 2) is the answer.

[0077] In some embodiments, Y is -P(OH)(NH2).

[0078] In some embodiments, Y is -P(O(C1~C6 alkyl))(N(C1~C6 alkyl)2), where C1~C6 alkyl is optionally substituted with one or more halogens or cyano compounds.

[0079] In some embodiments, Y is -P(=O)(OR Y )R Y That is the case.

[0080] In some embodiments, Y is -P(=O)(OH)(C1-C6 alkyl), and the C1-C6 alkyl is optionally substituted with one or more halogens or cyano compounds.

[0081] In some embodiments, Y is -P(=S)(OR Y )R Y That is the case.

[0082] In some embodiments, Y is -P(=S)(OH)(C1-C6 alkyl), and the C1-C6 alkyl is optionally substituted with one or more halogens or cyano compounds.

[0083] In some embodiments, Y is -P(=O)(SR Y )R Y That is the case.

[0084] In some embodiments, Y is -P(=O)(SH)(C1~C6 alkyl), and the C1~C6 alkyl is optionally substituted with one or more halogens or cyano compounds.

[0085] In some embodiments, Y is -P(=S)(SR Y )R Y That is the case.

[0086] In some embodiments, Y is -P(=S)(SH)(C1~C6 alkyl), and the C1~C6 alkyl is optionally substituted with one or more halogens or cyanonucleotides.

[0087] In some embodiments, Y is -P(=O)(OR Y )2.

[0088] In some embodiments, Y is -P(=O)(OH)2.

[0089] In some embodiments, Y is -P(=S)(OR Y )2.

[0090] In some embodiments, Y is -P(=S)(OH)2.

[0091] In some embodiments, Y is -P(=O)(SR Y )2.

[0092] In some embodiments, Y is -P(=O)(SH)².

[0093] In some embodiments, Y is -P(=S)(SR Y )2.

[0094] In some embodiments, Y is -P(=S)(SH)².

[0095] In some embodiments, Y is a hydroxy protecting group (e.g., silyl, Tr, DMTr, acyl, or benzyl).

[0096] In some embodiments, Y is a silyl (e.g., trimethylsilyl, triethylsilyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl, or triisopropylsilyl).

[0097] In some embodiments, Y is triphenylmethyl (Tr) or 4,4'-dimethoxytrityl (DMTr).

[0098] In some embodiments, Y is an optionally substituted acyl (e.g., an optionally substituted acetyl) or benzyl.

[0099] In some embodiments, at least one R Y H is H.

[0100] Several embodiments, each R Y H is H.

[0101] In some embodiments, at least one R Y is a C1-C6 alkyl group (e.g., methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, pentyl, or hexyl) optionally substituted with one or more halogens (e.g., F, Cl, Br, or I) or cyanopropyl.

[0102] Several embodiments, each R Y is a C1-C6 alkyl group (e.g., methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, pentyl, or hexyl) optionally substituted with one or more halogens (e.g., F, Cl, Br, or I) or cyanopropyl.

[0103] In some embodiments, at least one R Y H is H and at least one R Y is a C1-C6 alkyl group (e.g., methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, pentyl, or hexyl) optionally substituted with one or more halogens or cyanopropyl groups.

[0104] In some embodiments, Z is H.

[0105] In some embodiments, Z is a C1-C6 alkyl group (e.g., methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, pentyl, or hexyl) optionally substituted with one or more halogens (e.g., F, Cl, Br, or I).

[0106] In some embodiments, Z is a C1-C6 alkyl group (e.g., methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, pentyl, or hexyl).

[0107] In some embodiments, Z is methyl, ethyl, or propyl.

[0108] In some embodiments, Z is -P(R Z )2, -P(OR Z )(N(R Z )2), -P(=O)(OR Z )R Z , -P(=S)(OR Z )R Z -P(=O)(SR Z )R Z -P(=S)(SR Z )R Z , -P(=O)(OR Z )2, -P(=S)(OR Z )2, -P(=O)(SR Z )2, -P(=S)(SR Z )2.

[0109] In some embodiments, Z is -P(R Z )2.

[0110] In some embodiments, Z is -PH2.

[0111] In some embodiments, Z is -P(OR Z )(N(R Z )2) is.

[0112] In some embodiments, Z is -P(OH)(NH2).

[0113] In some embodiments, Z is -P(O(C1~C6 alkyl))(N(C1~C6 alkyl)2), where C1~C6 alkyl is optionally substituted with one or more halogens or cyano compounds.

[0114] In some embodiments, Z is -P(=O)(OR Z )R Z That is the case.

[0115] In some embodiments, Z is -P(=O)(OH)(C1-C6 alkyl), and the C1-C6 alkyl is optionally substituted with one or more halogens or cyano compounds.

[0116] In some embodiments, Z is -P(=S)(OR Z )R Z That is the case.

[0117] In some embodiments, Z is -P(=S)(OH)(C1-C6 alkyl), and the C1-C6 alkyl is optionally substituted with one or more halogens or cyano compounds.

[0118] In some embodiments, Z is -P(=O)(SR Z )R Z That is the case.

[0119] In some embodiments, Z is -P(=O)(SH)(C1-C6 alkyl), and the C1-C6 alkyl is optionally substituted with one or more halogens or cyanonucleotides.

[0120] In some embodiments, Z is -P(=S)(SR Z )R Z That is the case.

[0121] In some embodiments, Z is -P(=S)(SH)(C1~C6 alkyl), and the C1~C6 alkyl is optionally substituted with one or more halogens or cyano compounds.

[0122] In some embodiments, Z is -P(=O)(OR Z )2.

[0123] In some embodiments, Z is -P(=O)(OH)2.

[0124] In some embodiments, Z is -P(=S)(OR Z )2.

[0125] In some embodiments, Z is -P(=S)(OH)2.

[0126] In some embodiments, Z is -P(=O)(SR Z )2.

[0127] In some embodiments, Z is -P(=O)(SH)².

[0128] In some embodiments, Z is -P(=S)(SR Z )2.

[0129] In some embodiments, Z is -P(=S)(SH)².

[0130] In some embodiments, Z is a hydroxy protecting group (e.g., silyl, Tr, DMTr, acyl, or benzyl).

[0131] In some embodiments, Z is a silyl (e.g., trimethylsilyl, triethylsilyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl, or triisopropylsilyl).

[0132] In some embodiments, Z is triphenylmethyl (Tr) or 4,4'-dimethoxytrityl (DMTr).

[0133] In some embodiments, Z is a substituted acyl (e.g., optionally substituted acetyl) or benzyl.

[0134] In some embodiments, at least one R Z H is H.

[0135] In some embodiments, R Z H is H.

[0136] In some embodiments, at least one R Z is a C1-C6 alkyl group (e.g., methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, pentyl, or hexyl) optionally substituted with one or more halogens (e.g., F, Cl, Br, or I) or cyanopropyl.

[0137] Several embodiments, each R Z is a C1-C6 alkyl group (e.g., methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, pentyl, or hexyl) optionally substituted with one or more halogens (e.g., F, Cl, Br, or I) or cyanopropyl.

[0138] In some embodiments, at least one R Z H is H and at least one R Zis a C1-C6 alkyl group (e.g., methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, pentyl, or hexyl) optionally substituted with one or more halogens (e.g., F, Cl, Br, or I) or cyanopropyl.

[0139] In some embodiments, Y and Z in formula (I) are combined as -Si(R L )2-O-Si(R L ) forms 2-.

[0140] In some embodiments, Y and Z in formula (I) combine to form -Si(C1~C6 alkyl)2-O-Si(C1~C6 alkyl)2-.

[0141] In some embodiments, Y and Z in formula (I) combine to form -SiH(C1~C6 alkyl)-O-Si(C1~C6 alkyl)2-.

[0142] In some embodiments, Y and Z in formula (I) combine to form -Si(C1~C6 alkyl)2-O-SiH(C1~C6 alkyl)-.

[0143] In some embodiments, Y and Z in formula (I) combine to form -SiH(C1~C6 alkyl)-O-SiH(C1~C6 alkyl)-.

[0144] In some embodiments, Y and Z in formula (I) combine to form -Si(iPr)2-O-Si(iPr)2-.

[0145] In some embodiments, at least one R L H is H.

[0146] Several embodiments, each R L These are independently C1-C6 alkyl groups.

[0147] Several embodiments, each R LThese are independently methyl, ethyl, or propyl (e.g., iPr).

[0148] Variable element R a , R b , R 1 , R 2 , R 3 , R 4 , R 5 , and n Several embodiments, each R a H is H.

[0149] In some embodiments, at least one R a This is a halogen (e.g., F, Cl, Br, or I) or a C1-C6 alkyl (e.g., methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, pentyl, or hexyl) optionally substituted with one or more halogens (e.g., F, Cl, Br, or I).

[0150] In some embodiments, at least one R a This is a halogen (e.g., F, Cl, Br, or I).

[0151] In some embodiments, at least one R a It is either F or Cl.

[0152] In some embodiments, at least one R a This is a C1-C6 alkyl group (e.g., methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, pentyl, or hexyl) optionally substituted with one or more halogens (e.g., F, Cl, Br, or I).

[0153] In some embodiments, at least one R a The C1-C6 alkyl group is (for example, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, pentyl, or hexyl).

[0154] In some embodiments, at least one R a This is a C1-C6 alkyl group (e.g., methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, pentyl, or hexyl) substituted with one or more halogens (e.g., F, Cl, Br, or I).

[0155] In some embodiments, R b H is H.

[0156] In some embodiments, at least one R b This is a halogen (e.g., F, Cl, Br, or I) or a C1-C6 alkyl (e.g., methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, pentyl, or hexyl) optionally substituted with one or more halogens (e.g., F, Cl, Br, or I).

[0157] In some embodiments, at least one R b This is a halogen (e.g., F, Cl, Br, or I).

[0158] In some embodiments, at least one R b It is either F or Cl.

[0159] In some embodiments, at least one R b This is a C1-C6 alkyl group (e.g., methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, pentyl, or hexyl) optionally substituted with one or more halogens (e.g., F, Cl, Br, or I).

[0160] In some embodiments, at least one R b The C1-C6 alkyl group is (for example, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, pentyl, or hexyl).

[0161] In some embodiments, at least one R b This is a C1-C6 alkyl group (e.g., methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, pentyl, or hexyl) substituted with one or more halogens (e.g., F, Cl, Br, or I).

[0162] In some embodiments, R 1 H is H.

[0163] In some embodiments, R 1 This is a halogen (e.g., F, Cl, Br, or I).

[0164] In some embodiments, R 1 It is either F or Cl.

[0165] In some embodiments, R 1 This is a C1-C6 alkyl group (e.g., methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, pentyl, or hexyl) optionally substituted with one or more halogens (e.g., F, Cl, Br, or I).

[0166] In some embodiments, R 1 The C1-C6 alkyl group is (for example, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, pentyl, or hexyl).

[0167] In some embodiments, R 1 This is a C1-C6 alkyl group (e.g., methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, pentyl, or hexyl) substituted with one or more halogens (e.g., F, Cl, Br, or I).

[0168] In some embodiments, R 2 H is H.

[0169] In some embodiments, R 2 This is a halogen (e.g., F, Cl, Br, or I).

[0170] In some embodiments, R 2 It is either F or Cl.

[0171] In some embodiments, R 2 This is a C1-C6 alkyl group (e.g., methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, pentyl, or hexyl) optionally substituted with one or more halogens (e.g., F, Cl, Br, or I).

[0172] In some embodiments, R 2 The C1-C6 alkyl group is (for example, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, pentyl, or hexyl).

[0173] In some embodiments, R 2 This is a C1-C6 alkyl group (e.g., methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, pentyl, or hexyl) substituted with one or more halogens (e.g., F, Cl, Br, or I).

[0174] In some embodiments, R 3 H is H.

[0175] In some embodiments, R 3 This is a halogen (e.g., F, Cl, Br, or I).

[0176] In some embodiments, R 3 It is either F or Cl.

[0177] In some embodiments, R 3This is a C1-C6 alkyl group (e.g., methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, pentyl, or hexyl) optionally substituted with one or more halogens (e.g., F, Cl, Br, or I).

[0178] In some embodiments, R 3 The C1-C6 alkyl group is (for example, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, pentyl, or hexyl).

[0179] In some embodiments, R 3 This is a C1-C6 alkyl group (e.g., methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, pentyl, or hexyl) substituted with one or more halogens (e.g., F, Cl, Br, or I).

[0180] In some embodiments, R 4 H is H.

[0181] In some embodiments, R 4 This is a halogen (e.g., F, Cl, Br, or I).

[0182] In some embodiments, R 4 It is either F or Cl.

[0183] In some embodiments, R 4 This is a C1-C6 alkyl group (e.g., methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, pentyl, or hexyl) optionally substituted with one or more halogens (e.g., F, Cl, Br, or I).

[0184] In some embodiments, R 4 The C1-C6 alkyl group is (for example, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, pentyl, or hexyl).

[0185] In some embodiments, R 4 This is a C1-C6 alkyl group (e.g., methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, pentyl, or hexyl) substituted with one or more halogens (e.g., F, Cl, Br, or I).

[0186] In some embodiments, R 5 H is H.

[0187] In some embodiments, at least one R 5 This is a halogen (e.g., F, Cl, Br, or I) or a C1-C6 alkyl (e.g., methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, pentyl, or hexyl) optionally substituted with one or more halogens (e.g., F, Cl, Br, or I).

[0188] In some embodiments, at least one R 5 This is a halogen (e.g., F, Cl, Br, or I).

[0189] In some embodiments, at least one R 5 It is either F or Cl.

[0190] In some embodiments, at least one R 5 This is a C1-C6 alkyl group (e.g., methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, pentyl, or hexyl) optionally substituted with one or more halogens (e.g., F, Cl, Br, or I).

[0191] In some embodiments, at least one R 5 The C1-C6 alkyl group is (for example, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, pentyl, or hexyl).

[0192] In some embodiments, at least one R 5 This is a C1-C6 alkyl group (e.g., methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, pentyl, or hexyl) substituted with one or more halogens (e.g., F, Cl, Br, or I).

[0193] In some embodiments, R a , R b , R 1 , R 2 , R 3 , R 4 , and R 5 Each of these is H.

[0194] In some embodiments, n is an integer in the range of about 1 to about 10.

[0195] In some embodiments, n is an integer in the range of about 2 to about 10.

[0196] In some embodiments, n is an integer in the range of about 3 to about 10, about 4 to about 10, about 5 to about 10, or about 6 to about 10.

[0197] In some embodiments, n is an integer in the range of approximately 1 to approximately 8, approximately 1 to approximately 7, approximately 1 to approximately 6, approximately 1 to approximately 5, approximately 1 to approximately 4, or approximately 1 to approximately 3.

[0198] In some embodiments, n is an integer in the range of approximately 2 to approximately 8, approximately 2 to approximately 7, approximately 2 to approximately 6, approximately 2 to approximately 5, approximately 2 to approximately 4, or approximately 2 to approximately 3.

[0199] In some embodiments, n is 0.

[0200] In some embodiments, n is 1.

[0201] In some embodiments, n is 2.

[0202] In some embodiments, n is 3.

[0203] In some embodiments, n is 4.

[0204] In some embodiments, n is 5.

[0205] In some embodiments, n is 6.

[0206] In some embodiments, n is 7.

[0207] In some embodiments, n is 8.

[0208] In some embodiments, n is 9.

[0209] In some embodiments, n is 10.

[0210] Exemplary embodiments of compounds In some embodiments, the compound is of formula (I'-1), (I'-2), (II'-1), or (II'-2): [ka] things, or a pharmaceutically acceptable salt thereof.

[0211] In some embodiments, the compound is of formula (IA) or (II-A): [ka] things, or a pharmaceutically acceptable salt thereof.

[0212] In some embodiments, the compound is of formula (I-A'-1), (I-A'-2), (II-A'-1), or (II-A'-2): [ka] things, or a pharmaceutically acceptable salt thereof.

[0213] In some embodiments, the compound is of formula (IB) or (II-B): [ka] things, or [ka] or a pharmaceutically acceptable salt thereof.

[0214] In some embodiments, the compound is of formula (I-B'-1), (I-B'-2), (II-B'-1), or (II-B'-2): [ka] things, or a pharmaceutically acceptable salt thereof.

[0215] In some embodiments, Y is a hydroxy protecting group (e.g., silyl, Tr, DMTr, acyl, or benzyl) and Z is a hydroxy protecting group (e.g., silyl, Tr, DMTr, acyl, or benzyl), or Y and Z in formulas (I), (I'-1), (I'-2), (IA), (I-A'-1), (I-A'-2), (IB), (I-B'-1) or (I-B'-2) together form -Si(R L )2-O-Si(R L )2- forms, and each R L These are independently H or C1-C6 alkyl groups.

[0216] In some embodiments, Y is a hydroxy protecting group (e.g., silyl, Tr, DMTr, acyl, or benzyl), and Z is a hydroxy protecting group (e.g., silyl, Tr, DMTr, acyl, or benzyl).

[0217] In some embodiments, Y and Z in formulas (I), (I'-1), (I'-2), (IA), (I-A'-1), (I-A'-2), (IB), (I-B'-1), or (I-B'-2) are combined to form -Si(R L )2-O-Si(R L )2 is formed, and each R L These are independently H or C1-C6 alkyl groups.

[0218] In some embodiments, the compound is [ka] or a pharmaceutically acceptable salt thereof, in the formula, Y is -P(R Y )2, -P(OR Y )(N(R Y )2), -P(=O)(OR Y )R Y , -P(=S)(OR Y )R Y -P(=O)(SR Y )R Y -P(=S)(SR Y )R Y , -P(=O)(OR Y )2, -P(=S)(OR Y )2, -P(=O)(SR Y )2, -P(=S)(SR Y )2, or a hydroxy protecting group (e.g., silyl (e.g., trimethylsilyl, triethylsilyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl, or triisopropylsilyl), triphenylmethyl (Tr), 4,4'-dimethoxytrityl (DMTr), substituted acyl (e.g., optionally substituted acetyl), or benzyl), Each R Y These are independently C1-C6 alkyl groups optionally substituted with H or one or more halogens or cyano compounds. Z is -P(R Z )2, -P(OR Z )(N(R Z )2), -P(=O)(OR Z )RZ , -P(=S)(OR Z )R Z -P(=O)(SR Z )R Z -P(=S)(SR Z )R Z , -P(=O)(OR Z )2, -P(=S)(OR Z )2, -P(=O)(SR Z )2, -P(=S)(SR Z )2, or a hydroxy protecting group (e.g., silyl (e.g., trimethylsilyl, triethylsilyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl, or triisopropylsilyl), triphenylmethyl (Tr), 4,4'-dimethoxytrityl (DMTr), substituted acyl (e.g., optionally substituted acetyl), or benzyl), Each R Z These are independently C1-C6 alkyl groups optionally substituted with H or one or more halogens or cyano compounds. C1~C 30 Alkyl groups are optionally substituted.

[0219] In some embodiments, the compounds are selected from the compounds listed in Table L and their pharmaceutically acceptable salts. [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4]

[0220] In some embodiments, the Disclosure provides compounds that are isotopic derivatives (e.g., isotope-labeled compounds) of any one of the compounds of the formulas disclosed herein.

[0221] It is understood that isotopic derivatives can be prepared using any of the various techniques recognized in the art. For example, isotopic derivatives can generally be prepared by performing the procedures disclosed in the schemes and / or examples herein, by using isotopically labeled reagents in place of non-isotopically labeled reagents.

[0222] In some embodiments, the isotopic derivative is a deuterium-labeled compound.

[0223] In some embodiments, the isotopic derivative is a deuterium-labeled compound of any one of the compounds of the formulas disclosed herein.

[0224] As used herein, the term “isotope derivative” refers to a derivative of a compound in which one or more atoms are isotope-enriched or labeled. For example, an isotope derivative of a compound of formula (I) or (II) is isotope-enriched or labeled with respect to one or more isotopes compared to the corresponding compound of formula (I) or (II). In some embodiments, the isotope derivative is 2 H, 13 C, 14 C, 15 N, 18 O, 29 Si, 32 P, and 34 It is enriched with respect to one or more atoms selected from S, or labeled with respect to it. In some embodiments, the isotopic derivative is a deuterium-labeled compound (i.e., with respect to one or more atoms of it). 2 (Concentrated with H) In some embodiments, the compound is 2 It is an H-labeled compound. In some embodiments, the compound is 13 C-labeled compound or 14 It is a 1C-labeled compound. In some embodiments, the compound is 18 It is a fluorine-labeled compound. In some embodiments, the compound is 123 I-labeled compound, 124 I-labeled compound, 125 I-labeled compound, 129 I-labeled compound, 131I-labeled compound, 135 I-labeled compounds, or any combination thereof. In some embodiments, the compounds are 32 P-labeled compound or 32 It is a P-labeled compound. 33 S-labeled compound, 34 S-labeled compound, 35 S-labeled compound, 36 This is an S-labeled compound, or any combination thereof.

[0225] It is understood that isotopic derivatives can be prepared using any of the various techniques recognized in the art. For example, isotopic derivatives can generally be prepared by performing the procedures disclosed in the schemes and / or examples described herein, by using isotopically labeled reagents in place of non-isotopically labeled reagents.

[0226] It is also understood that isotope substitution may offer certain therapeutic benefits resulting from greater metabolic stability, such as an increased in vivo half-life or a reduced dosage requirement.

[0227] To avoid misunderstanding, where a base is conditioned in this specification by "as described herein," it should be understood that the base encompasses the broadest definition that first arises, as well as each and all of the specific definitions relating to that base.

[0228] It will be understood that the compounds disclosed herein may be presented in one particular stereoconfiguration. Such a particular stereoconfiguration should not be construed as limiting this disclosure to one or another isomer, tautomer, regioisomer, or stereoisomer, nor does it exclude mixtures of isomers, tautomers, regioisomers, or stereoisomers. In some embodiments, the presentation of a compound herein in a particular stereoconfiguration is intended to encompass and refer to each of the available isomers, tautomers, regioisomers, and stereoisomers of the compound, or any mixture thereof, and the presentation is further intended to refer to a particular stereoconfiguration of the compound.

[0229] On the other hand, it will be understood that the compounds disclosed herein may be presented without a specific configuration (for example, without a specific stereochemistry). Such presentations are intended to encompass all available isomers, tautomers, regioisomers, and stereoisomers of the compound. In some embodiments, presentations of compounds herein without a specific configuration are intended to refer to each of the available isomers, tautomers, regioisomers, and stereoisomers of the compound, or any mixture thereof.

[0230] As used herein, the term “isomer” means a compound having the same molecular formula but differing in the order of the bonding of its atoms or the arrangement of its atoms in space. Compounds having the same molecular formula but differing in the nature or order of the bonding of their atoms or the arrangement of their atoms in space are called “isomers.” Isomers that differ in the arrangement of their atoms in space are called “stereoisomers.” Stereoisomers that are not mirror images of each other are called “diastereomers,” and stereoisomers that are mirror images of each other but cannot be superimposed are called “enantiomers.” If a compound has a chiral center, for example, if it is bonded to four different groups, a pair of enantiomers is possible. Enantiomers can be characterized by the absolute configuration of their chiral center, described by the Cahn and Prelog R and S order rules, or by the way the molecule rotates its plane of polarization, and are designated as dextrorotatory or levorotatory (i.e., as (+) or (-)-isomers, respectively). Chiral compounds can exist as individual enantiomers or mixtures thereof. A mixture containing equal proportions of enantiomers is called a "racemic mixture."

[0231] The compounds of this disclosure may have one or more chiral centers, and therefore such compounds may be produced as individual (R)- or (S)-stereoisomers, or as mixtures thereof. Unless otherwise indicated, the description or naming of specific compounds in this specification and claims is intended to include both individual enantiomers and racemates or other mixtures thereof. Methods for determining stereochemistry and separating stereoisomers are well known in the art (see discussion in Chapter 4 of "Advanced Organic Chemistry", 4th edition J. March, John Wiley and Sons, New York, 2001), for example, by synthesis from optically active starting materials or by separation of racemic forms. Some of the compounds of this disclosure may have geometric isomer centers (E and Z isomers). It should be understood that this disclosure encompasses all optical isomers, diastereoisomers and geometric isomers, and mixtures thereof, that have inflammasome inhibitory activity.

[0232] As used herein, the term “chiral center” refers to a carbon atom bonded to four non-identical substituents.

[0233] As used herein, the term “chiral isomer” means a compound having at least one chiral center. Compounds having two or more chiral centers may exist as individual diastereomers or as a mixture of diastereomers, called a “diastereomer mixture.” When one chiral center is present, the stereoisomer can be characterized by the absolute configuration (R or S) of that chiral center. Absolute configuration refers to the spatial arrangement of substituents attached to the chiral center. Substituents attached to the chiral center under consideration are ranked according to the Cahn, Ingold, and Prelog priority rules. (Cahn et al.,Angew.Chem.Inter.Edit.1966,5,385;errata 511, Cahn et al.,Angew.Chem.1966,78,413;Cahn and Ingold,J.Chem.Soc.1951(London),612, Cahn et al.,Experientia 1956, 12, 81; Cahn, J. Chem. Educ. 1964, 41, 116).

[0234] As used herein, the term “geometric isomer” means a diastereomer whose existence is due to rotational hindrance around a double bond or a cycloalkyl linker (e.g., 1,3-cyclobutyl). These configurations are distinguished in their names by the prefixes cis and trans, or Z and E, indicating that the group is on the same side or opposite side of the double bond in the molecule, according to the Cahn-Ingold-Prelog rule.

[0235] It should be understood that the compounds disclosed herein may be represented as different chiral or geometric isomers. Furthermore, if a compound has chiral or geometric isomers, it is intended that all isomers are included within the scope of this disclosure, and that the naming of the compounds does not exclude any isomers, and that not all isomers may have the same level of activity.

[0236] It should be understood that the structures and other compounds discussed in this disclosure include all of their atropisomers. It should also be understood that not all atropisomers may have the same level of activity.

[0237] As used herein, the term “atropisomer” refers to a type of stereoisomer in which the atoms of two isomers are arranged differently in space. Atropisomers exist due to rotational binding caused by an obstruction of the rotation of a large group around a central bond. Such atropisomers typically exist as a mixture, but recent advances in chromatographic techniques have made it possible to separate a mixture of two atropisomers when selected.

[0238] As used herein, the term “tautomer” refers to one of two or more structural isomers that exist in equilibrium and are readily convertible from one isomer to another. This conversion results in a formal transfer of hydrogen atoms, involving the switching of adjacent conjugated double bonds. Tautomers exist in solution as a mixture of tautomer sets. In solutions where tautomerization is possible, a chemical equilibrium of tautomers is reached. The exact ratio of tautomers varies depending on several factors, including temperature, solvent, and pH. The concept of tautomers that can be interconverted by tautomerization is called tautomerism. Of the various types of tautomerism possible, two are commonly observed. Keto-enol tautomerism involves a simultaneous shift of electrons and hydrogen atoms. Ring-chain tautomerism occurs as a result of an aldehyde group (-CHO) in a sugar chain molecule reacting with one of the hydroxyl groups (-OH) in the same molecule, giving it a cyclic (ring-shaped) form, such as that exhibited by glucose.

[0239] It should be understood that the compounds of this disclosure may be represented as different tautomers. If a compound has tautomers, all tautomers are intended to be included within the scope of this disclosure, and the naming of the compounds does not exclude any tautomers. It will be understood that certain tautomers may have higher levels of activity than others.

[0240] It should be understood that any compound of any formula described herein includes the compound itself, and, where applicable, its salts and solvates. Salts can be formed, for example, between an anion and a positively charged group (e.g., amino) on a substituted compound disclosed herein. Suitable anions include chlorides, bromides, iodides, sulfate anions, bisulfate anions, sulfamate anions, nitrate anions, phosphate anions, citrate anions, methanesulfonate anions, trifluoroacetate anions, glutamate anions, glucuronate anions, glutarate anions, malate anions, maleate anions, succinate anions, fumarate anions, tartrate anions, tosylate anions, salicylate anions, lactate anions, naphthalenesulfonate anions, and acetate anions (e.g., trifluoroacetate anion).

[0241] As used herein, the term “pharmaceutically acceptable anion” refers to an anion suitable for forming a pharmaceutically acceptable salt. Similarly, salts may also be formed between a cation and a negatively charged group on a substituted compound disclosed herein (e.g., a carboxylate salt). Suitable cations include sodium, potassium, magnesium, and calcium ions, and ammonium cations such as tetramethylammonium or diethylamine ions. The substituted compounds disclosed herein also include salts containing a quaternary nitrogen atom.

[0242] It should be understood that the compounds of this disclosure, for example, salts of the compounds, may exist in either a hydrated or unhydrated (anhydrous) form, or as solvates with other solvent molecules. Non-limiting examples of hydrates include monohydrates and dihydrates. Non-limiting examples of solvates include ethanol solvate and acetone solvate.

[0243] As used herein, the term “solvate” means a solubilization form containing either a stoichiometric or non-stoichiometric amount of solvent. Some compounds tend to capture solvent molecules in a fixed molar ratio in a crystalline solid state, thereby forming solvates. When the solvent is water, the solvate formed is a hydrate; when the solvent is alcohol, the solvate formed is an alcolate. Hydrates are formed by a combination of one molecule of a substance in which water retains its molecular state as H2O, and one or more water molecules.

[0244] As used herein, the term “analog” refers to a chemical compound that is structurally similar to another but has a slightly different composition (e.g., substitution of one atom with an atom of a different element, or the presence of a particular functional group, or substitution of one functional group with another functional group). Thus, an analog is a compound that is similar or comparable to a reference compound in function and appearance, but not in structural origin.

[0245] As used herein, the term “derivative” refers to a compound having a common core structure and substituted with one of the various groups described herein.

[0246] As used herein, the term “biological equivalent” refers to a compound resulting from the exchange of an atom or group of atoms with another, more generally similar atom or group of atoms. The purpose of biological equivalent substitution is to create a novel compound having similar biological properties to the parent compound. Biological equivalent substitution may be physicochemical or topological. Examples of carboxylic acid biological equivalents include, but are not limited to, acylsulfonamides, tetrazoles, sulfonates, and phosphonates. See, for example, Patani and LaVoie, Chem. Rev. 96, 3147-3176, 1996.

[0247] It should be understood that any particular compound of any of the formulas disclosed herein may exist in non-solvated forms as well as solvated forms, such as hydrated forms. Preferred pharmaceutically acceptable solvates are hydrates, such as hemihydrate, monohydrate, dihydrate, or trihydrate. It should be understood that this disclosure encompasses all such solvated forms having inflammasome inhibitory activity.

[0248] It should be understood that any particular compound of any one of the formulas disclosed herein may exhibit pleomorphism, and that this disclosure encompasses all such forms or mixtures thereof that have inflammasome inhibitory activity. It is generally known that crystalline materials can be analyzed using prior arts such as X-ray powder diffraction, differential scanning calorimetry, thermogravimetric analysis, diffuse reflectance infrared Fourier transform (DRIFT) spectroscopy, near-infrared (NIR) spectroscopy, and solution and / or solid-state nuclear magnetic resonance spectroscopy. The water content of such crystalline materials can be determined by Karl Fischer analysis.

[0249] Any compound of any of the formulas disclosed herein may exist in a number of different tautomers, and any reference to any compound of any of the formulas includes all such forms. To avoid misunderstanding, if a compound may exist in one of several tautomers and only one is specifically described or shown, then nevertheless all the others are encompassed in the formulas disclosed herein. Examples of tautomers include, for example, the keto, enol, and enolate forms in the following tautomer pairs: keto / enol (shown below), imine / enamine, amide / iminoalcohol, amidine / amidine, nitroso / oxime, thioketone / enthiol, and nitro / acinitro. [ka]

[0250] Any compound of any of the formulas disclosed herein that contains an amine functional group may also form an N-oxide. References herein to any compound of any of the formulas containing an amine functional group also include N-oxides. If a compound contains several amine functional groups, one or more nitrogen atoms may be oxidized to form an N-oxide. Specific examples of N-oxides are N-oxides of nitrogen atoms in tertiary amines or nitrogen-containing heterocyclic compounds. N-oxides can be formed by treating the corresponding amine with an oxidizing agent such as hydrogen peroxide or a peracid (e.g., peroxycarboxylic acid), see, for example, Advanced Organic Chemistry, by Jerry March, 4th Edition, Wiley Interscience, pages. More specifically, N-oxides can be prepared by the procedure of LWDeady (Syn.Comm. 1977, 7, 509-514), in which an amine compound is reacted with meta-chloroperoxybenzoic acid (mCPBA) in an inert solvent such as dichloromethane.

[0251] Any compound of any of the formulas disclosed herein may be administered in the form of a prodrug, which is broken down in the body of a human or animal to release the compound disclosed herein. Prodrugs may be used to modify the physical and / or pharmacokinetic properties of the compound disclosed herein. Prodrugs can be formed when the compound disclosed herein contains a suitable group or substituent to which a characterizing group can be attached.

[0252] Accordingly, this disclosure includes any one compound of any of the formulas disclosed herein as defined earlier herein, when made available by organic synthesis and when made available in the body of a human or animal by cleavage of its prodrug. Accordingly, this disclosure also includes any one compound of any of the formulas disclosed herein produced by organic synthesis means and any compound produced in the body of a human or animal by metabolism of a precursor compound, i.e., any one compound of any of the formulas disclosed herein may be a synthetically produced compound or a metabolically produced compound.

[0253] A suitable pharmaceutically acceptable prodrug of any one compound of the formulas disclosed herein is based on reasonable medical judgment that it is free from undesirable pharmacological activity, free from excessive toxicity, and suitable for administration to the human or animal body. Various forms of prodrugs are described in the following literature, for example: a) Methods in Enzymology, Vol. 42, pp. 309-396, edited by K. Widder, et al. (Academic Press, 1985), b) Design of Pro-drugs, edited by H. Bundgaard, (Elsevier, 1985), c) A Textbook of Drug Design and Development, edited by Krogsgaard-Larsen and H. Bundgaard, Chapter 5 "Design and Application of Pro-drugs", by H. Bundgaard, pp. 113-191 (1991), d) H. Bundgaard, Advanced Drug Delivery Reviews, 8, 1-38 (1992), e) H. Bundgaard, et al., Journal of Pharmaceutical Sciences, 77, 285 (1988), f) N. Kakeya, et al. al., Chem. Pharm. Bull., 32, 692 (1984), g) T. Higuchi and V. Stella, "Pro-Drugs as Novel Delivery Systems", ACS Symposium Series, Volume 14, and h) E. Roche (editor), "Bioreversible Carriers in Drug Design", Pergamon Press, 1987.

[0254] The in vivo effect of any one compound of the formulas disclosed herein may be partially exerted by one or more metabolites formed in the human or animal body after administration of any one compound of the formulas disclosed herein. As previously stated, the in vivo effect of any one compound of the formulas disclosed herein may also be exerted by the metabolism of a precursor compound (prodrug).

[0255] Preferably, this disclosure excludes any individual compounds that do not have the biological activity defined herein.

[0256] Scaffolding and conjugate containing linker As used herein, the term “scaffold” refers to a compound or complex comprising the linker of this disclosure, the linker being covalently bound to either a ligand or a nucleic acid agent.

[0257] As used herein, the term “conjugate” refers to a compound or complex comprising a nucleic acid agent covalently bound to a ligand via the linker of this disclosure.

[0258] In some embodiments, the disclosure provides a scaffold or a pharmaceutically acceptable salt thereof, the scaffold being, (i) ligand, and (ii) A linker unit, where the linker unit is [ka] It includes linker units, In the formula, the variable element R 1 , R 2 , R 3 , R 4 , R 5 X, Y, Z, R a , R b n and n are as described herein, and # indicates binding to the ligand.

[0259] In some embodiments, the binding "#" is a direct binding to the ligand, i.e., there is no binding portion whatsoever.

[0260] In some embodiments, the linkage "#" is an indirect linkage to the ligand, i.e., a linkage exists between the linker unit and the ligand. In some embodiments, the linkage is C1~C 15 The alkylene chain may optionally have one or more carbon atoms in the alkylene chain independently replaced by one or more -C(O)-, -C(O)O-, -OC(O)-, -C(O)NH-, -NHC(O)-, -NHC(O)NH-, -C(S)-, -C(S)O-, -OC(S)-, -C(S)NH-, -NHC(S)-, or -NHC(S)NH-, and the alkylene chain may optionally be replaced by one or more groups independently selected from, for example, C1-C6 alkyl, halogen, OH, NH2, C1-C6 alkoxy, CN, and COOH. In some embodiments, the linking portion may have two, three, or more C1-C6 atoms. 15 A branched alkylene chain containing an alkylene chain, wherein one or more carbon atoms in each alkylene chain may optionally be independently replaced with one or more -C(O)-, -C(O)O-, -OC(O)-, -C(O)NH-, -NHC(O)-, -NHC(O)NH-, -C(S)-, -C(S)O-, -OC(S)-, -C(S)NH-, -NHC(S)-, or -NHC(S)NH-, and each alkylene chain may independently be optionally replaced with one or more groups independently selected from, for example, C1-C6 alkyl, halogen, OH, NH2, C1-C6 alkoxy, CN, and COOH. In some embodiments, the linking portion consists of two C1-C 15 It is a branched alkylene chain containing an alkylene chain. In some embodiments, the linking portion consists of three C1-C 15 It is a branched alkylene chain containing alkylene chains. In some embodiments, the linking portion consists of four C1-C 15 This is a branched alkylene chain containing alkylene chains.

[0261] In some embodiments, the disclosure provides a scaffold or a pharmaceutically acceptable salt thereof, the scaffold being, (i) one or more nucleic acid agents, and (ii) One or more linker units, each linker unit independently, [ka] It includes one or more linker units, In the formula, the variable element R 1 , R 2 , R 3 , R 4 , R 5 W, X, Y, Z, R a , R b , and n are as described herein, and ## indicates binding to a nucleic acid agent.

[0262] In some embodiments, the binding "##" is a direct binding to the nucleic acid agent, i.e., there is no binding portion whatsoever.

[0263] In some embodiments, the bond "##" is an indirect bond to the nucleic acid agent, i.e., a linking portion exists between the linker unit and the nucleic acid agent. In some embodiments, the linking portion is a radical formed from one of the groups defined herein for Y or Z. For example, the linking portion is -P(N(CH3)2)(O)-, i.e., a radical formed from -P(N(CH3)2)(OH). In some embodiments, the linking portion is -P(R Y )2, -P(OR Y )(N(R Y )2), -P(=O)(OR Y )R Y , -P(=S)(OR Y )R Y -P(=O)(SR Y )R Y -P(=S)(SR Y )R Y , -P(=O)(OR Y )2, -P(=S)(OR Y )2, -P(=O)(SR Y )2, or -P(=S)(SR Y )2 from either of the above, or -P(R Z )2, -P(OR Z )(N(R Z)2), -P(=O)(OR Z )R Z , -P(=S)(OR Z )R Z -P(=O)(SR Z )R Z -P(=S)(SR Z )R Z , -P(=O)(OR Z )2, -P(=S)(OR Z )2, -P(=O)(SR Z )2, or -P(=S)(SR Z It is a radical formed from either of the following:

[0264] In some embodiments, the scaffold includes double-stranded RNA (e.g., double-stranded siRNA).

[0265] In some embodiments, the scaffold comprises double-stranded RNA (e.g., double-stranded siRNA) and one or more linker units.

[0266] In some embodiments, the scaffold consists of double-stranded RNA (e.g., double-stranded siRNA) and 1-10 linker units (e.g., 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, or 1-3 linker units), 2-10 linker units (e.g., 2-10, 2-9, 2-8, 2-7, 2-6, 2-5, 2-4, or 2-3 linker units), 3-10 linker units (e.g., 3-10, Includes linker units of 3-9, 3-8, 3-7, 3-6, 3-5, or 3 or more), 4-10 linker units (e.g., 4-10, 4-9, 4-8, 4-7, 4-6, or 4-5 linker units), 5-10 linker units (e.g., 5-10, 5-9, 5-8, 5-7, or 5-6 linker units), or 6-10 linker units (e.g., 6-10, 6-9, 6-8, or 6-7 linker units).

[0267] In some embodiments, the scaffold comprises double-stranded RNA (e.g., double-stranded siRNA) and 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 linker units.

[0268] In some embodiments, the scaffold comprises double-stranded RNA (e.g., double-stranded siRNA) and one or more linker units. One or more linker units (e.g., 1-3 linker units) are contiguously or discretely bound to the sense strand (e.g., at the 3' or 5' end) of double-stranded RNA (e.g., double-stranded siRNA). One or more nucleosides or nucleotides at one or more consecutive or discrete internal positions (between the 3' and 5' ends) of the sense strand of double-stranded RNA (e.g., double-stranded siRNA) are replaced by one or more linker units (e.g., 1 to 3 linker units). One or more linker units (e.g., 1 to 3 linker units) are contiguously or discretely bound to the antisense strand (e.g., the 3' or 5' terminal) of double-stranded RNA (e.g., double-stranded siRNA), and / or One or more nucleosides or nucleotides at one or more consecutive or discrete internal positions of the antisense strand are replaced by one or more linker units (e.g., 1 to 3 linker units).

[0269] In some embodiments, the scaffold comprises double-stranded RNA (e.g., double-stranded siRNA) and one or more linker units. One or more linker units (e.g., 1-3 linker units) are contiguously or discretely bound to the sense strand (e.g., at the 3' or 5' end) of double-stranded RNA (e.g., double-stranded siRNA). One or more nucleosides or nucleotides at one or more contiguous or discrete internal positions (between the 3' and 5' ends) of the sense strand of double-stranded RNA (e.g., double-stranded siRNA) are replaced by one or more linker units (e.g., 1 to 3 linker units).

[0270] In some embodiments, the scaffold comprises double-stranded RNA (e.g., double-stranded siRNA) and one or more linker units. One or more linker units (e.g., 1-3 linker units) are contiguously or discretely bound to the antisense strand (e.g., the 3' or 5' terminal) of a double-stranded RNA (e.g., double-stranded siRNA). One or more nucleosides or nucleotides at one or more consecutive or discrete internal positions of the antisense strand are replaced by one or more linker units (e.g., 1 to 3 linker units).

[0271] In some embodiments, one or more linker units (e.g., 1 to 3 linker units) are contiguously or discretely bound to the sense strand (e.g., at the 3' or 5' end) of double-stranded RNA (e.g., double-stranded siRNA).

[0272] In some embodiments, one or more linker units (e.g., 1 to 3 linker units) are contiguously or discretely bound to the sense strand at the 3' end of double-stranded RNA (e.g., double-stranded siRNA).

[0273] In some embodiments, one or more linker units (e.g., 1 to 3 linker units) are contiguously or discretely bound to the sense strand at the 5' end of double-stranded RNA (e.g., double-stranded siRNA).

[0274] In some embodiments, one or more nucleosides or nucleotides at one or more consecutive or discrete internal positions on the sense strand of double-stranded RNA (e.g., double-stranded siRNA) are replaced by one or more linker units (e.g., 1 to 3 linker units).

[0275] In some embodiments, one or more linker units (e.g., 1 to 3 linker units) are contiguously or discretely bound to the antisense strand (e.g., at the 3' or 5' end) of double-stranded RNA (e.g., double-stranded siRNA).

[0276] In some embodiments, one or more linker units (e.g., 1 to 3 linker units) are contiguously or discretely bound to the antisense strand at the 3' end of double-stranded RNA (e.g., double-stranded siRNA).

[0277] In some embodiments, one or more linker units (e.g., 1 to 3 linker units) are contiguously or discretely bound to the antisense strand at the 5' end of double-stranded RNA (e.g., double-stranded siRNA).

[0278] In some embodiments, one or more nucleosides or nucleotides at one or more consecutive or discrete internal positions on the antisense strand of double-stranded RNA (e.g., double-stranded siRNA) are replaced by one or more linker units (e.g., 1 to 3 linker units).

[0279] In some embodiments, the scaffolding is (linker unit) p -((Nucleic acid agent)-(Linker unit) s ) r -(Nucleic acid agent) q And, Each linker unit is independent of other linker units, and each nucleic acid agent is independent of other nucleic acid agents. Each r is an independent integer in the range of 0 to 10. Each s is an independent integer in the range of 0 to 10. p is an integer in the range of 0 to 10. q is either 0 or 1, The scaffold comprises at least one linker unit and at least one nucleic acid agent.

[0280] In some embodiments, the scaffolding is (linker unit) p -((Nucleic acid agent)-(Linker unit) s ) r - (It is a nucleic acid agent.)

[0281] In some embodiments, the scaffolding is (linker unit) p -((Nucleic acid agent)-(Linker unit) s )r That is the case.

[0282] In some embodiments, the scaffolding is (linker unit) p - (It is a nucleic acid agent.)

[0283] In some embodiments, the scaffold is (nucleic acid agent)-(linker unit) s - (It is a nucleic acid agent.)

[0284] In some embodiments, the scaffolding is [ka] or a pharmaceutically acceptable salt thereof, in the formula, Y is -P(R Y )2, -P(OR Y )(N(R Y )2), -P(=O)(OR Y )R Y , -P(=S)(OR Y )R Y -P(=O)(SR Y )R Y -P(=S)(SR Y )R Y , -P(=O)(OR Y )2, -P(=S)(OR Y )2, -P(=O)(SR Y )2, -P(=S)(SR Y )2, or a hydroxy protecting group (e.g., silyl (e.g., trimethylsilyl, triethylsilyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl, or triisopropylsilyl), triphenylmethyl (Tr), 4,4'-dimethoxytrityl (DMTr), substituted acyl (e.g., optionally substituted acetyl), or benzyl), Each R Y These are independently C1-C6 alkyl groups optionally substituted with H or one or more halogens or cyano compounds. Z is -P(R Z )2, -P(OR Z )(N(R Z )2), -P(=O)(OR Z)R Z , -P(=S)(OR Z )R Z -P(=O)(SR Z )R Z -P(=S)(SR Z )R Z , -P(=O)(OR Z )2, -P(=S)(OR Z )2, -P(=O)(SR Z )2, -P(=S)(SR Z )2, or a hydroxy protecting group (e.g., silyl (e.g., trimethylsilyl, triethylsilyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl, or triisopropylsilyl), triphenylmethyl (Tr), 4,4'-dimethoxytrityl (DMTr), substituted acyl (e.g., optionally substituted acetyl), or benzyl), Each R Z These are independently C1-C6 alkyl groups optionally substituted with H or one or more halogens or cyano compounds. n is an integer in the range of approximately 0 to approximately 10.

[0285] In some embodiments, the scaffold is formed by linking linker units based on one of the linker compounds described herein with ligands.

[0286] In some embodiments, the scaffolding is [ka] A linker unit based on one of the linker compounds selected from It is formed by linking with a ligand.

[0287] In some embodiments, the scaffold is formed by linking linker units based on one of the linker compounds selected from Table L to a ligand.

[0288] In some embodiments, the ligand is GalNAc.

[0289] In some embodiments, the scaffolding is selected from the scaffolding listed in Table S1. [Table 2-1] [Table 2-2] [Table 2-3]

[0290] In some embodiments, the scaffolding is [ka] or a pharmaceutically acceptable salt thereof, in the formula, W is an amino substituent (e.g., fluorenylmethyloxycarbonyl (Fmoc), tert-butyloxycarbonyl (BOC), benzyloxycarbonyl (Cbz), optionally substituted acyl, trifluoroacetyl (TFA), benzyl, triphenylmethyl (Tr), 4,4'-dimethoxytrityl (DMTr), or toluenesulfonyl (Ts)), acyl (e.g., -C(=O)(C1~C) 30 Alkyl)), substituted acyl (for example, [ka] ), trifluoroacetyl (TFA), -C(=O)(C1~C 30 Alkyl), -C(=O)NH(C1~C 30 Alkyl), -C(=S)(C1~C 30 Alkyl), or -C(=S)NH(C1~C 30 Alkyl) (wherein C1~C 30 Alkyl is optionally substituted. n is an integer in the range of approximately 0 to approximately 10.

[0291] In some embodiments, the scaffold is formed by linking linker units based on one of the linker compounds described herein with a nucleic acid agent.

[0292] In some embodiments, the scaffolding is [ka] A linker unit based on one of the linker compounds selected from It is formed by binding with nucleic acid agents.

[0293] In some embodiments, the scaffold is formed by linking linker units based on one of the linker compounds selected from Table L with a nucleic acid agent.

[0294] In some embodiments, the scaffolding is selected from the scaffolding listed in Table S2. [Table 3-1] [Table 3-2] [Table 3-3] [Table 3-4] [Table 3-5] [Table 3-6]

[0295] In some embodiments, the Disclosure provides a conjugate or a pharmaceutically acceptable salt thereof, the conjugate is (i) One or more nucleic acid agents, (ii) one or more ligands, and (iii) One or more linker units, each linker unit independently [ka] It includes one or more linker units, In the formula, the variable element R 1 , R 2 , R 3 , R 4 , R 5 X, Y, Z, R a , R b , and n are as described herein, # indicates binding to a ligand, and ## indicates binding to a nucleic acid agent.

[0296] In some embodiments, the binding "#" is a direct binding to the ligand, i.e., there is no binding portion whatsoever.

[0297] In some embodiments, the linkage "#" is an indirect linkage to the ligand, i.e., a linkage exists between the linker unit and the ligand. In some embodiments, the linkage is C1~C 15 The alkylene chain may optionally have one or more carbon atoms in the alkylene chain independently replaced by one or more -C(O)-, -C(O)O-, -OC(O)-, -C(O)NH-, -NHC(O)-, -NHC(O)NH-, -C(S)-, -C(S)O-, -OC(S)-, -C(S)NH-, -NHC(S)-, or -NHC(S)NH-, and the alkylene chain may optionally be replaced by one or more groups independently selected from, for example, C1-C6 alkyl, halogen, OH, NH2, C1-C6 alkoxy, CN, and COOH. In some embodiments, the linking portion may have two, three, or more C1-C6 atoms. 15A branched alkylene chain containing an alkylene chain, wherein one or more carbon atoms in each alkylene chain may optionally be independently replaced with one or more -C(O)-, -C(O)O-, -OC(O)-, -C(O)NH-, -NHC(O)-, -NHC(O)NH-, -C(S)-, -C(S)O-, -OC(S)-, -C(S)NH-, -NHC(S)-, or -NHC(S)NH-, and each alkylene chain may independently be optionally replaced with one or more groups independently selected from, for example, C1-C6 alkyl, halogen, OH, NH2, C1-C6 alkoxy, CN, and COOH. In some embodiments, the linking portion consists of two C1-C 15 It is a branched alkylene chain containing an alkylene chain. In some embodiments, the linking portion consists of three C1-C 15 It is a branched alkylene chain containing alkylene chains. In some embodiments, the linking portion consists of four C1-C 15 This is a branched alkylene chain containing alkylene chains.

[0298] In some embodiments, the binding "##" is a direct binding to the nucleic acid agent, i.e., there is no binding portion whatsoever.

[0299] In some embodiments, the bond "##" is an indirect bond to the nucleic acid agent, i.e., a linking portion exists between the linker unit and the nucleic acid agent. In some embodiments, the linking portion is a radical formed from one of the groups defined herein for Y or Z. For example, the linking portion is -P(N(CH3)2)(O)-, i.e., a radical formed from -P(N(CH3)2)(OH). In some embodiments, the linking portion is -P(R Y )2, -P(OR Y )(N(R Y )2), -P(=O)(OR Y )R Y , -P(=S)(OR Y )R Y -P(=O)(SR Y )R Y -P(=S)(SR Y )R Y , -P(=O)(ORY )2, -P(=S)(OR Y )2, -P(=O)(SR Y )2, or -P(=S)(SR Y )2 from either of the above, or -P(R Z )2, -P(OR Z )(N(R Z )2), -P(=O)(OR Z )R Z , -P(=S)(OR Z )R Z -P(=O)(SR Z )R Z -P(=S)(SR Z )R Z , -P(=O)(OR Z )2, -P(=S)(OR Z )2, -P(=O)(SR Z )2, or -P(=S)(SR Z It is a radical formed from either of the following:

[0300] In some embodiments, the conjugate comprises double-stranded RNA (e.g., double-stranded siRNA), one or more ligands, and one or more linker units.

[0301] In some embodiments, the conjugate is double-stranded RNA (e.g., double-stranded siRNA) and 1-10 linker units (e.g., 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, or 1-3 linker units), 2-10 linker units (e.g., 2-10, 2-9, 2-8, 2-7, 2-6, 2-5, 2-4, or 2-3 linker units), or 3-10 linker units (e.g., 3-1 Includes 0, 3-9, 3-8, 3-7, 3-6, 3-5, or 3-4 linker units), 4-10 linker units (e.g., 4-10, 4-9, 4-8, 4-7, 4-6, or 4-5 linker units), 5-10 linker units (e.g., 5-10, 5-9, 5-8, 5-7, or 5-6 linker units), or 6-10 linker units (e.g., 6-10, 6-9, 6-8, or 6-7 linker units).

[0302] In some embodiments, the conjugate comprises double-stranded RNA (e.g., double-stranded siRNA) and 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 linker units.

[0303] In some embodiments, the conjugate comprises double-stranded RNA (e.g., double-stranded siRNA), one or more ligands, and one or more linker units. One or more linker units (e.g., 1-3 linker units) are contiguously or discretely bound to the sense strand (e.g., at the 3' or 5' end) of double-stranded RNA (e.g., double-stranded siRNA). One or more nucleosides or nucleotides at one or more consecutive or discrete internal positions on the sense strand of double-stranded RNA (e.g., double-stranded siRNA) are replaced by one or more linker units (e.g., 1 to 3 linker units). One or more linker units (e.g., 1 to 3 linker units) are contiguously or discretely bound to the antisense strand (e.g., the 3' or 5' terminal) of double-stranded RNA (e.g., double-stranded siRNA), and / or One or more nucleosides or nucleotides at one or more consecutive or discrete internal positions of the antisense strand are replaced by one or more linker units (e.g., 1 to 3 linker units).

[0304] In some embodiments, the conjugate comprises double-stranded RNA (e.g., double-stranded siRNA), one or more ligands, and one or more linker units. One or more linker units (e.g., 1-3 linker units) are contiguously or discretely bound to the sense strand (e.g., at the 3' or 5' end) of double-stranded RNA (e.g., double-stranded siRNA). One or more nucleosides or nucleotides at one or more consecutive or discrete internal positions on the sense strand of double-stranded RNA (e.g., double-stranded siRNA) are replaced by one or more linker units (e.g., 1 to 3 linker units).

[0305] In some embodiments, the conjugate comprises double-stranded RNA (e.g., double-stranded siRNA), one or more ligands, and one or more linker units. One or more linker units (e.g., 1-3 linker units) are contiguously or discretely bound to the antisense strand (e.g., the 3' or 5' terminal) of a double-stranded RNA (e.g., double-stranded siRNA). One or more nucleosides or nucleotides at one or more consecutive or discrete internal positions of the antisense strand are replaced by one or more linker units (e.g., 1 to 3 linker units).

[0306] In some embodiments, one or more linker units (e.g., 1 to 3 linker units) are contiguously or discretely bound to the sense strand (e.g., at the 3' or 5' end) of double-stranded RNA (e.g., double-stranded siRNA).

[0307] In some embodiments, one or more linker units (e.g., 1 to 3 linker units) are contiguously or discretely bound to the 3' end of the sense strand of double-stranded RNA (e.g., double-stranded siRNA).

[0308] In some embodiments, one or more linker units (e.g., 1 to 3 linker units) are contiguously or discretely bound to the 5' end of the sense strand of double-stranded RNA (e.g., double-stranded siRNA).

[0309] In some embodiments, one or more nucleosides or nucleotides at one or more consecutive or discrete internal positions on the sense strand of double-stranded RNA (e.g., double-stranded siRNA) are replaced by one or more linker units (e.g., 1 to 3 linker units).

[0310] In some embodiments, one or more linker units (e.g., 1 to 3 linker units) are contiguously or discretely bound to the antisense strand (e.g., at the 3' or 5' end) of double-stranded RNA (e.g., double-stranded siRNA).

[0311] In some embodiments, one or more linker units (e.g., 1 to 3 linker units) are contiguously or discretely bound to the antisense strand at the 3' end of double-stranded RNA (e.g., double-stranded siRNA).

[0312] In some embodiments, one or more linker units (e.g., 1 to 3 linker units) are contiguously or discretely bound to the antisense strand at the 5' end of double-stranded RNA (e.g., double-stranded siRNA).

[0313] In some embodiments, one or more nucleosides or nucleotides at one or more consecutive or discrete internal positions on the antisense strand of double-stranded RNA (e.g., double-stranded siRNA) are replaced by one or more linker units (e.g., 1 to 3 linker units).

[0314] In some embodiments, the conjugate is (linker unit - (ligand) 0-1 ) p -((Nucleic acid agent)-(Linker unit-(Ligand) 0-1 ) s ) r -(Nucleic acid agent) q And in the formula, Each linker unit is independent of other linker units, each nucleic acid agent is independent of other nucleic acid agents, and each ligand is independent of other ligands. Each r is an independent integer in the range of 0 to 10. Each s is an independent integer in the range of 0 to 10. p is an integer in the range of 0 to 10. q is either 0 or 1, The conjugate comprises at least one linker unit, at least one nucleic acid agent, and at least one ligand.

[0315] In some embodiments, the conjugate is (linker unit - (ligand) 0-1 ) p -((Nucleic acid agent)-(Linker unit-(Ligand) 0-1 ) s ) r - (It is a nucleic acid agent.)

[0316] In some embodiments, the conjugate is (linker unit - (ligand) 0-1 ) p -((Nucleic acid agent)-(Linker unit-(Ligand) 0-1 ) s ) r That is the case.

[0317] In some embodiments, the conjugate is (linker unit - (ligand) 0-1 ) p - (It is a nucleic acid agent.)

[0318] In some embodiments, the conjugate is (nucleic acid agent)-(linker unit-(ligand) 0-1 ) s - (It is a nucleic acid agent.)

[0319] In some embodiments, the conjugate is selected from the conjugates listed in Table C, the nucleic acid agent is conjugated with ##, where ## is a direct or indirect conjugation as described herein. [Table 4-1] [Table 4-2] [Table 4-3] [Table 4-4] [Table 4-5] [Table 4-6] [Table 4-7] [Table 4-8] [Table 4-9]

[0320] Linker unit As used herein, “linker unit” or “linker unit” refers to the portion of a linker compound in which W, Y, and / or Z are replaced by binding to a ligand and / or nucleic acid agent. In some embodiments, the binding, e.g., # or ## as described herein, is a direct or indirect binding as described herein.

[0321] In some embodiments, the linker unit is of formula (I), where W is replaced by a bond to a ligand. In some embodiments, the bond, e.g., # as described herein, is a direct or indirect bond as described herein.

[0322] In some embodiments, the linker unit is of formula (I), where Y and / or Z are replaced by a bond to a nucleic acid agent. In some embodiments, the bond, e.g., ## as described herein, is a direct or indirect bond as described herein.

[0323] In some embodiments, the linker unit is of formula (I), where, W is replaced by binding to the ligand. Y and / or Z are replaced by binding to a nucleic acid agent.

[0324] In some embodiments, the linker unit is of formula (I'-1), (I'-2), (II'-1), or (II'-2), where W is replaced by binding to a ligand.

[0325] In some embodiments, the linker unit is of formula (I'-1), (I'-2), (II'-1), or (II'-2), where Y and / or Z are replaced by binding to a nucleic acid agent.

[0326] In some embodiments, the linker unit is of formula (IA) or (II-A), where W is replaced by binding to a ligand.

[0327] In some embodiments, the linker unit is of formula (IA) or (II-A), where Y and / or Z are replaced by binding to a nucleic acid agent.

[0328] In some embodiments, the linker unit is of formula (IA) or (II-A), where, W is replaced by binding to the ligand. Y and / or Z are replaced by binding to a nucleic acid agent.

[0329] In some embodiments, the linker unit is of formula (I-A'-1), (I-A'-2), (II-A'-1), or (II-A'-2), where W is replaced by binding to a ligand.

[0330] In some embodiments, the linker unit is of formula (I-A'-1), (I-A'-2), (II-A'-1), or (II-A'-2), where Y and / or Z are replaced by binding to a nucleic acid agent.

[0331] In some embodiments, the linker unit is of formula (I-A'-1), (I-A'-2), (II-A'-1), or (II-A'-2), where, W is replaced by binding to the ligand. Y and / or Z are replaced by binding to a nucleic acid agent.

[0332] In some embodiments, the linker unit is of formula (IB) or (II-B), where W is replaced by binding to a ligand.

[0333] In some embodiments, the linker unit is of formula (IB) or (II-B), where Y and / or Z are replaced by binding to a nucleic acid agent.

[0334] In some embodiments, the linker unit is of formula (IB) or (II-B), where, W is replaced by binding to the ligand. Y and / or Z are replaced by binding to a nucleic acid agent.

[0335] In some embodiments, the linker unit is of formula (I-B'-1), (I-B'-2), (II-B'-1), or (II-B'-2), where W is replaced by binding to a ligand.

[0336] In some embodiments, the linker unit is of formula (I-B'-1), (I-B'-2), (II-B'-1), or (II-B'-2), where Y and / or Z are replaced by binding to a nucleic acid agent.

[0337] In some embodiments, the linker unit is of formula (I-B'-1), (I-B'-2), (II-B'-1), or (II-B'-2), where, W is replaced by binding to the ligand. Y and / or Z are replaced by binding to a nucleic acid agent.

[0338] In some embodiments, the linker unit before bonding is a linker compound described herein.

[0339] In some embodiments, the linker unit before bonding is a compound of formula (I) or a pharmaceutically acceptable salt thereof.

[0340] In some embodiments, the linker unit before bonding is a compound of formula (I'-1), (I'-2), (II'-1), or (II'-2) or a pharmaceutically acceptable salt thereof.

[0341] In some embodiments, the linker unit before bonding is a compound of formula (IA) or (II-A), or a pharmaceutically acceptable salt thereof.

[0342] In some embodiments, the linker unit before bonding is a compound of formula (I-A'-1), (I-A'-2), (II-A'-1), or (II-A'-2), or a pharmaceutically acceptable salt thereof.

[0343] In some embodiments, the linker unit before bonding is a compound of formula (IB) or (II-B), or a pharmaceutically acceptable salt thereof.

[0344] In some embodiments, the linker unit before bonding is a compound of formula (I-B'-1), (I-B'-2), (II-B'-1), or (II-B'-2), or a pharmaceutically acceptable salt thereof.

[0345] In some embodiments, the linker unit before bonding is a compound selected from the compounds listed in Table L and a pharmaceutically acceptable salt thereof.

[0346] In any of the embodiments described above, the combination, for example, # or ## as described herein, is a direct or indirect combination as described herein.

[0347] Ligand As used herein, the term “ligand” refers to a portion of a nucleic acid agent (e.g., an oligonucleotide) that, when covalently bound to it, can mediate its entry into a target site (e.g., a target cell or tissue) or facilitate its delivery to a target site. A ligand or ligand, together with a linker unit, may form a scaffold as described herein, or one or more ligands or ligands, together with one or more linker units and one or more nucleic acid agents, may form a conjugate as described herein.

[0348] In some embodiments, the ligand includes a glycoligand moiety (e.g., N-acetylgalactosamine (GalNAc)) that can direct the uptake of the oligonucleotide into the liver.

[0349] In some embodiments, the ligand binds to the asialoclycoprotein receptor (ASGPR). In some embodiments, the ligand binds to the liver (e.g., via ASGPR), such as to parenchymal cells of the liver.

[0350] Suitable ligands include, but are not limited to, those disclosed in Winkler (Ther. Deliv., 2013, 4(7):791-809), International Publication Nos. 2016 / 100401, 2012 / 089352, and 2009 / 082607, and U.S. Patent Application Publications Nos. 2009 / 0239814, 2012 / 0136042, 2013 / 0158824, and 2009 / 0247608 (each of which is incorporated by reference).

[0351] In some embodiments, the ligand includes a carbohydrate moiety.

[0352] As used herein, “carbohydrate portion” refers to a portion comprising one or more monosaccharide units, each having at least six carbon atoms (which may be linear, branched, or cyclic) and each carbon atom bonded to an oxygen, nitrogen, or sulfur atom. In some embodiments, the carbohydrate portion comprises monosaccharides, disaccharides, trisaccharides, or tetrasaccharides. In some embodiments, the carbohydrate portion comprises oligosaccharides containing about 4 to 9 monosaccharide units. In some embodiments, the carbohydrate portion comprises polysaccharides (e.g., starch, glycogen, cellulose, or polysaccharide gums).

[0353] In some embodiments, the carbohydrate portion includes monosaccharides, disaccharides, trisaccharides, or tetrasaccharides.

[0354] In some embodiments, the carbohydrate portion includes oligosaccharides (for example, containing about 4 to 9 monosaccharide units).

[0355] In some embodiments, the carbohydrate portion includes polysaccharides (e.g., starch, glycogen, cellulose, or polysaccharide gum).

[0356] In some embodiments, the ligand can bind to a human asialoglycoprotein receptor (ASGPR), for example, human asialoglycoprotein receptor 2 (ASGPR2).

[0357] In some embodiments, the carbohydrate portion includes sugars (e.g., 1, 2, or 3 sugars).

[0358] In some embodiments, the carbohydrate portion comprises galactose or its derivatives (e.g., 1, 2, or 3 galactoses or their derivatives).

[0359] In some embodiments, the carbohydrate portion comprises N-acetylgalactosamine or a derivative thereof (e.g., 1, 2, or 3 N-acetylgalactosamines or derivatives thereof).

[0360] In some embodiments, the carbohydrate portion comprises N-acetyl-D-galactosylamine or a derivative thereof (e.g., 1, 2, or 3 N-acetyl-D-galactosylamines or derivatives thereof).

[0361] In some embodiments, the carbohydrate portion comprises N-acetylgalactosamine (e.g., 1, 2, or 3 N-acetylgalactosamines).

[0362] In some embodiments, the carbohydrate portion comprises N-acetyl-D-galactosylamine (e.g., 1, 2, or 3 N-acetyl-D-galactosylamines).

[0363] In some embodiments, the carbohydrate portion comprises mannose or a derivative thereof (e.g., mannose-6-phosphate).

[0364] In some embodiments, the carbohydrate portion further includes a linking portion that connects one or more sugars (e.g., N-acetyl-D-galactosylamine) to a linker unit.

[0365] In some embodiments, the linking portion includes a thioether (e.g., thiosuccinimide or its hydrolysis analog), a disulfide, a triazole, a phosphorothioate, a phosphodiester, an ester, an amide, or any combination thereof.

[0366] In some embodiments, the connecting portion is a trivalent connecting portion.

[0367] Suitable ligands include, but are not limited to, those disclosed in International Publication Nos. 2015 / 006740, 2016 / 100401, 2017 / 214112, 2018 / 039364, and 2018 / 045317 (each of which is incorporated herein by reference in its entirety).

[0368] In some embodiments, the ligand is [ka] (For example, 1, 2, or 3 [ka] ) includes.

[0369] In some embodiments, the ligand is [ka] (For example, 1, 2, or 3 [ka] ) includes.

[0370] In some embodiments, the ligand is [ka] (For example, 1, 2, or 3 [ka] ) includes.

[0371] In some embodiments, the ligand is [ka] (For example, 1, 2, or 3 [ka] ) includes.

[0372] In some embodiments, the ligand is [ka] (For example, 1, 2, or 3 [ka] ) includes.

[0373] In some embodiments, the ligand is [ka] (For example, 1, 2, or 3 [ka] ) includes.

[0374] In some embodiments, the ligand is [ka] (For example, 1, 2, or 3 [ka] ) includes.

[0375] In some embodiments, the ligand is [ka] (For example, 1, 2, or 3 [ka] ) includes.

[0376] In some embodiments, the ligand is [ka] Includes.

[0377] In some embodiments, the ligand is [ka] Includes.

[0378] In some embodiments, the ligand is [ka] Includes.

[0379] In some embodiments, the ligand is [ka] Includes.

[0380] In some embodiments, the ligand is [ka] Includes.

[0381] In some embodiments, the ligand is [ka] Includes.

[0382] In some embodiments, the ligand is [ka] Includes.

[0383] In some embodiments, the ligand is [ka] Includes.

[0384] In some embodiments, the ligand includes a lipid moiety (e.g., one, two, or three lipid moieties).

[0385] In some embodiments, the lipid portion is (e.g., one, two, three) C8-C 24 It contains fatty acids, cholesterol, vitamins, sterols, phospholipids, or any combination thereof.

[0386] In some embodiments, the ligand includes a peptide moiety (e.g., one, two, or three peptide moieties).

[0387] In some embodiments, the peptide moiety comprises (e.g., one, two, or three) integrins, insulin, glucagon-like peptides, or any combination thereof.

[0388] In some embodiments, the ligand includes an antibody moiety (e.g., transferrin).

[0389] In some embodiments, the ligand comprises one, two, or three antibody moieties (e.g., transferrin).

[0390] In some embodiments, the ligand includes an oligonucleotide (e.g., an aptamer or CpG).

[0391] In some embodiments, the ligand comprises one, two, or three oligonucleotides (e.g., aptamers or CpGs).

[0392] In some embodiments, the ligand is One, two, or three sugars (for example, N-acetyl-D-galactosylamine), One, two, or three lipid parts, One, two, or three peptide moieties, One, two, or three antibody moieties, One, two, or three oligonucleotides, or This includes any combination of those.

[0393] Nucleic acid agents In some embodiments, the nucleic acid agent includes an oligonucleotide.

[0394] In some embodiments, the nucleic acid agent (e.g., an oligonucleotide) comprises one or more phosphate groups or one or more analogues of a phosphate group.

[0395] In some embodiments, the linker unit is bonded to the nucleic acid agent (e.g., an oligonucleotide) via a phosphate group or a phosphate group analogue in the nucleic acid agent.

[0396] In some embodiments, the oligonucleotide has a length of 1 to 40 nucleotides, 10 to 40 nucleotides, 12 to 35 nucleotides, 15 to 30 nucleotides, 18 to 25 nucleotides, or 20 to 23 nucleotides. In some embodiments, the oligonucleotide has a length of 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides. In some embodiments, the oligonucleotide has a length of 19, 20, 21, 22, or 23 nucleotides.

[0397] In some embodiments, the nucleic acid agent includes RNA, DNA, or a mixture thereof.

[0398] In some embodiments, the nucleic acid agent includes RNA.

[0399] In some embodiments, the oligonucleotide is siRNA (e.g., single-stranded siRNA (e.g., hairpin single-stranded siRNA) or double-stranded siRNA), microRNA, anti-microRNA, microRNA mimetic, anti-miR, antagomir, dsRNA, ssRNA, aptamer, immunostimulatory oligonucleotide, decoy oligonucleotide, splice-modified oligonucleotide, triple-helix-forming oligonucleotide, G-quadrivalent, or antisense oligonucleotide.

[0400] In some embodiments, the nucleic acid agent comprises double-stranded RNA (dsRNA), which includes a sense strand and an antisense strand, as described herein.

[0401] In some embodiments, the nucleic acid agent comprises a double-stranded siRNA (ds-siRNA), which comprises a sense strand and an antisense strand as described herein.

[0402] The sense chain is also known as the passenger chain, and the terms "sense chain" and "passenger chain" are understood to be used interchangeably in this specification.

[0403] The antisense chain is also known as the guide chain, and it is understood that the terms “antisense chain” and “guide chain” are used interchangeably herein.

[0404] In some embodiments, the oligonucleotide is an iRNA.

[0405] The term "iRNA" refers to an RNA agent capable of downregulating the expression of a target gene (e.g., siRNA), such as endogenous or pathogen-targeting RNA. While not theoretically bound, iRNAs may act through one or more mechanisms, including post-transcriptional cleavage of target mRNA (referred to as RNAi in this field), or pre-transcriptional or pre-translational mechanisms. iRNAs may be single-stranded or consist of two or more strands, for example, a double-stranded iRNA. If an iRNA is single-stranded, it may include 5' modifications containing one or more phosphate groups or one or more analogs of phosphate groups. In some embodiments, iRNAs are double-stranded. In some embodiments, one or both strands of a double-stranded iRNA may be modified, for example, 5' modified.

[0406] The iRNA typically contains a region of sufficient homology to the target gene and is of sufficient length with respect to nucleotides, so that the iRNA or a fragment thereof can mediate the downregulation of the target gene. The iRNA is a region that is at least partially, and in some embodiments, fully complementary to, the target RNA, or contains such a region. While complete complementarity between the iRNA and the target is not necessarily required, the correspondence may be sufficient to allow the iRNA or its cleavage product to direct sequence-specific silencing, for example, by RNAi cleavage of the target RNA, e.g., mRNA.

[0407] Nucleotides in iRNA can be modified (for example, one or more nucleotides may contain a 2'-F or 2'-OCH3 group, or may be nucleotide substitutes). Single-stranded or double-stranded regions of iRNA may be modified or contain nucleotide substitutes, for example, unpaired regions of hairpin structures, e.g., regions linking two complementary regions, may have modifications or nucleotide substitutes. For example, modifications to stabilize one or more 3' or 5' ends of iRNA with respect to exonucleases. Modifications may include C3 (or C6, C7, C12) aminolinkers, thiol linkers, carboxyl linkers, non-nucleotide spacers (C3, C6, C9, C12, debase, triethylene glycol, hexaethylene glycol), phosphoramidites, and certain biotin or fluorescein reagents having other DMT-protected hydroxyl groups, enabling multiple couplings during RNA synthesis. Modifications may also include, for example, the use of modifications at the 2'OH group of ribose sugar, such as the use of deoxyribonucleotides instead of ribonucleotides, such as deoxythymidine, and modifications at the phosphate group, such as phosphothioate modifications. In some embodiments, different chains may contain different modifications.

[0408] In some embodiments, the strands are selected such that the iRNA contains single-stranded or unpaired regions at one or both ends of the molecule. Double-stranded iRNA may have overhangs, e.g., one or two 5' or 3' overhangs (e.g., at least 3' overhangs of 2-3 nucleotides). In some embodiments, the iRNA has overhangs of 1, 2, or 3 nucleotides in length at each end, e.g., 3' overhangs. The overhangs may result in one strand being longer than the other, or in two strands of equal length being staggered.

[0409] In some embodiments, the length of the double-stranded region between iRNA strands is 6 to 30 nucleotides. In some embodiments, the double-stranded region is 15 to 30 nucleotides long, most preferably 18, 19, 20, 21, 22, and 23 nucleotides. In some embodiments, the double-stranded region is 6 to 20 nucleotides long, most preferably 6, 7, 8, 9, 10, 11, and 12 nucleotides.

[0410] Oligonucleotides may be those described in U.S. Patent Publication Nos. 2009 / 0239814, 2012 / 0136042, 2013 / 0158824, or 2009 / 0247608, each of which is incorporated herein by reference.

[0411] In some embodiments, the oligonucleotide is siRNA.

[0412] In some embodiments, the oligonucleotide is a single-stranded siRNA.

[0413] In some embodiments, the oligonucleotide is a double-stranded siRNA, for example, the double-stranded siRNA described herein.

[0414] As used herein, "single-stranded siRNA" refers to siRNA composed of a single strand, including a double-stranded region formed by intra-strand pairing, which may, for example, have a hairpin or panhandle structure, or may include such a structure. Single-stranded siRNA may be antisense with respect to a target molecule.

[0415] The single-stranded siRNA may be long enough to enter RISC and participate in RISC-mediated cleavage of target mRNA. The single-stranded siRNA is at least 14 nucleotides long, and in some embodiments, at least 15, 20, 25, 29, 35, 40, or 50 nucleotides long. In some embodiments, the single-stranded siRNA is 200, 100, 80, 60, 50, 40, or 30 nucleotides long.

[0416] In some embodiments, the single-stranded siRNA has a length of 10–40 nucleotides, 12–35 nucleotides, 15–30 nucleotides, 18–25 nucleotides, or 20–23 nucleotides. In some embodiments, the single-stranded siRNA has a length of 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides. In some embodiments, the single-stranded siRNA has a length of 20, 21, 22, or 23 nucleotides.

[0417] A hairpin siRNA may have a double-stranded region corresponding to 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotide pairs, or a double-stranded region of at least 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotide pairs. The double-stranded region may be 200, 100, or 50 nucleotide pairs or less in length. In some embodiments, the range for the double-stranded region is 15-30, 17-23, 19-23, and 19-21 nucleotide pairs in length. The hairpin may have a single-stranded overhang or an unpaired terminal region. In some embodiments, the oligonucleotide is 2-3 nucleotides in length. In some embodiments, the overhang is on the sense side of the hairpin, and in some embodiments, it is on the antisense side of the hairpin.

[0418] In some embodiments, the oligonucleotide is a double-stranded siRNA.

[0419] As used herein, "double-stranded siRNA" refers to siRNA comprising two or more strands, possibly two strands, in which interstrand hybridization can form a region of double-stranded structure.

[0420] In some embodiments, the sense strand of a double-stranded siRNA may be 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 29, 40, or 60 nucleotides long, or at least that length. The sense strand of a double-stranded siRNA may be 200, 100, or 50 nucleotides or less long. The range may be 17-25, 19-23, 19-21, 21-23, or 20-22 nucleotides long.

[0421] In some embodiments, the sense strand has a length of 10–40 nucleotides, 12–35 nucleotides, 15–30 nucleotides, 18–25 nucleotides, or 20–23 nucleotides. In some embodiments, the sense strand has a length of 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides. In some embodiments, the sense strand has a length of 20, 21, 22, or 23 nucleotides.

[0422] In some embodiments, the sense strand has a length of 18, 19, 20, 21, or 22 nucleotides.

[0423] In some embodiments, the antisense strand of a double-stranded siRNA may be 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 29, 40, or 60 nucleotides long, or at least that length. The antisense strand of a double-stranded siRNA may be 200, 100, or 50 nucleotides or less long. The range may be 17-25, 19-23, 19-21, 21-23, or 20-22 nucleotides long.

[0424] In some embodiments, the antisense chain has a length of 10–40 nucleotides, 12–35 nucleotides, 15–30 nucleotides, 18–25 nucleotides, or 20–23 nucleotides. In some embodiments, the antisense chain has a length of 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides. In some embodiments, the antisense chain has a length of 20, 21, 22, or 23 nucleotides.

[0425] In some embodiments, the antisense chain has a length of 20, 21, 22, 23, or 24 nucleotides.

[0426] In some embodiments, the sense strand has a length of 18, 19, 20, 21, or 22 nucleotides, and the antisense strand has a length of 20, 21, 22, 23, or 24 nucleotides.

[0427] In some embodiments, the sense strand has a length of 18 nucleotides, and the antisense strand has a length of 20 nucleotides.

[0428] In some embodiments, the sense strand has a length of 19 nucleotides, and the antisense strand has a length of 21 nucleotides.

[0429] In some embodiments, the sense strand has a length of 20 nucleotides, and the antisense strand has a length of 22 nucleotides.

[0430] In some embodiments, the sense strand has a length of 21 nucleotides, and the antisense strand has a length of 23 nucleotides.

[0431] In some embodiments, the sense strand has a length of 22 nucleotides, and the antisense strand has a length of 24 nucleotides.

[0432] The double-stranded portion of a double-stranded siRNA may be, or may be, at least 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 29, 40, or 60 nucleotide pairs long. It may be 200, 100, or 50 nucleotide pairs or less long. The range may be 15-30, 17-23, 19-23, and 19-21 nucleotide pairs long.

[0433] In some embodiments, the siRNA is large enough to be cleaved by endogenous molecules, for example by a dicer, to produce smaller siRNAs, such as siRNA agents.

[0434] The sense and antisense strands can be selected such that the double-stranded siRNA contains single-stranded or unpaired regions at one or both ends of the molecule. Thus, the double-stranded siRNA may contain sense and antisense strands paired to include overhangs, e.g., one or two 5' or 3' overhangs, or a 3' overhang of 1-3 nucleotides. The overhangs may result from one strand being longer than the other, or from two strands of equal length being staggered. Some embodiments have at least one 3' overhang. In some embodiments, both ends of the siRNA molecule have 3' overhangs. In some embodiments, the overhang is 2 nucleotides.

[0435] In some embodiments, the length of the double-stranded region is 15–30, or 18, 19, 20, 21, 22, and 23 nucleotides, e.g., the ssiRNA range described above. The ssiRNA may be similar in length and structure to natural dicer-treated products from longer dsiRNAs. Embodiments in which the two strands of the ssiRNA are joined, e.g., covalently, are also included. Hairpin or other single-stranded structures that provide the required double-stranded region and 3' overhang are also intended.

[0436] The siRNAs described herein, including double-stranded and single-stranded siRNAs, can mediate the silencing of target RNA, such as mRNA, or transcripts of protein-coding genes. For convenience, such mRNA is also referred herein as mRNA to be silenced. Such genes are also referred to as target genes. Generally, RNA to be silenced is endogenous or pathogenic. Furthermore, RNA other than mRNA, such as tRNA and viral RNA, can also be targeted.

[0437] As used herein, the phrase "mediated by RNAi" refers to the ability to silence target RNA in a sequence-specific manner. While not theoretically bound, silencing is thought to involve an RNAi mechanism or process and guide RNA, such as a 21-23 nucleotide ssiRNA.

[0438] In some embodiments, the siRNA is "sufficiently complementary" to the target RNA, e.g., the target mRNA, so that the siRNA silences the production of the protein encoded by the target mRNA. In other embodiments, the siRNA is "exactly complementary" to the target RNA, e.g., the target RNA and the siRNA anneal to form a hybrid made up of only Watson-Crick base pairs in the exact complementary region. A "sufficiently complementary" target RNA may contain an internal region (e.g., at least 10 nucleotides) that is exactly complementary to the target RNA. Furthermore, in some embodiments, the siRNA specifically recognizes a single nucleotide difference. In this case, the siRNA mediates RNAi only when exact complementarity is found in the region of the single nucleotide difference (e.g., within 7 nucleotides).

[0439] MicroRNAs: MicroRNAs (miRNAs) are a type of highly conserved low RNA molecule that is transcribed from DNA in plant and animal genomes but is not translated into proteins. Treated miRNAs are single-stranded, approximately 17-25 nucleotide (nt)RNA molecules that are incorporated into the RNA-induced silencing complex (RISC) and have been identified as important regulators of development, cell proliferation, apoptosis, and differentiation. They are thought to play a role in regulating gene expression by binding to the 3'-untranslated region of specific mRNAs. RISCs mediate downregulation of gene expression through translation inhibition, transcription cleavage, or both. RISCs are also involved in transcriptional silencing in the nuclei of a wide range of eukaryotes.

[0440] The number of miRNA sequences identified to date is large and continues to grow. Examples can be found, for instance, in "miRBase: microRNA sequences, targets and gene nomenclature" Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright A J. NAR, 2006, 34, Database Issue, D140-D144; and "The microRNA Registry" Griffiths-Jones S. NAR, 2004, 32, Database Issue, D109-D111.

[0441] Antisense Oligonucleotides: In some embodiments, the nucleic acid is an antisense oligonucleotide directed to a target polynucleotide. The term “antisense oligonucleotide” or simply “antisense” means that it includes an oligonucleotide that is complementary to a target polynucleotide sequence. An antisense oligonucleotide is a single strand of DNA or RNA that is complementary to a selected sequence, e.g., a target gene mRNA. Antisense oligonucleotides are thought to inhibit gene expression by binding to complementary mRNA. Binding to the target mRNA can result in inhibition of gene expression by interfering with the translation of the complementary mRNA strand by binding to it, or by causing degradation of the target mRNA. Antisense DNA can be used to target specific complementary (coding or non-coding) RNA. If binding occurs, this DNA / RNA hybrid can be degraded by the enzyme RNase H. In some embodiments, the antisense oligonucleotide contains about 10 to about 50 nucleotides, more preferably about 15 to about 30 nucleotides. The term also includes antisense oligonucleotides that do not have to be exactly complementary to the desired target gene. Therefore, the intention is to consider cases where non-target-specific activity is found in the antisense, or where an antisense sequence containing one or more mismatches with the target sequence is most preferred for a particular use.

[0442] Antisense oligonucleotides have been demonstrated to be effective targeted inhibitors of protein synthesis and can therefore be used to specifically inhibit protein synthesis by target genes. The effectiveness of antisense oligonucleotides for inhibiting protein synthesis is well established. For example, the synthesis of polygalacturonase and muscarinic acetylcholine receptor type 2 is inhibited by antisense oligonucleotides directed to their respective mRNA sequences (U.S. Patents 5,739,119 and 5,759,829, each incorporated by reference). Furthermore, examples of antisense inhibition have been demonstrated for nucleoprotein cyclins, multidrug resistance genes (MDG1), ICAM-1, E-selectin, STK-1, striatal GABAA receptors, and human EGF (Jaskulski et al., Science. 1988 Jun. 10; 240(4858): 1544-6; Vasanthakumar and Ahmed, Cancer Commun. 1989; 1(4): 225-32; Peris et al., Brain Res Mol Brain Res. 1998 Jun. 15; 57(2): 310-20; U.S. Patents No. 5,801,154, 5,789,573, 5,718,709, and 5,610,288 (each of which is incorporated by reference)). Furthermore, antisense constructs that can be used to inhibit and treat various abnormal cell proliferations (e.g., cancer) are also described (U.S. Patents No. 5,747,470, No. 5,591,317, and No. 5,783,683, each incorporated by reference).

[0443] Methods for producing antisense oligonucleotides are known in the art and can be readily adapted to produce antisense oligonucleotides targeting any polynucleotide sequence. Selection of antisense oligonucleotide sequences specific to a given target sequence is based on analysis of the selected target sequence and determination of its secondary structure, Tm, binding energy, and relative stability. Antisense oligonucleotides may be selected based on their relative inability to form dimers, hairpins, or other secondary structures that reduce or hinder specific binding to the target mRNA in host cells. Highly preferred target regions of mRNA include the AUG translation start codon or its vicinity, and sequences substantially complementary to the 5' region of the mRNA. These secondary structure analyses and considerations for target site selection can be performed, for example, using OLIGO primer analysis software v.4 (Molecular Biology Insights) and / or BLASTN 2.0.5 algorithm software (Altschul et al., Nucleic Acids Res. 1997, 25(17):3389-402).

[0444] Antagomil: Antagomil is an RNA-like oligonucleotide with various modifications for pharmacological properties such as RNase protection and enhanced tissue and cellular uptake. Antagomil differs from normal RNA, for example, in complete 2'-O-methylation of sugars, a phosphorothioate backbone, and a cholesterol moiety at the 3' terminus. Antagomil can be used to efficiently silence endogenous miRNA by forming a double helix containing the antagomil and endogenous miRNA, thereby preventing miRNA-induced gene silencing. An example of antagomil-mediated miRNA silencing is the silencing of miR-122 described in Krutzfeldt et al., Nature, 2005, 438:685-689, which is expressly incorporated herein in its entirety by reference. Antagomil RNA can be synthesized using standard solid-phase oligonucleotide synthesis protocols. See U.S. Patent Application Publications 2007 / 0123482 and 2007 / 0213292 (each incorporated herein by reference).

[0445] Antagomils may comprise ligand-conjugate monomer subunits and monomers for oligonucleotide synthesis. Exemplary monomers are described in U.S. Patent Application Publication 2005 / 0107325, which is incorporated in whole by reference. Antagomils may have a ZXY structure, such as those described in International Publication 2004 / 080406 (which is incorporated in whole by reference). Antagomils can be compounded with amphiphilic moieties. Exemplary amphiphilic moieties for use in oligonucleotide agents are described in International Publication 2004 / 080406, which is incorporated in whole by reference.

[0446] Aptamers: Aptamers are nucleic acid or peptide molecules that bind to specific molecules of interest with high affinity and specificity (Tuerk and Gold, Science 249:505 (1990); Ellington and Szostak, Nature 346:818 (1990), each of which is incorporated in its entirety by reference). We have succeeded in producing DNA or RNA aptamers that bind to many different entities, from large proteins to small organic molecules. See Eaton, Curr. Opin. Chem. Biol. 1:10-16 (1997), Famulok, Curr. Opin. Struct., J. Biol. 9:324-9 (1999), and Hermann and Patel, Science 287:820-5 (2000) (each of which is incorporated in its entirety by reference). Aptamers may be RNA or DNA-based and may contain a riboswitch. A riboswitch is a part of an mRNA molecule that can directly bind to a small target molecule, and the binding of that target affects the activity of the gene. Therefore, mRNA containing a riboswitch is directly involved in the regulation of its own activity depending on the presence or absence of its target molecule. Generally, aptamers are manipulated through repeated in vitro selection or equivalently through SELEX (phylogenetic evolution of ligands by exponential enrichment) to bind to a variety of molecular targets, including small molecules, proteins, nucleic acids, and even cells, tissues, and organisms. Aptamers can be prepared by any known method, including synthesis, recombination, and purification, and can be used alone or in combination with other aptamers specific to the same target. Furthermore, as will be more fully described herein, the term “aptamer” specifically includes “secondary aptamers” containing a consensus sequence derived from comparing two or more known aptamers with a given target.

[0447] Ribozymes: In another embodiment, nucleic acid-lipid particles associate with ribozymes. Ribozymes are RNA molecular complexes having a specific catalytic domain with endonuclease activity (Kim and Cech, Proc Natl Acad Sci USA. 1987 December; 84(24): 8788-92; Forster and Symons, Cell. 1987 Apr. 24; 49(2): 211-20). For example, many ribozymes accelerate phosphoesterification reactions with a high degree of specificity, often cleaving only one of several phosphoesters in an oligonucleotide substrate (Cech et al., Cell. 1981 December; 27(3 Pt 2): 487-96; Michel and Westhof, J Mol Biol. 1990 Dec. 5; 216(3): 585-610; Reinhold-Hurek and Shub, Nature. 1992 May 14; 357(6374): 173-6). This specificity stems from the requirement that the substrate binds to the internal guide sequence ("IGS") of the ribozyme via specific base-pairing interactions before the chemical reaction.

[0448] At least six basic types of naturally occurring enzymatic RNAs are currently known. Each can catalyze the hydrolysis of RNA phosphodiester bonds during transit under physiological conditions (and thus can cleave other RNA molecules). Generally, enzymatic nucleic acids act by first binding to a target RNA. Such binding occurs via a target-binding portion of the enzymatic nucleic acid, which is held in close contact with the enzymatic portion of the molecule that acts to cleave the target RNA. Thus, an enzymatic nucleic acid first recognizes the target RNA, then binds to the target RNA via complementary base pairing, and once bound to the correct site, acts enzymatically to cleave the target RNA. Such strategic cleavage of a target RNA disrupts its ability to be directed toward the synthesis of the encoded protein. After binding to and cleaving its RNA target, an enzymatic nucleic acid can be released from its RNA to search for another target and can repeatedly bind to and cleave a new target.

[0449] Enzymatic nucleic acid molecules can be formed, for example, in hammerhead, hairpin, δ-type hepatitis virus, group I introns, or RNaseP RNA (associated with an RNA guide sequence) or Neurospora VS RNA motifs. Specific examples of hammerhead motifs are described in Rossi et al. Nucleic Acids Res. 1992 Sep. 11; 20(17): 4559-65. Examples of hairpin motifs are described in Hampel et al. (European Patent Publication No. 0360257), Hampel and Tritz, Biochemistry 1989 Jun. 13; 28(12): 4929-33, Hampel et al., Nucleic Acids Res. 1990 Jan. 25; 18(2): 299-304, and U.S. Patent No. 5,631,359. Examples of δ hepatitis virus motifs are described in Perrotta and Been, Biochemistry. 1992 Dec. 1;31(47):11843-52, examples of RNaseP motifs are described in Guerrier-Takada et al., Cell. 1983 December;35(3 Pt 2):849-57, Neurospora VS RNA ribozyme motifs are described in Collins (Saville and Collins, Cell. 1990 May 18;61(4):685-96; Saville and Collins, Proc Natl Acad Sci USA. 1991 Oct. 1;88(19):8826-30; Collins and Olive, Biochemistry. 1993 Mar. 23;32(11):2795-9), and examples of group I introns are described in U.S. Patent No. 4,987,071. A key characteristic of the enzymatic nucleic acid molecules used is that they possess a specific substrate-binding site complementary to one or more target gene DNA or RNA regions, and that they have a nucleotide sequence within or around the substrate-binding site that confers RNA cleavage activity to the molecule. Therefore, ribozyme constructs do not need to be limited to the specific motifs mentioned herein.

[0450] Methods for producing ribozymes targeting any polynucleotide sequence are known in the art. Ribozymes can be designed as described in International Publication No. 93 / 23569 and International Publication No. 94 / 02595 (each specifically incorporated herein by reference), and can be synthesized to be tested in vitro and in vivo, as described therein.

[0451] Ribozyme activity can be optimized by altering the length of the ribozyme-binding arms, or by chemically synthesizing ribozymes with modifications that prevent their degradation by serum ribonucleases (see, for example, International Publications 92 / 07065, 93 / 15187, and 91 / 03162, European Patent Application No. 92110298.4, U.S. Patent No. 5334711, and International Publication 94 / 13688 (these describe various chemical modifications that can be added to the sugar portion of enzymatic RNA molecules)), modifications that enhance intracellular efficacy, and removal of stem II bases to shorten RNA synthesis time and reduce the amount of chemicals required.

[0452] Immunostimulatory oligonucleotides: Nucleic acids associated with lipid particles may be immunostimulatory, such as immunostimulatory oligonucleotides (ISSs, single-stranded or double-stranded), which can induce an immune response when administered to mammals or other potentially patient subjects. ISSs include, for example, specific palindromes resulting in hairpin secondary structures (see Yamamoto S., et al. (1992) J.Immunol. 148:4072-4076 (the whole is incorporated by reference)), or CpG motifs, as well as other known ISS features (e.g., multi-G domains, see International Publication No. 96 / 11266 (the whole is incorporated by reference)).

[0453] The immune response can be an innate immune response or an adaptive immune response. The immune system is divided into the more innate immune system and the acquired adaptive immune system in vertebrates, and the acquired adaptive immune system is further divided into humoral cellular components. In some embodiments, the immune response can be mucosal.

[0454] In some embodiments, immunostimulant nucleic acids are immunostimulant only when administered in combination with lipid particles, and not when administered in their "free form." Such oligonucleotides are considered immunostimulant.

[0455] Immunostimulating nucleic acids are considered non-sequence-specific if it is not required that they specifically bind to a target polynucleotide to induce an immune response and reduce its expression. Therefore, certain immunostimulating nucleic acids may contain sequences corresponding to naturally occurring gene or mRNA regions, but they can still be considered non-sequence-specific immunostimulating nucleic acids.

[0456] In some embodiments, the immunostimulatory nucleic acid or oligonucleotide comprises at least one CpG dinucleotide. The oligonucleotide or CpG dinucleotide may be methylated or unmethylated. In another embodiment, the immunostimulatory nucleic acid comprises at least one CpG dinucleotide having methylated cytosine. In some embodiments, the nucleic acid comprises a single CpG dinucleotide, the cytosine in the CpG dinucleotide is methylated. In another embodiment, the nucleic acid comprises at least two CpG dinucleotides, the cytosine in at least one of the CpG dinucleotides is methylated. In a further embodiment, each cytosine in the CpG dinucleotide present in the sequence is methylated. In another embodiment, the nucleic acid comprises multiple CpG dinucleotides, at least one of which contains methylated cytosine.

[0457] Binding between linker units, nucleic acid agents, and ligands. In some embodiments, the binding between the linker unit and the nucleic acid agent is a bond.

[0458] In some embodiments, the bond between the linker unit and the nucleic acid agent is a portion (e.g., a portion containing a cleavable group).

[0459] In some embodiments, the binding between the linker unit and the ligand is a bond.

[0460] In some embodiments, the bond between the linker unit and the ligand is a partial bond (e.g., a partial bond containing a cleavable group).

[0461] In some embodiments, the binding between the linker unit and the ligand includes -C(=O)- connected to the linker unit.

[0462] This group may be cleavable or non-cleavable. Suitable groups include, for example, -NR-, -C(=O)-, -C(=O)NH-, -S(=O)-, -S(=O)2-, -S(=O)2NH, or, but not limited to, alkylene, alkenylene, alkylylenearyl, alkylenearyl, alkenylenearyl, alkylene heteroaryl, alkenylene heteroaryl, alkylene heterocyclyl, alkylene heterocyclyl, alkenylene heterocyclyl, alkylene arylene hetero, arylene heterocyclylene, cycloalkylene, cyclo Alkenylene alkylarylalkylylene alkylarylalkenylene alkylarylalkylylenealkynylene alkenylarylalkylylenealkenylene alkenylarylalkylylenealkynylarylalkylylenealkenylene alkenylarylalkylalkylylenealkynylarylalkylylenealkenylene alkyl heteroarylalkylalkylarylalkylarylalkylylenealkenylene alkyl heteroarylalkyl Examples include chains of atoms such as ylarylene, alkynylarylene, alkylhetearylene, alkenylhetearylene, alkynylheroarylene, and each of these may be substituted or unsubstituted, and one or more methylene groups may be interrupted or terminated by -O-, -S-, -S(=O)-, -S(=O)2-, -NR-, -C(=O)-, substituted or unsubstituted aryl groups, substituted or unsubstituted heteroaryl groups, or substituted or unsubstituted heterocycles, where R is hydrogen, acyl, aliphatic, or substituted aliphatic.

[0463] A cleavable group is a group that is sufficiently stable outside the cell but is cleaved upon entering a target cell, releasing the two parts it holds together. In a preferred embodiment, the cleavable group is cleaved at least 10 times, preferably at least 100 times faster, under a first reference condition (which may be selected to replicate or represent intracellular conditions, for example) or a second reference condition (which may be selected to replicate or represent conditions found in blood or serum) than in the target cell or in the target blood.

[0464] Cleavable groups are sensitive to cleavage agents (e.g., pH, redox redox potential, or the presence of degradable molecules). Generally, cleavage agents are more prevalent or found at higher levels or activity within cells than in serum or blood. Examples of such degrading agents include: redox agents that are selected for a specific substrate or do not have substrate specificity (e.g., oxidases or reductases present in cells, or reducing agents such as mercaptans, which can degrade redox-cleavable groups by reduction), esterases; agents that can create an endosome or acidic environment, e.g., those that result in a pH of 5 or less, general acids, peptidases (which may be substrate-specific), and enzymes that can hydrolyze or degrade acid-cleavable groups by acting as phosphatases.

[0465] Cleavable groups, such as disulfide bonds, can be pH-sensitive. While the pH of human serum is 7.4, the average intracellular pH is slightly lower, ranging from approximately 7.1 to 7.3. Endosomes have a more acidic pH in the range of 5.5 to 6.0, and lysosomes have an even more acidic pH of approximately 5.0. Some linkers have cleavable groups that are cleaved at a favorable pH, thereby releasing cationic lipids from intracellular ligands or into desired compartments of the cell.

[0466] Conjugates can contain cleavable groups that can be cleaved by specific enzymes. The type of cleavable group incorporated into the conjugate may vary depending on the cell to be targeted. For example, liver-targeting ligands may bind to cationic lipids via a chemical moiety containing an ester group. Hepatocytes are rich in esterases, and therefore this group is cleaved more efficiently in hepatocytes than in cell types that are not rich in esterases. Other cell types rich in esterases include lung, renal cortex, and testicular cells.

[0467] Coupling groups containing peptide bonds can be used when targeting peptidase-rich cell types such as hepatocytes and synovial cells.

[0468] In general, the suitability of a candidate cleavable group can be evaluated by testing the ability (or conditions) of a degrading agent to cleave the candidate group. It is also desirable to test the candidate cleavable group for its ability to resist cleavage in blood or in contact with other non-target tissues. Thus, the relative sensitivity to cleavage between a first condition and a second condition can be determined, with the first condition selected to demonstrate cleavage in target cells and the second condition selected to demonstrate cleavage in other tissues or biological fluids, such as blood or serum. Evaluations can be performed in cell-free systems, in cells, in cell cultures, in organ or tissue cultures, or in whole animals. It may be useful to perform the initial evaluation in cell-free or culture conditions and confirm it with further evaluation in whole animals. In preferred embodiments, useful candidate compounds are cleaved at least 2, 4, 10, or 100 times faster in cells (or under in vitro conditions selected to replicate intracellular conditions) compared with blood or serum (or under in vitro conditions selected to replicate extracellular conditions).

[0469] Redox-cleavable groups. One class of cleavable groups is redox-cleavable groups that are cleaved upon reduction or oxidation. An example of a reductively cleavable group is a disulfide linkage (-SS-). Methods described herein can be considered to determine whether a candidate cleavable group is a suitable “reductively cleavable linkage” or suitable for use, for example, with a specific iRNA moiety and a specific targeting agent. For example, a candidate can be evaluated by incubation with dithiothreitol (DTT) or other reducing agents using reagents known in the art that replicate the cleavage rate observed in cells, e.g., target cells. Candidates can also be evaluated under conditions selected to replicate blood or serum conditions. In a preferred embodiment, the candidate compound is cleaved by at most 10% in blood. In a preferred embodiment, a useful candidate compound is degraded at least 2, 4, 10, or 100 times faster in cells (or under in vitro conditions selected to replicate intracellular conditions) compared to blood (or under in vitro conditions selected to replicate extracellular conditions). The cleavage rate of candidate compounds can be determined using a standard enzyme kinetics assay under conditions selected to replicate intracellular media and compared to conditions selected to replicate extracellular media.

[0470] Phosphate-based cleavable groups. Phosphate-based cleavable groups are cleaved by agents that decompose or hydrolyze phosphate groups. Examples of agents that cleave intracellular phosphate groups (phosphate groups) include intracellular enzymes such as phosphatases. In some embodiments, the phosphate-based linking group is -OP(=O)(OR k )-O-, -OP(=S)(OR k )-O-, -OP(=S)(SR k )-O-, -SP(=O)(OR k )-O-, -OP(=O)(OR k )-S-, -SP(=O)(OR k )-S-, -OP(=S)(OR k )-s-, -SP(=S)(OR k )-O-, -OP(=O)(R k)-O-, -OP(=S)(R k )-O-, -SP(=O)(R k )-O-, -SP(=S)(R k )-O-, -SP(=O)(R k )-S-, or -OP(=S)(R k In some embodiments, the phosphate-based linking group is -OP(=O)(OH)-O-, -OP(=S)(OH)-O-, -OP(=S)(SH)-O-, -SP(=O)(OH)-O-, -OP(=O)(OH)-S-, -SP(=O)(OH)-S-, -OP(=S)(OH)-S-, -SP(=S)(OH)-O-, -OP(=O)(H)-O-, -OP(=S)(H)-O-, -SP(=O)(H)-O-, -SP(=O)(H)-O-, -SP(=O)(H)-S-, or -OP(=S)(H)-S-. In some embodiments, the phosphate-based linking group is -OP(=O)(OH)-O-.

[0471] Acid-cleavable groups. Acid-cleavable groups are linking groups that are cleaved under acidic conditions. In preferred embodiments, acid-cleavable groups are cleaved in an acidic environment having a pH of about 6.5 or less (e.g., about 6.0, 5.5, 5.0 or less), or by agents such as enzymes that can act as general acids. In cells, certain low-pH organelles such as endosomes and lysosomes can provide a cleavage environment for acid-cleavable linking groups. Examples of acid-cleavable groups include, but are not limited to, hydrazones, esters, and amino acid esters. Acid-cleavable groups can have the general formula -C=NN-, C(O)O, or -OC(O). In preferred embodiments, the carbon bonded to the oxygen of the ester (alkoxy group) is an aryl group, a substituted alkyl group, or a tertiary alkyl group such as dimethylpentyl or t-butyl. These candidates can be evaluated using methods similar to those described above.

[0472] Ester-based cleavable groups. Ester-based cleavable groups are cleaved by enzymes such as esterases and amidases in cells. Examples of ester-based cleavable groups include, but are not limited to, esters of alkylene, alkenylene, and alkylylene groups. Ester-cleavable linking groups have the general formula -C(O)O- or -OC(O)-. These candidates can be evaluated using methods similar to those described above.

[0473] Peptide-based cleavable groups. Peptide-based cleavable groups are cleaved by enzymes such as peptidases and proteases in cells. Peptide-based cleavable groups are peptide bonds formed between amino acids to produce oligopeptides (e.g., dipeptides, tripeptides, etc.) and polypeptides. Peptide-based cleavable groups do not contain amide groups (-C(O)NH-). Amide groups can be formed between any alkylene, alkenylene, or alkynylene. A peptide bond is a specific type of amide bond formed between amino acids to produce peptides and proteins. Peptide-based cleavable groups are generally limited to peptide bonds (i.e., amide bonds) formed between amino acids that produce peptides and proteins, and do not include the entire amide functional group. The general formula for a peptide-based cleavable linkage is -NHCHR A C(O)NHCHR B It contains C(O)-, in the formula, R A and R BThese are the R groups of two adjacent amino acids. These candidates can be evaluated using methods similar to those described above. As used herein, “carbohydrate” means either a compound that is essentially composed of one or more monosaccharide units having at least six carbon atoms (which may be linear, branched, or cyclic) and each carbon atom bonded to an oxygen, nitrogen, or sulfur atom, or a compound that has as part a carbohydrate portion composed of one or more monosaccharide units, each having at least six carbon atoms (which may be linear, branched, or cyclic) and each carbon atom bonded to an oxygen, nitrogen, or sulfur atom. Typical carbohydrates include sugars (monosaccharides, disaccharides, trisaccharides, and oligosaccharides containing about 4 to 9 monosaccharide units), as well as polysaccharides such as starch, glycogen, cellulose, and polysaccharide gums. Specific monosaccharides include C5 and the above (preferably C5 to C8) sugars, and disaccharides and trisaccharides include sugars having two or three monosaccharide units (preferably C5 to C8).

[0474] Synthesis method In some embodiments, the Disclosure provides a method for preparing the compounds of the Disclosure.

[0475] In some embodiments, the present disclosure provides compounds that can be obtained by methods for preparing the compounds described herein, or compounds that can be obtained by such methods.

[0476] In some embodiments, the present disclosure provides intermediates described herein that are suitable for use in methods for preparing the compounds described herein.

[0477] The compounds of this disclosure can be prepared by any suitable technique known in the art. Specific processes for the preparation of these compounds are further described in the accompanying examples.

[0478] In the descriptions of the synthesis methods described herein, and in any reference synthesis methods used to prepare the starting materials, it should be understood that all proposed reaction conditions, including the choice of solvent, reaction atmosphere, reaction temperature, experimental duration, and work-up procedure, can be selected by those skilled in the art.

[0479] Those skilled in organic synthesis will understand that the functional groups present in various parts of a molecule must be compatible with the reagents and reaction conditions used.

[0480] It will be understood that during the synthesis of the compounds of this disclosure in the processes defined herein, or during the synthesis of certain starting materials, it may be desirable to protect certain substituents to prevent undesirable reactions. A skilled chemist will understand when such protection is needed and how such protecting groups are placed in place and can be removed later. For examples of protecting groups, see one of the many general documents on the subject, e.g., 'Protective Groups in Organic Synthesis' by Theodora Green (publisher: John Wiley & Sons). Protecting groups can be removed by any convenient method described in the literature as appropriate for the removal of the protecting group in question, or known to a skilled chemist, such method being chosen to remove the protecting group with minimal interference to groups elsewhere in the molecule. Thus, if the reactants contain groups such as amino, carboxy, or hydroxy, it may be desirable to protect these groups in some of the reactions referred to herein.

[0481] For example, suitable protecting groups for amino or alkylamino groups include acyl groups, such as alkanoyl groups like acetyl; alkoxycarbonyl groups, such as methoxycarbonyl, ethoxycarbonyl, or t-butoxycarbonyl groups; arylmethoxycarbonyl groups, such as benzyloxycarbonyl; or aroyl groups, such as benzoyl. Suitable protecting groups for hydroxyl groups or alkylhydroxy groups may be, for example, acetyl (Ac), benzoyl (Bz), benzyl (Bn), β-methoxyethoxymethyl ether (MEM), dimethoxytrityl (DMT), methoxymethyl ether (MOM), methoxytrityl (MMT), p-methoxybenzyl ether (PMB), p-methoxyphenyl ether (PMP), pivaloyl (Piv), tetrahydropyranyl (THP), tetrahydrofuran (THF), trityl (triphenylmethyl, Tr), silyl ethers (e.g., trimethylsilyl (TMS), tert-butyldimethylsilyl (TBDMS), tri-isopropylsilyloxymethyl (TOM), and triisopropylsilyl (TIPS) ethers), methyl ethers, or ethoxyethyl ethers (EE). Suitable protecting groups for 1,2-diols may be, for example, acetals. A suitable protecting group for 1,3-diols may be, for example, tetraisopropyldisiloxanylidene (TIPDS).

[0482] The deprotection conditions for the above protecting groups inevitably change depending on the choice of protecting group. For example, acyl groups such as alkanoyl or alkoxycarbonyl groups or aroyl groups can be removed by hydrolysis with a suitable base such as an alkali metal hydroxide, such as lithium hydroxide or sodium hydroxide. Alternatively, acyl groups such as tert-butoxycarbonyl groups can be removed by treatment with a suitable acid such as hydrochloric acid, sulfuric acid or phosphoric acid, or trifluoroacetic acid. Arylmethoxycarbonyl groups such as benzyloxycarbonyl groups can be removed by hydrogenation on a catalyst such as carbon-supported palladium, or by treatment with a Lewis acid such as tris(trifluoroacetate) borate. A suitable alternative protecting group for primary amino groups is, for example, the phthaloyl group, which can be removed by treatment with an alkylamine, such as dimethylaminopropylamine, or hydrazine.

[0483] Suitable protecting groups for hydroxyl groups include, for example, acyl groups, such as alkanoyl groups like acetyl, alloyl groups, such as benzoyl, or arylmethyl groups, such as benzyl. The deprotection conditions for these protecting groups inevitably change depending on the choice of protecting group. Therefore, for example, acyl groups such as alkanoyl or alloyl groups can be removed by hydrolysis with a suitable base such as an alkali metal hydroxide, such as lithium hydroxide, sodium hydroxide, or ammonia. Alternatively, arylmethyl groups such as benzyl can be removed by hydrogenation on a catalyst such as carbon-supported palladium.

[0484] Suitable protecting groups for carboxyl groups include, for example, esterifying groups such as methyl or ethyl groups that can be removed by hydrolysis with a base such as sodium hydroxide, or tert-butyl groups that can be removed by treatment with an acid such as an organic acid such as trifluoroacetic acid, or benzyl groups that can be removed by hydrogenation on a catalyst such as carbon-supported palladium.

[0485] Conveniently, the reaction of the compounds is preferably carried out in the presence of a suitable solvent that is inert under the respective reaction conditions. Examples of suitable solvents include hydrocarbons such as hexane, petroleum ether, benzene, toluene, or xylene; chlorinated hydrocarbons such as trichloroethylene, 1,2-dichloroethane, tetrachloromethane, chloroform, or dichloromethane; alcohols such as methanol, ethanol, isopropanol, n-propanol, n-butanol, or tert-butanol; ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran (THF), 2-methyltetrahydrofuran, cyclopentyl methyl ether (CPME), methyl tert-butyl ether (MTBE), or dioxane; and ethylene glycol. Examples of solvents include, but are not limited to, glycol ethers such as methyl ether, ethylene glycol monoethyl ether, or ethylene glycol dimethyl ether (diglym); ketones such as acetone, methyl isobutyl ketone (MIBK), or butanone; amides such as acetamide, dimethylacetamide, dimethylformamide (DMF), and N-methylpyrrolidinone (NMP); nitriles such as acetonitrile; sulfoxides such as dimethyl sulfoxide (DMSO); nitro compounds such as nitromethane or nitrobenzene; esters such as ethyl acetate or methyl acetate, or mixtures of such solvents or mixtures with water.

[0486] The reaction temperature is preferably about -100°C to 300°C, depending on the reaction steps and conditions used.

[0487] The reaction time generally ranges from a few minutes to several days, depending on the reactivity of each compound and the respective reaction conditions. A suitable reaction time can be easily determined by methods known in the art (e.g., reaction monitoring). Based on the above reaction temperature, a suitable reaction time generally ranges from 10 minutes to 48 hours.

[0488] Furthermore, by utilizing the procedures described herein in conjunction with the usual art in this field, further compounds of the Disclosure can be readily prepared. Those skilled in the art will readily understand that known variations of the conditions and processes of the following preparation procedures can be used to prepare these compounds.

[0489] As will be understood by those skilled in the art of organic synthesis, the compounds of this disclosure are readily available through a variety of synthetic routes, some of which are illustrated in the accompanying examples. Those skilled in the art will readily recognize what kinds of reagents and reaction conditions should be used to obtain the compounds of this disclosure, and how they should be applied and adapted in any particular case (whenever necessary or useful). Furthermore, some of the compounds of this disclosure can be readily synthesized by reacting other compounds of this disclosure under preferred conditions, by applying standard synthetic methods such as reduction, oxidation, addition, or substitution reactions, to convert one particular functional group present in the compounds of this disclosure or their preferred precursor molecules to another, and these methods are well known to those skilled in the art. Similarly, methods for applying synthetic protecting (or protecting) groups, preferred protecting groups, and for introducing and removing them, are well known to those skilled in the art, when necessary or useful, and are described in more detail, for example, PGMWuts, TW Greene, "Greene's Protective Groups in Organic Synthesis," 4th edition (2006) (John Wiley & Sons).

[0490] A general preparation route for the compounds of this application is described in Scheme 1 of this specification. [ka]

[0491] Biological assays Compounds, scaffolds, or conjugates designed, selected, prepared, and / or optimized by the methods described above can, once produced, be characterized using a variety of assays known to those skilled in the art to determine whether the compounds, scaffolds, or conjugates have biological activity. For example, compounds, scaffolds, or conjugates can be characterized by conventional assays, including but not limited to those described below, to determine whether they have desired activity, such as target-binding activity and / or specificity and / or stability.

[0492] Furthermore, high-throughput screening can be used to accelerate analyses using such assays. As a result, it may be possible to rapidly screen for the activity of the molecules described herein using techniques known in the art. General methodologies for performing high-throughput screening are described, for example, in Devlin (1998) High Throughput Screening, Marcel Dekker, and U.S. Patent No. 5,763,263. High-throughput assays may use one or more different assay techniques, including but not limited to those described below.

[0493] Various in vitro or in vivo biological assays may be suitable for detecting the effects of the compounds, scaffolds, or conjugates of this disclosure. These in vitro or in vivo biological assays may include, but are not limited to, enzyme activity assays, electrophoretic mobility shift assays, reporter gene assays, in vitro cell viability assays, and assays described herein.

[0494] In some embodiments, biological assays are described in the examples herein.

[0495] Pharmaceutical composition In some embodiments, the Disclosure provides a pharmaceutical composition comprising a compound, scaffold, or conjugate of the Disclosure as an active ingredient.

[0496] As used herein, the term “composition” is intended to encompass products containing a particular component in a specific amount, as well as any products resulting directly or indirectly from a combination of a particular component in a specific amount.

[0497] Suitable pharmaceutical compositions for injection include sterile aqueous solutions (if water-soluble) or dispersions, and sterile powders for the rapid preparation of sterile injection solutions or dispersions. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL® (BASF, Parsippany, NJ), or phosphate-buffered saline (PBS). In all cases, the composition must be sterile and fluid enough to be easily injected. It must be stable under manufacturing and storage conditions and protected from contamination by microorganisms such as bacteria and fungi. The carrier may be a solvent or dispersion medium containing, for example, water, ethanol, polyols (e.g., glycerol, propylene glycol, and liquid polyethylene glycol), and suitable mixtures thereof. Adequate fluidity can be maintained, for example, by the use of coatings such as lecithin, by maintaining the required particle size in the case of dispersions, and by the use of surfactants. Microbial action can be prevented by various antimicrobial and antifungal agents, such as parabens, chlorobutanol, phenol, ascorbic acid, and thimerosal. In many cases, it is preferable to include isotonic agents, such as sugars, mannitol, and polyalcohols such as sorbitol, as well as sodium chloride in the composition. Sustained absorption of the injectable composition can be achieved by including absorption-delaying agents, such as aluminum monostearate and gelatin, in the composition.

[0498] Sterile injectable solutions can be prepared by incorporating the required amount of the active compound into a suitable solvent, along with one or a combination of the components listed above as needed, followed by sterilization by filtration. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle containing a basic dispersion medium and other necessary components from those listed above. In the case of sterile powders for the preparation of sterile injectable solutions, the preparation method includes vacuum drying and freeze-drying, from which powders of the active component and any further desired components are obtained from a pre-sterilized filtered solution.

[0499] The formulations of this disclosure may be in the form of aqueous solutions containing an aqueous vehicle. The aqueous vehicle component may comprise water and at least one pharmaceutically acceptable excipient. Suitable acceptable excipients include those selected from the group consisting of solubilizers, chelating agents, preservatives, isotonic agents, viscosity / suspensioning agents, buffers, and pH adjusters, as well as mixtures thereof.

[0500] Any suitable dissolution accelerator can be used. Examples of dissolution accelerators include cyclodextrins selected from the group consisting of hydroxypropyl-β-cyclodextrin, methyl-β-cyclodextrin, randomly methylated-β-cyclodextrin, ethylated-β-cyclodextrin, triacetyl-β-cyclodextrin, totally acetylated-β-cyclodextrin, carboxymethyl-β-cyclodextrin, hydroxyethyl-β-cyclodextrin, 2-hydroxy-3-(trimethylammonio)propyl-β-cyclodextrin, glucosyl-β-cyclodextrin, sulfated-β-cyclodextrin (S-β-CD), maltosyl-β-cyclodextrin, β-cyclodextrin sulfobutyl ether, branched-β-cyclodextrin, hydroxypropyl-γ-cyclodextrin, randomly methylated-γ-cyclodextrin, and trimethyl-γ-cyclodextrin, as well as mixtures thereof.

[0501] Any suitable chelating agent can be used. Examples of suitable chelating agents include those selected from the group consisting of ethylenediaminetetraacetic acid and its metal salts, disodium edetate, trisodium edetate, and tetrasodium edetate, and mixtures thereof.

[0502] Any suitable preservative can be used. Examples of preservatives include those selected from the group consisting of quaternary ammonium salts, such as benzalkonium halide (preferably benzalkonium chloride), chlorhexidine gluconate, benzethonium chloride, cetylpyridinium chloride, benzyl bromide, phenylmercury nitrate, phenylmercury acetate, phenylmercury neodecanoate, melthiolate, methylparaben, propylparaben, sorbic acid, potassium sorbate, sodium benzoate, sodium propionate, ethyl p-hydroxybenzoate, propylaminopropyl biguanide, and butyl p-hydroxybenzoate, and sorbic acid, as well as mixtures thereof.

[0503] The aqueous vehicle may also contain an isotonic agent to adjust the tonicity (osmotic pressure). The isotonic agent can be selected from the group consisting of glycols (such as propylene glycol, diethylene glycol, and triethylene glycol), glycerol, dextrose, glycerin, mannitol, potassium chloride, and sodium chloride, as well as mixtures thereof.

[0504] To adjust the formulation to an acceptable pH (typically within the range of about 5.0 to about 9.0, more preferably about 5.5 to about 8.5, particularly about 6.0 to about 8.5, about 7.0 to about 8.5, about 7.2 to about 7.7, about 7.1 to about 7.9, or about 7.5 to about 8.0), the formulation may contain a pH adjuster. The pH adjuster is typically a mineral acid or metal hydroxide base selected from the group consisting of potassium hydroxide, sodium hydroxide, hydrochloric acid, and mixtures thereof, preferably sodium hydroxide and / or hydrochloric acid. These acidic and / or basic pH adjusters are added to adjust the formulation to a target acceptable pH range. Therefore, it may not be necessary to use both an acid and a base; depending on the formulation, adding only one of the acid or base may be sufficient to bring the mixture to the desired pH range.

[0505] The aqueous vehicle may also contain a buffer to stabilize the pH. If used, the buffer is selected from the group consisting of phosphate buffer (such as sodium dihydrogen phosphate and disodium hydrogen phosphate), borate buffer (such as boric acid or its salts containing disodium tetraborate), citrate buffer (such as citric acid or its salts containing sodium citrate), and ε-aminocaproic acid, as well as mixtures thereof.

[0506] A further aspect of this disclosure provides a pharmaceutical composition comprising a compound of the disclosure as defined herein, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, together with a pharmaceutically acceptable diluent or carrier.

[0507] The compositions of this disclosure may be in a form suitable for oral use (e.g., as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), topical use (e.g., as creams, ointments, gels, or aqueous or oily solutions or suspensions), administration by inhalation (e.g., as fine powders or liquid aerosols), administration by air (e.g., as fine powders), or parenteral administration (e.g., as sterile aqueous or oily solutions for intravenous, subcutaneous, intramuscular, intraperitoneal or intramuscular administration, or as suppositories for rectal administration).

[0508] The compositions of this disclosure can be obtained by conventional procedures using conventional pharmaceutical excipients well known in the art. Accordingly, compositions intended for oral use may contain, for example, one or more colorants, sweeteners, flavorings and / or preservatives.

[0509] An effective amount of the compounds of this disclosure for use in therapy is sufficient to treat or prevent, slow the progression of, and / or reduce the symptoms associated with, the inflammasome-associated conditions referred to herein.

[0510] An effective amount of the compounds of this disclosure for use in therapy is sufficient to treat, slow the progression of, and / or reduce the symptoms associated with the inflammasome-associated conditions referred to herein.

[0511] The size of the therapeutic or prophylactic dose of a compound of formula (I) or (II) naturally varies according to well-known medical principles, depending on the nature and severity of the condition, the age and sex of the animal or patient, and the route of administration.

[0512] How to use In some embodiments, the Disclosure provides a method for modulating (e.g., reducing or eliminating) the expression of a target gene in a subject, the method comprising administering a conjugate of the Disclosure to the subject.

[0513] In some embodiments, the Disclosure provides a method for modulating (e.g., reducing or eliminating) the expression of a target gene in a target cell or tissue, the method comprising administering a conjugate of the Disclosure to the target.

[0514] In some embodiments, the Disclosure provides a method for delivering a nucleic acid agent, which includes administering it to a conjugate of the Disclosure.

[0515] In some embodiments, the Disclosure provides a method for treating or preventing a disease in a subject requiring such treatment, comprising administering a therapeutically effective amount of the Conjugate of the Disclosure to the subject.

[0516] In some embodiments, the Disclosure provides a conjugate of the Disclosure for modulating (e.g., reducing or eliminating) the expression of a target gene in a subject.

[0517] In some embodiments, the Disclosure provides a conjugate of the Disclosure for modulating (e.g., reducing or eliminating) the expression of a target gene in a cell or tissue of interest.

[0518] In some embodiments, the Disclosure provides a conjugate of the Disclosure for delivering nucleic acid agents to a subject.

[0519] In some aspects, the Disclosure provides a conjugate of the Disclosure for use in subjects requiring treatment or prevention of a disease.

[0520] In some aspects, the Disclosure provides the use of the conjugates of the Disclosure in the manufacture of a pharmaceutical product for modulating (e.g., reducing or eliminating) the expression of a target gene in a subject.

[0521] In some aspects, the Disclosure provides the use of the conjugates of the Disclosure in the manufacture of a pharmaceutical product for modulating (e.g., reducing or eliminating) the expression of a target gene in a cell or tissue of interest.

[0522] In some aspects, the Disclosure provides the use of the Conjugate of the Disclosure in the manufacture of a pharmaceutical product for target delivery of nucleic acid agents.

[0523] In some aspects, the Disclosure provides the use of the conjugates of the Disclosure in the manufacture of a pharmaceutical product for a subject requiring treatment or prevention of a disease.

[0524] In some embodiments, the subject is a cell.

[0525] In some embodiments, the subject is an organization.

[0526] In some embodiments, the subject is a human.

[0527] In some embodiments, the target genes are Factor VII, Eg5, PCSK9, TPX2, apoB, SAA, TTR, HBV, HCV, RSV, PDGF beta gene, Erb-B gene, Src gene, CRK gene, GRB2 gene, RAS gene, MEKK gene, JNK gene, RAF gene, Erk1 / 2 gene, PCNA(p21) gene, MYB gene, JUN gene, FOS gene, BCL-2 gene, cyclin D gene, and VEGF. The mutations include those in the following genes: EGFR gene, cyclin A gene, cyclin E gene, WNT-1 gene, beta-catenin gene, c-MET gene, PKC gene, NFKB gene, STAT3 gene, survivor gene, Her2 / Neu gene, topoisomerase I gene, topoisomerase II alpha gene, p73 gene, p21 (WAF1 / CIP1) gene, p27 (KIP1) gene, PPM1D gene, RAS gene, caveolin I gene, MIB I gene, MTAI gene, M68 gene, tumor suppressor gene mutations, p53 tumor suppressor gene, LDHA, or any combination thereof.

[0528] In some embodiments, the disease is characterized by the unwanted expression of a target gene.

[0529] In some embodiments, administration results in a reduction or elimination of the expression of a target gene in the subject.

[0530] In some embodiments, the disease is a viral infection, such as HCV, HBV, HPV, HSV, or HIV infection.

[0531] In some embodiments, the disease is cancer.

[0532] In some embodiments, cancer includes biliary tract cancer, bladder cancer, transitional cell carcinoma, urothelial carcinoma, brain cancer, glioma, astrocytoma, breast cancer, metaplastic carcinoma, cervical cancer, cervical squamous cell carcinoma, rectal cancer, colorectal cancer, colon cancer, hereditary nonpolyposis colorectal cancer, colorectal adenocarcinoma, gastrointestinal stromal tumor (GIST), endometrial cancer, endometrial stromal sarcoma, esophageal cancer, esophageal squamous cell carcinoma, esophageal adenocarcinoma, ocular melanoma, uveal melanoma, gallbladder cancer, gallbladder adenocarcinoma, renal cell carcinoma, clear cell renal cell carcinoma, transitional cell carcinoma, urothelial carcinoma, Wilms' tumor, leukemia, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic These include lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), chronic myelomonocytic leukemia (CMML), liver cancer, hepatocellular carcinoma, cholangiocarcinoma, hepatoblastoma, lung cancer, non-small cell lung cancer (NSCLC), mesothelioma, B-cell lymphoma, non-Hodgkin lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, T-cell lymphoma, non-Hodgkin lymphoma, progenitor T-lymphoblastic lymphoma / leukemia, peripheral T-cell lymphoma, multiple myeloma, nasopharyngeal cancer (NPC), neuroblastoma, oropharyngeal cancer, oral squamous cell carcinoma, osteosarcoma, ovarian cancer, pancreatic cancer, pancreatic ductal adenocarcinoma, pseudopapillary neoplasm, and acinar cell carcinoma. Prostate cancer, prostate adenocarcinoma, skin cancer, melanoma, malignant melanoma, cutaneous melanoma, small intestine cancer, stomach cancer, gastrointestinal stromal tumor (GIST), uterine cancer, or uterine sarcoma.

[0533] In some embodiments, the cancer is liver cancer, hepatocellular carcinoma, cholangiocarcinoma, or hepatoblastoma.

[0534] In some embodiments, the disease is a proliferative, inflammatory, autoimmune, neurological, ocular, respiratory, metabolic, cutaneous, auditory, hepatic, renal, or infectious disease. In some embodiments, the disease is a hepatic disease.

[0535] definition Unless otherwise specified, the following terms used in this specification and in the claims have the meanings set forth below.

[0536] While we do not intend to limit ourselves by this statement, it should be understood that while various options for the variable elements are described herein, this disclosure is intended to encompass operable embodiments having combinations of options. This disclosure may be construed as excluding non-operational embodiments caused by particular combinations of options.

[0537] As used herein, “alkyl,” “C1, C2, C3, C4, C5 or C6 alkyl,” or “C1-C6 alkyl” is intended to include C1, C2, C3, C4, C5 or C6 linear saturated aliphatic hydrocarbon groups and C3, C4, C5 or C6 branched saturated aliphatic hydrocarbon groups. For example, C1-C6 alkyl is intended to include C1, C2, C3, C4, C5 and C6 alkyl groups. Examples of alkyls include, but are not limited to, moieties having 1 to 6 carbon atoms, such as methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, t-butyl, n-pentyl, i-pentyl, or n-hexyl. In some embodiments, linear or branched alkyls have 6 or fewer carbon atoms (e.g., C1-C6 for linear chains, C3-C6 for branched chains), and in other embodiments, linear or branched alkyls have 4 or fewer carbon atoms.

[0538] As used herein, the term “optionally substituted alkyl” refers to an unsubstituted alkyl or an alkyl having specified substituents that substitute one or more hydrogen atoms on one or more carbons of a hydrocarbon skeleton. Examples of such substituents include alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, amino (including alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfate, alkylsulfinyl, sulfonate, sulfamoyl, sulfonamide, nitro, trifluoromethyl, cyano, azide, heterocyclyl, alkylaryl, or aromatic or heteroaromatic moieties.

[0539] As used herein, the term “alkenyl” includes unsaturated aliphatic groups that are similar in length and possible substitutions to the alkyl groups described above, but contain at least one double bond. For example, the term “alkenyl” includes linear alkenyl groups (e.g., ethenyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, nonenyl, decenyl) and branched alkenyl groups. In some embodiments, linear or branched alkenyl groups have six or fewer carbon atoms in their skeleton (e.g., C2-C6 for linear groups, C3-C6 for branched groups). The term “C2-C6” includes alkenyl groups containing two to six carbon atoms. The term “C3-C6” includes alkenyl groups containing three to six carbon atoms.

[0540] As used herein, the term “optionally substituted alkenyl” refers to an unsubstituted alkenyl or an alkenyl having specified substituents that substitute one or more hydrogen atoms on one or more carbon atoms of a hydrocarbon skeleton. Examples of such substituents include alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, amino (including alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfate, alkylsulfinyl, sulfonate, sulfamoyl, sulfonamide, nitro, trifluoromethyl, cyano, heterocyclyl, alkylaryl, or aromatic or heteroaromatic moieties.

[0541] As used herein, the term “alkynyl” includes unsaturated aliphatic groups that are similar in length and possible substitutions to the alkyl groups described above, but contain at least one triple bond. For example, “alkynyl” includes linear alkynyl groups (e.g., ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octinyl, noninyl, desynyl) and branched alkynyl groups. In some embodiments, the linear or branched alkynyl groups have six or fewer carbon atoms in their skeleton (e.g., C2-C6 for linear groups, C3-C6 for branched groups). The term “C2-C6” includes alkynyl groups containing two to six carbon atoms. The term “C3-C6” includes alkynyl groups containing three to six carbon atoms. As used herein, "C2-C6 alkenylene linker" or "C2-C6 alkynylene linker" is intended to contain a C2, C3, C4, C5, or C6 chain (straight or branched) divalent unsaturated aliphatic hydrocarbon group. For example, a C2-C6 alkenylene linker is intended to contain a C2, C3, C4, C5, and C6 alkenylene linker group.

[0542] As used herein, the term “optionally substituted alkynyl” refers to an unsubstituted alkynyl or an alkynyl having specified substituents that substitute one or more hydrogen atoms on one or more carbon atoms of a hydrocarbon skeleton. Examples of such substituents include alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, amino (including alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfate, alkylsulfinyl, sulfonate, sulfamoyl, sulfonamide, nitro, trifluoromethyl, cyano, azide, heterocyclyl, alkylaryl, or aromatic or heteroaromatic moieties.

[0543] Other optionally substituted moieties (e.g., optionally substituted cycloalkyl, heterocycloalkyl, aryl, or heteroaryl) include both an unsubstituted moiety and a moiety having one or more specified substituents. For example, substituted heterocycloalkyls include those substituted with one or more alkyl groups such as 2,2,6,6-tetramethyl-piperidinyl and 2,2,6,6-tetramethyl-1,2,3,6-tetrahydropyridinyl.

[0544] As used herein, the term "cycloalkyl" means having 3 to 30 carbon atoms (e.g., C3 to C3). 12 , C3~C 10This refers to monocyclic or polycyclic (e.g., condensed, cross-linked, or spirocyclic) saturated or partially unsaturated hydrocarbon systems (C3-C8). Examples of cycloalkyls include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, 1,2,3,4-tetrahydronaphthalenyl, and adamantyl. In the case of polycyclic cycloalkyls, at least one of the rings in the cycloalkyl must be non-aromatic.

[0545] As used herein, the term "heterocycloalkyl" means, unless otherwise specified, one or more heteroatoms (such as O, N, S, P, or Se) independently selected from the group consisting of nitrogen, oxygen, and sulfur, for example, one or one-to-two or one-to-three or one-to-four or one-to-five or one-to-six heteroatoms, or saturated or partially unsaturated 3-to-8 member monocyclic, 7-to-12 member bicyclic (condensed, bridged, or spiro-ring), or 11-to-14 member tricyclic ring systems (condensed, bridged, or spiro-ring) having, for example, one, two, three, four, five, or six heteroatoms.Examples of heterocycloalkyl groups include piperidinyl, piperazinyl, pyrrolidinyl, dioxanil, tetrahydrofuranil, isoindolinyl, indolinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, triazolidinyl, oxyranil, azetidinyl, oxetanil, thietanil, 1,2,3,6-tetrahydropyridinyl, tetrahydropyranil, dihydropyranil, pyranil, morpholinil, tetrahydrothiopyranil, 1,4-diazepanil, and 1,4-oxa Zepanyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl, 2,5-diazabicyclo[2.2.1]heptanyl, 2-oxa-6-azaspiro[3.3]heptanyl, 2,6-diazaspiro[3.3]heptanyl, 1,4-dioxa-8-azaspiro[4.5]decanyl, 1,4-dioxaspiro[4.5]decanyl, 1-oxaspiro[4.5]decanyl, 1-azaspiro[4.5]decanyl, 3'H-spiro[cyclohexane-1,1'-isobenzofuran]yl, 7'H-spiro[cyclohex San-1,5'-Flo[3,4-b]pyridine]-yl, 3'H-Spiro[cyclohexane-1,1'-Flo[3,4-c]pyridine]-yl, 3-azabicyclo[3.1.0]hexanyl, 3-azabicyclo[3.1.0]hexane-3-yl, 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazolyl, 3,4,5,6,7,8-hexahydropyrido[4,3-d]pyrimidinyl, 4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridinyl, 5,6,7,8-tetrahydropyrido[4 Examples include, but are not limited to, [3-d]pyrimidinyl, 2-azaspiro[3.3]heptanyl, 2-methyl-2-azaspiro[3.3]heptanyl, 2-azaspiro[3.5]nonanyl, 2-methyl-2-azaspiro[3.5]nonanyl, 2-azaspiro[4.5]decanyl, 2-methyl-2-azaspiro[4.5]decanyl, 2-oxazaspiro[3.4]octanyl, 2-oxazaspiro[3.4]octan-6-yl, and 5,6-dihydro-4H-cyclopenta[b]thiophenyl.In the case of polycyclic heterocycloalkyls, at least one of the rings in the heterocycloalkyl must be non-aromatic (for example, 4,5,6,7-tetrahydrobenzo[c]isoxazolyl).

[0546] As used herein, the term “aryl” includes aromatic groups having one or more aromatic rings and containing no heteroatoms in the ring structure, including “conjugated” or polycyclic systems. The term aryl includes both monovalent and divalent species. Examples of aryl groups include, but are not limited to, phenyl, biphenyl, and naphthyl. Conveniently, aryl is phenyl.

[0547] As used herein, the term “heteroaryl” is intended to include a carbon atom and one or more heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, for example, 1 or 1-2 or 1-3 or 1-4 or 1-5 or 1-6 heteroatoms, or a stable 5, 6 or 7-membered monocyclic or 7, 8, 9, 10, 11 or 12-membered bicyclic aromatic heterocycle consisting of, for example, 1, 2, 3, 4, 5 or 6 heteroatoms. The nitrogen atom may be substituted or unsubstituted (i.e., N or NR, where R is H or another defined substituent). The nitrogen and sulfur heteroatoms may optionally be oxidized (i.e., N → O and S(O)). pThe formula is (where p=1 or 2). It should be noted that the total number of S and O atoms in the aromatic heterocycle is 1 or less. Examples of heteroaryl groups include pyrrole, furan, thiophene, thiazole, isothiazole, imidazole, triazole, tetrazole, pyrazole, oxazole, isoxazole, isothiazole, pyridine, pyrazine, pyridazine, and pyrimidine. Heteroaryl groups can also be fused or bridged with non-aromatic alicyclic or heterocyclic rings to form polycyclic systems (e.g., 4,5,6,7-tetrahydrobenzo[c]isoxazolyl). In some embodiments, the heteroaryl is thiophenyl or benzothiophenyl. In some embodiments, the heteroaryl is thiophenyl. In some embodiments, the heteroaryl is benzothiophenyl.

[0548] Furthermore, the terms "aryl" and "heteroaryl" include polycyclic aryl and heteroaryl groups, such as tricyclic and bicyclic groups, including naphthalene, benzoxazole, benzodioxazole, benzothiazole, benzimidazole, benzothiophene, quinoline, isoquinoline, naphthyridine, indole, benzofuran, purine, benzofuran, deazapurine, and indoridine.

[0549] A cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring may have substituents such as alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkoxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkylaminocarbonyl, aralkylaminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, aralkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, amino The groups may be substituted with carbonyl, alkylthiocarbonyl, phosphate, phosphonato, phosphinato, amino (including alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfate, alkylsulfinyl, sulfonate, sulfamoyl, sulfonamide, nitro, trifluoromethyl, cyano, azide, heterocyclyl, alkylaryl, or aromatic or heteroaromatic moieties. The aryl and heteroaryl groups may also be condensed or crosslinked with non-aromatic alicyclic or heterocyclic rings to form polycyclic systems (e.g., methylenedioxyphenyl such as tetralin and benzo[d][1,3]dioxol-5-yl).

[0550] As used herein, the term “substituted” means that any one or more hydrogen atoms on a given atom are replaced with one or more selected from the indicated groups, provided that the substitution does not exceed the normal valency of the given atom and that the substitution results in a stable compound. If the substituent is oxo or keto (i.e., =O), two hydrogen atoms on the atom are replaced. Keto substituents are not present in aromatic moieties. A ring double bond, as used herein, is a double bond formed between two adjacent ring atoms (e.g., C=C, C=N, or N=N). “Stable compound” and “stable structure” mean a compound that is robust enough to withstand isolation from a reaction mixture to a useful degree of purity and formulation into an effective therapeutic agent.

[0551] If the bond to a substituent is shown to intersect with a bond connecting two atoms in the ring, such substituent may be bonded to any atom in the ring. If substituents are enumerated without indicating the atom to which such substituent is bonded in the remainder of the compound of a given formula, such substituent may be bonded via any atom in such formula. Combinations of substituents and / or variable elements are permitted only if such combination results in a stable compound.

[0552] If any variable element (e.g., R) appears two or more times in any component or formula of a compound, its definition in each appearance is independent of its definition in all other appearances. Therefore, for example, if a group is shown to be substituted with 0 to 2 R moieties, that group may be optionally substituted with up to 2 R moieties, and the R in each appearance is selected independently of the definition of R. Furthermore, combinations of substituents and / or variable elements are permitted only if such combinations result in a stable compound.

[0553] As used herein, the terms "hydroxy" or "hydroxyl" mean -OH or -O - It contains a group having a group.

[0554] As used herein, the terms "halo" or "halogen" refer to fluoro, chloro, bromo, and iodine.

[0555] The terms "haloalkyl" or "haloalkoxyl" refer to alkyl or alkoxyl molecules substituted with one or more halogen atoms.

[0556] As used herein, the term “optionally substituted haloalkyl” refers to an unsubstituted haloalkyl having specified substituents that substitute one or more hydrogen atoms on one or more hydrocarbon backbone carbon atoms. Examples of such substituents include alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, amino (including alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfate, alkylsulfinyl, sulfonate, sulfamoyl, sulfonamide, nitro, trifluoromethyl, cyano, azide, heterocyclyl, alkylaryl, or aromatic or heteroaromatic moieties.

[0557] As used herein, the terms “alkoxy” or “alkoxyl” include substituted and unsubstituted alkyl, alkenyl, and alkynyl groups covalently bonded to an oxygen atom. Examples of alkoxy or alkoxyl radicals include, but are not limited to, methoxy, ethoxy, isopropyloxy, propoxy, butoxy, and pentoxy groups. Examples of substituted alkoxy groups include halogenated alkoxy groups. The alkoxy group may be substituted with groups such as alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, amino (including alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfate, alkylsulfinyl, sulfonate, sulfamoyl, sulfonamide, nitro, trifluoromethyl, cyano, azide, heterocyclyl, alkylaryl, or aromatic or heteroaromatic moieties. Examples of halogen-substituted alkoxy groups include, but are not limited to, fluoromethoxy, difluoromethoxy, trifluoromethoxy, chloromethoxy, dichloromethoxy, and trichloromethoxy.

[0558] As used herein, expressions such as "one or more of A, B, or C," "one or more A, B, or C," "one or more of A, B, and C," "one or more A, B, and C," "selected from the group consisting of A, B, and C," and "selected from A, B, and C" are used interchangeably and all refer to a selection from the group consisting of A, B, and / or C, i.e., one or more A, one or more B, one or more C, or any combination thereof, unless otherwise indicated.

[0559] It should be understood that this disclosure provides methods for the synthesis of the compounds, scaffolds, and conjugates described herein. This disclosure also provides detailed methods for the synthesis of various disclosed compounds, scaffolds, and conjugates according to the schemes shown herein and in the examples.

[0560] Throughout the description, where a composition is described as having, containing, or comprising certain components, it should be understood that the composition is also intended to be essentially composed of or comprise the listed components. Similarly, where a method or process is described as having, containing, or comprising certain process steps, the process is also intended to be essentially composed of or comprise the listed process steps. Furthermore, it should be understood that the order of the steps, the order in which certain operations are performed, is not important as long as the invention remains operational. Moreover, two or more steps or operations can be performed simultaneously.

[0561] It should be understood that the synthesis processes described herein are accommodating a wide variety of functional groups, and therefore various substituted starting materials can be used. These processes generally provide the desired final compound at or near the end of the entire process, but in certain cases it may be desirable to further convert the compound to its pharmaceutically acceptable salt.

[0562] It should be understood that the compounds, scaffolds, and conjugates of this disclosure can be prepared in a variety of ways using commercially available starting materials, compounds known in the literature, or readily prepared intermediates, by employing standard synthetic methods and procedures known to those skilled in the art or evident to those skilled in the art in light of the teachings herein. Standard synthetic methods and procedures for the preparation of organic molecules and functional group transformations and manipulations can be obtained from relevant scientific literature or from standard textbooks in the field. Not limited to any one or more sources, but incorporated herein by reference, is Smith, MB, March, J., March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 5 th edition,John Wiley & Sons:New York,2001;Greene,TW,Wuts,PGM,Protective Groups in Organic Synthesis,3 rd Representative textbooks such as John Wiley & Sons (New York, 1999), R. Larock (Comprehensive Organic Transformations, VCH Publishers, 1989), L. Fieser and M. Fieser (Fieser and Fieser's Reagents forganic Synthesis, John Wiley and Sons, 1994), and L. Paquette (ed., Encyclopedia of Reagents forganic Synthesis, John Wiley and Sons, 1995) are useful and well-regarded reference texts for organic synthesis known to those skilled in the art.

[0563] Those skilled in the art will note that the order of certain steps, such as the introduction and removal of protecting groups, in the reaction sequences and synthetic schemes described herein may be modified. Those skilled in the art will recognize that certain groups may require protection from reaction conditions by the use of protecting groups. Protecting groups may also be used to distinguish similar functional groups in a molecule. A list of protecting groups and methods for introducing and removing these groups can be found in Greene, TW, Wuts, PGM, Protective Groups in Organic Synthesis, 3. rd This can be found in edition, John Wiley & Sons: New York, 1999.

[0564] Unless otherwise specified, any description of a treatment or preventive method should be understood to include the use of compounds, scaffolds, and conjugates to provide a treatment or preventive as described herein. Unless otherwise specified, any description of a treatment or preventive method should be understood to include the use of compounds, scaffolds, and conjugates to prepare a medicament for the treatment or prevention of such a condition. Treatment or prevention includes the treatment or prevention of non-human animals, including humans and rodents, and other disease models.

[0565] Unless otherwise specified, any description of a treatment method should be understood to include the use of compounds, scaffolds, and conjugates to provide treatments as described herein. Unless otherwise specified, any description of a treatment method should be understood to include the use of compounds, scaffolds, and conjugates to prepare pharmaceuticals for treating such conditions. Treatments include treatment of non-human animals, including humans and rodents, and other disease models.

[0566] As used herein, the term “subject” is interchangeable with the term “subject in need of it,” both of which refer to a subject that has a disease or is at high risk of developing a disease. “Subject” includes mammals. Mammals may be, for example, humans or appropriate non-human mammals, such as primates, mice, rats, dogs, cats, cattle, horses, goats, camels, sheep, or pigs. A subject may be a bird or poultry. In some embodiments, the mammal is a human. A subject in need may be a subject that has been previously diagnosed or identified as having one of the diseases or disorders disclosed herein. A subject in need may also be a subject suffering from one of the diseases or disorders disclosed herein. Alternatively, a subject in need may be a subject at high risk of developing such a disease or disorder compared to the population as a whole (i.e., a subject more likely to develop such a disorder compared to the population as a whole). A subject in need may be refractory or resistant to one of the diseases or disorders disclosed herein (i.e., one that does not respond to treatment or has not yet responded to treatment). The subject may be resistant at the start of treatment or may become resistant during treatment. In some embodiments, the subject in question has received and failed all known effective therapies for the disease or disorder disclosed herein. In some embodiments, the subject in question has received at least one prior treatment.

[0567] As used herein, the terms “to treat” or “to heal” describe the management and care of a patient for the purpose of combating a disease, condition, or disorder, and include the administration of any of the compounds disclosed herein, or their pharmaceutically acceptable salts, polymorphs, or solvates, to alleviate the symptoms or complications of a disease, condition, or disorder, or to eliminate the disease, condition, or disorder. The term “to treat” may also include the treatment of cell or animal models in vitro. References to “to treat” or “to heal” should be understood to include the alleviation of established symptoms of a condition. Therefore, “treating” a condition, disorder, or state, or “treating” a condition, disorder, or state, includes (1) preventing or delaying the onset of clinical symptoms of a condition, disorder, or state in a person who has or is susceptible to the condition, disorder, or state but has not yet experienced or shown any clinical or preclinical symptoms of the condition, disorder, or state; (2) inhibiting a condition, disorder, or state, i.e., stopping, reducing, or delaying the onset or recurrence of the disease (in the case of maintenance treatment), or at least one clinical or preclinical symptom thereof; or (3) reducing or attenuating the disease, i.e., causing regression of the condition, disorder, or state, or at least one clinical or preclinical symptom thereof.

[0568] It should be understood that the compounds, scaffolds, and conjugates of this disclosure, or any pharmaceutically acceptable salts, polymorphs, or solvates thereof, may also be used to prevent related diseases, conditions, or disorders, or to identify suitable candidates for such purposes.

[0569] As used herein, the terms “prevent,” “prevent,” or “protect from” describe reducing or eliminating the onset of symptoms or complications of such disease, condition, or disorder.

[0570] It should be understood that this disclosure also provides pharmaceutical compositions comprising any of the compounds, scaffolds, or conjugates described herein in combination with at least one pharmaceutically acceptable excipient or carrier.

[0571] As used herein, the term “pharmaceutical composition” refers to a formulation containing the compounds, scaffolds, or conjugates of the Disclosure in a form suitable for administration to a subject. In some embodiments, the pharmaceutical composition is a bulk or unit dosage form. A unit dosage form is any of various forms, including, for example, capsules, IV bags, tablets, a single pump on an aerosol inhaler, or a vial. The amount of the active ingredient (e.g., a formulation of the disclosed compound or its salts, hydrates, solvates, or isomers) in a unit dose of the composition is an effective amount and varies according to the specific treatment being addressed. Those skilled in the art will understand that it may be necessary to routinely change the dosage depending on the patient’s age and condition. The dosage also varies depending on the route of administration. Various routes are intended, including oral, pulmonary, rectal, parenteral, transdermal, subcutaneous, intravenous, intramuscular, intraperitoneal, inhalation, buccal, sublingual, intrapleural, intrathecal, and intranasal. Dosage forms for topical or transdermal administration of the compounds of this disclosure include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches, and inhalants. In some embodiments, the active compound is mixed under sterile conditions with a pharmaceutically acceptable carrier and any necessary preservatives, buffers, or sprays.

[0572] As used herein, the term “pharmaceutically acceptable” means a compound, scaffold, conjugate, anion, cation, material, composition, carrier, and / or dosage form that is suitable for use in contact with human and animal tissues without excessive toxicity, irritation, allergic response, or other problems or complications, within reasonable medical judgment, and that is commensurate with a reasonable benefit / risk ratio.

[0573] As used herein, the term “pharmaceutically acceptable excipient” means an excipient that is generally safe, non-toxic, and not biologically or otherwise undesirable, and is useful in preparing a pharmaceutical composition, and includes excipients that are acceptable for veterinary and human pharmaceutical use. As used herein and in the claims, “pharmaceutically acceptable excipient” includes both one excipient and two or more such excipients.

[0574] It should be understood that the pharmaceutical compositions of this disclosure are formulated to suit their intended route of administration. Examples of routes of administration include parenteral administration, e.g., intravenous, intradermal, subcutaneous, oral (e.g., ingestion), inhalation, transdermal (topical), and transmucosal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application may contain the following components: sterile diluents, e.g., water for injection, physiological saline, fixative oil, polyethylene glycol, glycerin, propylene glycol, or other synthetic solvents; antimicrobial agents, e.g., benzyl alcohol or methylparaben; antioxidants, e.g., ascorbic acid or sodium bisulfite; chelating agents, e.g., ethylenediaminetetraacetic acid; buffers, e.g., acetates, citrates, or phosphates; and isotonic modifiers, e.g., sodium chloride or dextrose. The pH can be adjusted with an acid or base such as hydrochloric acid or sodium hydroxide. Parenteral preparations may be sealed in glass or plastic ampoules, disposable syringes, or multi-dose vials.

[0575] It should be understood that the compounds or pharmaceutical compositions of this disclosure can be administered to subjects using many of the well-known methods currently used for chemotherapy. For example, the compounds of this disclosure may be injected into the bloodstream or body cavities, or ingested orally, or applied through the skin using a patch. The selected dose must be sufficient to constitute an effective treatment, but not so high as to cause unacceptable side effects. The state of the disease condition (e.g., the disease or disorder disclosed herein) and the patient's health condition should preferably be closely monitored for a reasonable period during and after treatment.

[0576] As used herein, the term “therapeutic effective dose” refers to the amount of an agent used to treat, improve or prevent a specific disease or condition, or to produce a detectable therapeutic or inhibitory effect. The effect can be detected by any assay method known in the art. The exact effective dose for a subject will vary depending on the subject’s weight, size, and health status, the nature and severity of the condition, and the therapeutic agent or combination of therapeutic agents selected for administration. The therapeutic effective dose for a given situation can be determined by routine experiments, within the scope of the clinician’s skill and judgment.

[0577] As used herein, the term “therapeutic effective dose” refers to the amount of an agent used to treat or improve a specific disease or condition, or to produce a detectable therapeutic or inhibitory effect. The effect can be detected by any assay method known in the art. The exact effective dose for a subject will vary depending on the subject’s weight, size, and health status, the nature and severity of the condition, and the therapeutic agent or combination of therapeutic agents selected for administration. The therapeutic effective dose for a given situation can be determined by routine experiments, within the scope of the clinician’s skill and judgment.

[0578] It should be understood that for any compound, the therapeutically effective dose can first be estimated, for example, in cell culture assays of neoplastic cells, or in animal models, usually rats, mice, rabbits, dogs, or pigs. Animal models can also be used to determine appropriate concentration ranges and routes of administration. Such information can then be used to determine useful doses and routes of administration in humans. Therapeutic / prophylactic efficacy and toxicity can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, for example, ED 50 (A therapeutically effective dose in 50% of the population), and LD 50 It can be determined by (the dose that is lethal to 50% of the population). The dose ratio between toxicity and therapeutic effect is the therapeutic index, LD 50 / ED 50It can be expressed as a ratio. Pharmaceutical compositions exhibiting a large therapeutic index are preferred. The dosage may vary within this range depending on the dosage form used, the patient's sensitivity, and the route of administration.

[0579] Dosage and administration are adjusted to provide a sufficient level of active agent or to maintain the desired effect. Factors to consider include the severity of the disease state, the subject's overall health status, age, weight, and sex, diet, timing and frequency of administration, drug combinations, sensitivity to response, and tolerability / response to treatment. Long-acting pharmaceutical compositions may be administered every 3-4 days, weekly, or every 2 weeks, depending on the half-life and clearance rate of the particular formulation.

[0580] Pharmaceutical compositions containing the active compounds of this disclosure can be manufactured in generally known ways, for example, by conventional mixing, dissolution, granulation, sugar-coating, polishing, emulsification, encapsulation, encapsulation, or lyophilization processes. The pharmaceutical compositions can be formulated in conventional ways using one or more pharmaceutically acceptable carriers containing excipients and / or adjuvants that facilitate the processing of the active compounds into pharmaceutically usable preparations. Naturally, the appropriate formulation will vary depending on the chosen route of administration.

[0581] Suitable pharmaceutical compositions for injection include sterile aqueous solutions (if water-soluble) or dispersions, and sterile powders for the rapid preparation of sterile injection solutions or dispersions. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL® (BASF, Parsippany, NJ), or phosphate-buffered saline (PBS). In all cases, the composition must be sterile and fluid enough to be easily injected. It must be stable under manufacturing and storage conditions and protected from contamination by microorganisms such as bacteria and fungi. The carrier may be a solvent or dispersion medium containing, for example, water, ethanol, polyols (e.g., glycerol, propylene glycol, and liquid polyethylene glycol), and suitable mixtures thereof. Adequate fluidity can be maintained, for example, by the use of coatings such as lecithin, by maintaining the required particle size in the case of dispersions, and by the use of surfactants. Microbial action can be prevented by various antimicrobial and antifungal agents, such as parabens, chlorobutanol, phenol, ascorbic acid, and thimerosal. In many cases, it is preferable to include isotonic agents, such as sugars, polyalcohols such as mannitol and sorbitol, and sodium chloride in the composition. Sustained absorption of the injectable composition can be achieved by including absorption-delaying agents, such as aluminum monostearate and gelatin, in the composition.

[0582] Sterile injectable solutions can be prepared by incorporating the required amount of the active compound into a suitable solvent, along with one or a combination of the components listed above as needed, followed by sterilization by filtration. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle containing a basic dispersion medium and other necessary components from those listed above. In the case of sterile powders for the preparation of sterile injectable solutions, the preparation method includes vacuum drying and freeze-drying, from which powders of the active component and any further desired components are obtained from a pre-sterilized filtered solution.

[0583] Oral compositions generally contain an inert diluent or a pharmaceutically acceptable food-grade carrier. They can be encapsulated in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, lozenges, or capsules. Oral compositions may also be prepared using a fluid carrier for use as a mouthwash, in which the compound in the fluid carrier is applied orally, gargled, spat out, or swallowed. Pharmaceutically compatible binders and / or auxiliary materials may be included as part of the composition. Tablets, pills, capsules, lozenges, etc. may contain any of the following ingredients or compounds of similar properties: binders such as microcrystalline cellulose, tragacanth gum, or gelatin; excipients such as starch or lactose; disintegrants such as alginic acid, Primogel, or corn starch; lubricants such as magnesium stearate or Sterotes; flow promoters such as colloidal silicon dioxide; sweeteners such as sucrose or saccharin; or flavoring agents such as peppermint, methyl salicylate, or orange flavoring agents.

[0584] For administration by inhalation, the compound is delivered in the form of an aerosol spray from a pressurized container or dispenser containing a suitable propellant, such as a gas like carbon dioxide, or from a nebulizer.

[0585] For intranasal administration, the compound is delivered in solution or solid form. In some embodiments, the compound is delivered as a solution, such as a mist, infusion, or swab. In some embodiments, the compound is delivered as a powder. In some embodiments, the compound is included in a kit further comprising an intranasal applicator.

[0586] Systemic administration may be by mucosal or transdermal means. In the case of mucosal or transdermal administration, a penetration agent suitable for the barrier to be penetrated is used in the formulation. Such penetration agents are generally known in the art, and examples of those for mucosal administration include surfactants, bile salts, and fusidic acid derivatives. Mucosal administration can be achieved by the use of nasal sprays or suppositories. For transdermal administration, the active compound is formulated into an ointment, plaster, gel, or cream, as is generally known in the art.

[0587] The active compound can be prepared with a pharmaceutically acceptable carrier that protects the compound from rapid elimination from the body, such as controlled-release formulations including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers such as ethylene vinyl acetate, polyanhydride, polyglycolic acid, collagen, polyorthoesters, and polylactic acid can be used. Methods for preparing such formulations will be apparent to those skilled in the art. The materials are also commercially available from Alza Corporation and Nova Pharmaceuticals, Inc. Liposome suspensions (containing liposomes targeted to infected cells with monoclonal antibodies against viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.

[0588] For ease of administration and uniformity of dosage, it is particularly advantageous to formulate oral or parenteral compositions into unit dosage forms. As used herein, a unit dosage form refers to a physically distinct unit suitable as a unit dose for the target to be treated, and each unit contains a predetermined amount of the active compound calculated to produce the desired therapeutic effect in conjunction with the necessary pharmaceutical carrier. The specifications of the unit dosage forms in this disclosure are determined by the inherent characteristics of the active compound and the specific therapeutic effect to be achieved, and vary directly accordingly.

[0589] In therapeutic applications, the dosage of a pharmaceutical composition used in accordance with this disclosure will vary depending on factors influencing the selected dosage, particularly the drug, the age, weight, and clinical condition of the recipient patient, and the experience and judgment of the clinician or practitioner administering the treatment. Generally, the dosage should be sufficient to delay, preferably regress, and preferably cause complete regression of the symptoms of the disease or disorder disclosed herein. Dosages may range from about 0.01 mg / kg / day to about 5000 mg / kg / day. The effective dose of a pharmaceutical is the amount that provides an objectively identifiable improvement as recognized by a clinician or other qualified observer. Improvement in survival and growth indicates regression. As used herein, the term “dose-effective mode” refers to the amount of the active compound that produces the desired biological effect in the subject or cell.

[0590] Please understand that the pharmaceutical composition may be included in the container, pack, or dispenser along with instructions for administration.

[0591] It should be understood that all forms of the compounds, scaffolds, or conjugates of this disclosure that can further form salts are also contemplated within the scope of the claimed disclosure.

[0592] As used herein, the term “pharmaceutically acceptable salt” refers to a derivative of a compound of the disclosed herein, wherein the parent compound is modified by forming an acid or base salt thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral acid organic salts of basic residues such as amines, and alkali organic salts of acidic residues such as carboxylic acids. Examples of pharmaceutically acceptable salts include conventional non-toxic salts or quaternary ammonium salts of the parent compound formed from non-toxic inorganic organic acids. For example, such conventional non-toxic salts include 2-acetoxybenzoic acid, 2-hydroxyethanesulfonic acid, acetic acid, ascorbic acid, benzenesulfonic acid, benzoic acid, bicarbonate, carbonic acid, citric acid, edetic acid, ethanedisulfonic acid, 1,2-ethanesulfonic acid, fumaric acid, glucoheptonic acid, gluconic acid, glutamic acid, glycolic acid, glycolyarsanilic acid, hexylresorcinic acid, hydrabamic acid, hydrobromic acid, hydrochloric acid, hydroiodic acid, hydroxymaleic acid, and hydroxy Examples include, but are not limited to, those derived from inorganic and organic acids selected from commonly existing amine acids, such as naphthoic acid, isethionic acid, lactic acid, lactobionic acid, lauryl sulfonic acid, maleic acid, malic acid, mandelic acid, methanesulfonic acid, napsylic acid, nitric acid, oxalic acid, pamoic acid, pantothenic acid, phenylacetic acid, phosphoric acid, polygalacturonic acid, propionic acid, salicylic acid, stearic acid, hypoacetic acid, succinic acid, sulfamic acid, sulfanilic acid, sulfuric acid, tannic acid, tartaric acid, toluenesulfonic acid, and inorganic and organic acids selected from commonly existing amine acids, such as glycine, alanine, phenylalanine, and arginine.

[0593] In some embodiments, pharmaceutically acceptable salts include sodium salts, potassium salts, calcium salts, magnesium salts, diethylamine salts, choline salts, meglumine salts, benzathine salts, trometamic acid salts, ammonia salts, arginine salts, or lysine salts.

[0594] Other examples of pharmaceutically acceptable salts include hexanoic acid, cyclopentanepropionic acid, pyruvate, malonic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo-[2.2.2]-octa-2-ene-1-carboxylic acid, 3-phenylpropionic acid, trimethylacetic acid, tert-butylacetic acid, and muconic acid. The disclosure also includes salts formed when an acidic proton present in the parent compound is substituted with a metal ion, such as an alkali metal ion, an alkaline earth ion, or an aluminum ion, or when it coordinates with an organic base such as ethanolamine, diethanolamine, triethanolamine, tromethamine, or N-methylglucamine. In salt form, it is understood that the ratio of the compound to the salt cation or anion can be 1:1, or any other ratio, such as 3:1, 2:1, 1:2, or 1:3.

[0595] It should be understood that all references to pharmaceutically acceptable salts include the solubilated form (solvate) or crystalline form (polymorph) of the same salt as defined herein.

[0596] The compound or a pharmaceutically acceptable salt thereof may be administered orally, nasally, percutaneously, pulmonaryly, by inhalation, orally, sublingually, intraperitoneally, subcutaneously, intramuscularly, intravenously, rectally, intrapleurally, intrathecally, and parenterally. In some embodiments, the compound is administered orally. Those skilled in the art will recognize the advantages of specific routes of administration.

[0597] The dosage regimen utilizing the compound is selected according to various factors including the patient's type, breed, age, weight, sex, and medical condition, the severity of the condition to be treated, the route of administration, the patient's renal and hepatic function, and the specific compound or salt thereof used. A normally skilled physician or veterinarian can easily determine and prescribe the effective dose of the drug necessary to prevent, counteract, or halt the progression of the condition. A normally skilled physician or veterinarian can easily determine and prescribe the effective dose of the drug necessary to counteract or halt the progression of the condition.

[0598] The technologies for formulation and administration of the compounds disclosed in this disclosure are described in Remington: The Science and Practice of Pharmacy, 19 th This can be found in edition, Mack Publishing Co., Easton, PA (1995). In one embodiment, the compounds described herein and their pharmaceutically acceptable salts are used in combination with a pharmaceutically acceptable carrier or diluent in a pharmaceutical preparation. Suitable pharmaceutically acceptable carriers include inert solid fillers or diluents and sterile organic aqueous solutions. The compounds are present in such pharmaceutical compositions in an amount sufficient to provide a desired dosage within the range described herein.

[0599] All percentages and ratios used herein are by weight unless otherwise indicated. Other features and advantages of this disclosure are evident from the various examples. The provided examples illustrate different components and methodologies useful in carrying out this disclosure. The examples do not limit the claimed disclosure. Based on this disclosure, those skilled in the art can identify and use other components and methods useful in carrying out this disclosure.

[0600] In the synthetic schemes described herein, compounds may be depicted in one particular stereoconfiguration for simplification. Such a particular stereoconfiguration should not be construed as limiting this disclosure to one or another isomer, tautomer, regioisomer, or stereoisomer, nor does it exclude mixtures of isomers, tautomers, regioisomers, or stereoisomers. However, it will be understood that a given isomer, tautomer, regioisomer, or stereoisomer may have a higher level of activity than another isomer, tautomer, regioisomer, or stereoisomer.

[0601] All publications and patent documents are incorporated herein by reference to the same extent as each such publication or patent document is specifically and individually indicated as being incorporated herein by reference. No citation of publications or patent documents is intended to be considered relevant prior art and does not constitute any endorsement of their content or date. While the present invention has been described in writing, those skilled in the art will recognize that the invention can be carried out in various embodiments, and that the foregoing description and the following examples are illustrative and not intended to limit the following embodiments and claims.

[0602] Further Embodiments Embodiment 1. A compound of formula (I) or (II), [ka] or a pharmaceutically acceptable salt thereof, in the formula, W is H, a C1-C6 alkyl group optionally substituted with one or more halogens, or an amino substituent. X is H, halogen, or -OR X And, R X However, H, C1-C6 alkyl, or -(C1-C6 alkyl)-(C6-C 10 It is an aryl and is C1-C6 alkyl or -(C1-C6 alkyl)-(C6-C 10 aryl) has one or more R Xa Replaced by optional selection, Each R Xa However, independently, they are halogens, C1-C6 alkyls, or -O-(C1-C6 alkyls), and the C1-C6 alkyl or -O-(C1-C6 alkyl) is optionally substituted with one or more halogens. Y is a C1-C6 alkyl group optionally substituted with H, one or more halogens, -P(R Y )2, -P(OR Y )(N(R Y )2), -P(=O)(OR Y )R Y , -P(=S)(ORY )R Y -P(=O)(SR Y )R Y -P(=S)(SR Y )R Y , -P(=O)(OR Y )2, -P(=S)(OR Y )2, -P(=O)(SR Y )2, -P(=S)(SR Y )2, or a hydroxy protecting group, Each R Y However, independently, they are C1-C6 alkyl groups optionally substituted with H, or one or more halogens or cyano compounds. Z is a C1-C6 alkyl group optionally substituted with H or one or more halogens, -P(R Z )2, -P(OR Z )(N(R Z )2), -P(=O)(OR Z )R Z , -P(=S)(OR Z )R Z -P(=O)(SR Z )R Z -P(=S)(SR Z )R Z , -P(=O)(OR Z )2, -P(=S)(OR Z )2, -P(=O)(SR Z )2, -P(=S)(SR Z )2, or a hydroxy protecting group, Each R Z However, independently, it is a C1-C6 alkyl group optionally substituted with H, or one or more halogens or cyano compounds. Alternatively, Y and Z in equation (I) together become -Si(R L )2-O-Si(R L )2- forms, and each R L However, independently, they are H or C1-C6 alkyl, Each R a However, independently, they are C1-C6 alkyl groups optionally substituted with H, a halogen, or one or more halogens, or two R atoms on two adjacent carbon atoms. aHowever, together with two adjacent carbon atoms, it forms a double bond. Each R b However, independently, they are C1-C6 alkyl groups optionally substituted with H, a halogen, or one or more halogens. R 1 However, it is a C1-C6 alkyl group optionally substituted with H, a halogen, or one or more halogens. R 2 However, it is a C1-C6 alkyl group optionally substituted with H, a halogen, or one or more halogens. R 3 However, it is a C1-C6 alkyl group optionally substituted with H, a halogen, or one or more halogens. R 4 However, it is a C1-C6 alkyl group optionally substituted with H, a halogen, or one or more halogens. Each R 5 However, independently, they are C1-C6 alkyl groups optionally substituted with H, a halogen, or one or more halogens. A compound in which n is an integer in the range of approximately 0 to approximately 10.

[0603] Embodiment 2. A scaffold or a pharmaceutically acceptable salt thereof, wherein the scaffold is (i) ligand, and (ii) A linker unit, where the linker unit is [ka] It includes linker units, In the formula, the variable element R 1 , R 2 , R 3 , R 4 , R 5 X, Y, Z, R a , R b , and n are as described in Embodiment 1, and # indicates a scaffold or a pharmaceutically acceptable salt thereof, wherein # indicates binding to a ligand.

[0604] Embodiment 3. A scaffold or a pharmaceutically acceptable salt thereof, wherein the scaffold is (i) one or more nucleic acid agents, and (ii) One or more linker units, each linker unit independently [ka] It includes one or more linker units, In the formula, the variable element R 1 , R 2 , R 3 , R 4 , R 5 W, X, Y, Z, R a , R b and n are as described in Embodiment 1, and ## is a scaffold or a pharmaceutically acceptable salt thereof that exhibits binding to a nucleic acid agent.

[0605] Embodiment 4. A conjugate or a pharmaceutically acceptable salt thereof, wherein the conjugate is (i) One or more nucleic acid agents, (ii) one or more ligands, and (iii) One or more linker units, each linker unit independently [ka] It includes one or more linker units, In the formula, the variable element R 1 , R 2 , R 3 , R 4 , R 5 X, Y, Z, R a , R b A conjugate or a pharmaceutically acceptable salt thereof, wherein n is as described in Embodiment 1, # indicates binding to a ligand, and ## indicates binding to a nucleic acid agent.

[0606] Embodiment 5. A compound, scaffold, or conjugate of any one of the prior embodiments in which W is H.

[0607] Embodiment 6. A compound, scaffold, or conjugate of any one of the preceding embodiments, wherein W is a C1-C6 alkyl group optionally substituted with one or more halogens.

[0608] Embodiment 7. A compound, scaffold, or conjugate of any one of the preceding embodiments, wherein W is an amino substituent.

[0609] Embodiment 8. A compound, scaffold, or conjugate from any one of the preceding embodiments, wherein W is fluorenylmethyloxycarbonyl (Fmoc), tert-butyloxycarbonyl (BOC), benzyloxycarbonyl (Cbz), optionally substituted acyl, trifluoroacetyl (TFA), benzyl, triphenylmethyl (Tr), 4,4'-dimethoxytrityl (DMTr), or toluenesulfonyl (Ts).

[0610] Embodiment 9. A compound, scaffold, or conjugate of any one of the preceding embodiments, wherein W is an optionally substituted acyl.

[0611] Embodiment 10. A compound, scaffold, or conjugate from any one of the prior embodiments, wherein W is trifluoroacetyl (TFA).

[0612] Embodiment 11.X is a compound, scaffold, or conjugate of any one of the prior embodiments, wherein H is the compound, scaffold, or conjugate.

[0613] Embodiment 12.X is a compound, scaffold, or conjugate of any one of the prior embodiments, wherein the compound is a halogen.

[0614] Embodiment 13.X is -OR X A compound, scaffold, or conjugate of any one of the prior embodiments.

[0615] Embodiment 14.X is a compound, scaffold, or conjugate of any one of the prior embodiments, wherein the compound is -OH.

[0616] Embodiment 15.X is a compound, scaffold, or conjugate of any one of the preceding embodiments, wherein the compound is -O-(C1-C6 alkyl).

[0617] Embodiment 16.X is a compound, scaffold, or conjugate of any one of the preceding embodiments, wherein the compound is -O-(C1~C6 alkyl)-O-(C1~C6 alkyl).

[0618] Embodiment 17.X is one or more R Xa -O-(C1~C6 alkyl)-(C6~C 10 A compound, scaffold, or conjugate of any one of the prior embodiments, which is an aryl compound.

[0619] Embodiment 18.X is -O-(C1~C6 alkyl)-(C6~C 10 A compound, scaffold, or conjugate of any one of the prior embodiments, which is an aryl compound.

[0620] Embodiment 19.R X However, H is a compound, scaffold, or conjugate of any one of the prior embodiments.

[0621] Embodiment 20.R X However, the compound, scaffold, or conjugate of any one of the preceding embodiments is a C1-C6 alkyl or an -O-(C1-C6 alkyl) optionally substituted with one or more halogens.

[0622] Embodiment 21.R X However, -(C1~C6 alkyl)-(C6~C) is optionally substituted with one or more halogens. 10 A compound, scaffold, or conjugate from any one of the preceding embodiments, which is aryl, C1-C6 alkyl, or -O-(C1-C6 alkyl), where the C1-C6 alkyl or -O-(C1-C6 alkyl) is optionally substituted with one or more halogens.

[0623] Embodiment 22.R X However, -(C1~C6 alkyl)-(C6~C 10 A compound, scaffold, or conjugate of any one of the prior embodiments, which is an aryl compound.

[0624] Embodiment 23. A compound, scaffold, or conjugate of any one of the prior embodiments in which Y is H.

[0625] Embodiment 24. A compound, scaffold, or conjugate from any one of the preceding embodiments, wherein Y is a C1-C6 alkyl group optionally substituted with one or more halogens.

[0626] Embodiment 25.Y is -P(R Y )2, -P(OR Y )(N(R Y )2), -P(=O)(OR Y )R Y , -P(=S)(OR Y )R Y -P(=O)(SR Y )R Y -P(=S)(SR Y )R Y , -P(=O)(OR Y )2, -P(=S)(OR Y )2, -P(=O)(SR Y )2, -P(=S)(SR Y )2, a compound, scaffold, or conjugate of any one of the prior embodiments.

[0627] Embodiment 26. A compound, scaffold, or conjugate from any one of the preceding embodiments, wherein Y is a hydroxy protecting group.

[0628] Embodiment 27. A compound, scaffold, or conjugate of any one of the preceding embodiments, wherein Y is silyl.

[0629] Embodiment 28. A compound, scaffold, or conjugate from any one of the preceding embodiments, wherein Y is triphenylmethyl (Tr) or 4,4'-dimethoxytrityl (DMTr).

[0630] Embodiment 29. A compound, scaffold, or conjugate from any one of the preceding embodiments, wherein Y is optionally substituted with an acyl or benzyl.

[0631] Embodiment 30. At least one R Y However, H is a compound, scaffold, or conjugate of any one of the prior embodiments.

[0632] Embodiment 31. At least one R Y However, the compound, scaffold, or conjugate of any one of the preceding embodiments is a C1-C6 alkyl which is optionally substituted with one or more halogens or cyanosides.

[0633] Embodiment 32. At least one R Y However, H is and at least one R Y However, the compound, scaffold, or conjugate of any one of the preceding embodiments is a C1-C6 alkyl which is optionally substituted with one or more halogens or cyanosides.

[0634] Embodiment 33. A compound, scaffold, or conjugate of any one of the prior embodiments in which Z is H.

[0635] Embodiment 34. A compound, scaffold, or conjugate of any one of the preceding embodiments, wherein Z is a C1-C6 alkyl group optionally substituted with one or more halogens.

[0636] Embodiment 35.Z is -P(R Z )2, -P(OR Z )(N(R Z )2), -P(=O)(OR Z )R Z , -P(=S)(OR Z )R Z -P(=O)(SR Z )R Z -P(=S)(SR Z )R Z , -P(=O)(OR Z )2, -P(=S)(OR Z)2, -P(=O)(SR Z )2, -P(=S)(SR Z )2, a compound, scaffold, or conjugate of any one of the prior embodiments.

[0637] Embodiment 36. A compound, scaffold, or conjugate of any one of the preceding embodiments, wherein Z is a hydroxy protecting group.

[0638] Embodiment 37.Z is a compound, scaffold, or conjugate of any one of the prior embodiments, wherein Z is silyl.

[0639] Embodiment 38.Z is a compound, scaffold, or conjugate from any one of the preceding embodiments, wherein Z is triphenylmethyl (Tr) or 4,4'-dimethoxytrityl (DMTr).

[0640] Embodiment 39.Z is a compound, scaffold, or conjugate from any one of the preceding embodiments, wherein Z is a substituted acyl or benzyl.

[0641] Embodiment 40. At least one R Z However, H is a compound, scaffold, or conjugate of any one of the prior embodiments.

[0642] Embodiment 41. At least one R Z However, the compound, scaffold, or conjugate of any one of the preceding embodiments is a C1-C6 alkyl which is optionally substituted with one or more halogens or cyanosides.

[0643] Embodiment 42. At least one R Z However, H is and at least one R Z However, the compound, scaffold, or conjugate of any one of the preceding embodiments is a C1-C6 alkyl which is optionally substituted with one or more halogens or cyanosides.

[0644] Embodiment 43. In formula (I), Y and Z together become -Si(R L )2-O-Si(RL )2- A compound, scaffold, or conjugate of any one of the prior embodiments that forms a compound, scaffold, or conjugate.

[0645] Embodiment 44. At least one R L However, H is a compound, scaffold, or conjugate of any one of the prior embodiments.

[0646] Embodiment 45. Each R L However, independently, one of the compounds, scaffolds, or conjugates of the preceding embodiments, which is a C1-C6 alkyl group.

[0647] Embodiment 46. Each R a However, H is a compound, scaffold, or conjugate of any one of the prior embodiments.

[0648] Embodiment 47. At least one R a However, the compound, scaffold, or conjugate of any one of the preceding embodiments is a halogen, or a C1-C6 alkyl optionally substituted with one or more halogens.

[0649] Embodiment 48. Each R b However, H is a compound, scaffold, or conjugate of any one of the prior embodiments.

[0650] Embodiment 49. At least one R b However, the compound, scaffold, or conjugate of any one of the preceding embodiments is a halogen, or a C1-C6 alkyl optionally substituted with one or more halogens.

[0651] Embodiment 50.R 1 However, H is a compound, scaffold, or conjugate of any one of the prior embodiments.

[0652] Embodiment 51.R 1 However, the compound, scaffold, or conjugate of any one of the prior embodiments is a halogen.

[0653] Embodiment 52.R 1 However, the compound, scaffold, or conjugate of any one of the preceding embodiments is a C1-C6 alkyl which is optionally substituted with one or more halogens.

[0654] Embodiment 53.R 2 However, H is a compound, scaffold, or conjugate of any one of the prior embodiments.

[0655] Embodiment 54.R 2 However, the compound, scaffold, or conjugate of any one of the prior embodiments is a halogen.

[0656] Embodiment 55.R 2 However, the compound, scaffold, or conjugate of any one of the preceding embodiments is a C1-C6 alkyl which is optionally substituted with one or more halogens.

[0657] Embodiment 56.R 3 However, H is a compound, scaffold, or conjugate of any one of the prior embodiments.

[0658] Embodiment 57.R 3 However, the compound, scaffold, or conjugate of any one of the prior embodiments is a halogen.

[0659] Embodiment 58.R 3 However, the compound, scaffold, or conjugate of any one of the preceding embodiments is a C1-C6 alkyl which is optionally substituted with one or more halogens.

[0660] Embodiment 59.R 4 However, H is a compound, scaffold, or conjugate of any one of the prior embodiments.

[0661] Embodiment 60.R 4 However, the compound, scaffold, or conjugate of any one of the prior embodiments is a halogen.

[0662] Embodiment 61.R 4 However, the compound, scaffold, or conjugate of any one of the preceding embodiments is a C1-C6 alkyl which is optionally substituted with one or more halogens.

[0663] Embodiment 62.R 5 However, H is a compound, scaffold, or conjugate of any one of the prior embodiments.

[0664] Embodiment 63.R 5 However, the compound, scaffold, or conjugate of any one of the prior embodiments is a halogen.

[0665] Embodiment 64.R 5 However, the compound, scaffold, or conjugate of any one of the preceding embodiments is a C1-C6 alkyl which is optionally substituted with one or more halogens.

[0666] Embodiment 65.R a , R b , R 1 , R 2 , R 3 , R 4 , and R 5 Each of the compounds, scaffolds, or conjugates of any one of the preceding embodiments is H.

[0667] Embodiment 66.n is a compound, scaffold, or conjugate of any one of the preceding embodiments, where the integer is in the range of about 1 to about 10, about 2 to about 10, about 3 to about 10, about 4 to about 10, about 5 to about 10, or about 6 to about 10.

[0668] Embodiment 67.n is a compound, scaffold, or conjugate of any one of the preceding embodiments, where the integer is in the range of about 2 to about 8, about 2 to about 7, about 2 to about 6, about 2 to about 5, about 2 to about 4, or about 2 to about 3.

[0669] Embodiment 68. The compound is of formula (I'-1), (I'-2), (II'-1), or (II'-2): [ka] things, A compound from any one of the preceding embodiments, or a pharmaceutically acceptable salt thereof.

[0670] Embodiment 69. The compound is of formula (IA) or (II-A): [ka] things, A compound from any one of the preceding embodiments, or a pharmaceutically acceptable salt thereof.

[0671] Embodiment 70. The compound is of formula (I-A'-1), (I-A'-2), (II-A'-1), or (II-A'-2): [ka] things, A compound from any one of the preceding embodiments, or a pharmaceutically acceptable salt thereof.

[0672] Embodiment 71. The compound is of formula (IB) or (II-B): [ka] things, A compound from any one of the preceding embodiments, or a pharmaceutically acceptable salt thereof.

[0673] Embodiment 72. The compound is of formula (I-B'-1), (I-B'-2), (II-B'-1), or (II-B'-2): [ka] things, A compound from any one of the preceding embodiments, or a pharmaceutically acceptable salt thereof.

[0674] Embodiment 73. Y is a hydroxy protecting group, and Z is a hydroxy protecting group, or In equations (I), (I'-1), (I'-2), (IA), (I-A'-1), (I-A'-2), (IB), (I-B'-1), or (I-B'-2), Y and Z together form -Si(R L )2-O-Si(R L )2- forms, and each R L However, independently, one of the compounds from the preceding embodiments is H or C1-C6 alkyl.

[0675] Embodiment 74. The compound is [ka] or a pharmaceutically acceptable salt thereof, in the formula, Y is -P(R Y )2, -P(OR Y )(N(R Y )2), -P(=O)(OR Y )R Y , -P(=S)(OR Y )R Y -P(=O)(SR Y )R Y -P(=S)(SR Y )R Y , -P(=O)(OR Y )2, -P(=S)(OR Y )2, -P(=O)(SR Y )2, -P(=S)(SR Y )2, or a hydroxy protecting group, Each R Y However, independently, they are C1-C6 alkyl groups optionally substituted with H, or one or more halogens or cyano compounds. Z is -P(R Z )2, -P(OR Z )(N(R Z )2), -P(=O)(OR Z )R Z , -P(=S)(OR Z )R Z -P(=O)(SR Z )R Z -P(=S)(SR Z )R Z , -P(=O)(ORZ )2, -P(=S)(OR Z )2, -P(=O)(SR Z )2, -P(=S)(SR Z )2, or a hydroxy protecting group, Each R Z However, independently, any one of the compounds from the preceding embodiments is a C1-C6 alkyl group optionally substituted with H, or one or more halogens or cyano compounds.

[0676] Embodiment 75. A compound from any one of the preceding embodiments, wherein the compound is selected from the compounds listed in Table L and their pharmaceutically acceptable salts.

[0677] Embodiment 76. A compound that is an isotopic derivative of any one of the compounds in the preceding embodiments.

[0678] Embodiment 77. The scaffolding is (in linker units) p -((Nucleic acid agent)-(Linker unit) s ) r -(Nucleic acid agent) q And, Each linker unit is independent of other linker units, and each nucleic acid agent is independent of other nucleic acid agents. Each r is an independent integer in the range of 0 to 10. Each s is an independent integer in the range of 0 to 10. p is an integer in the range of 0 to 10. q is 0 or 1, A scaffold from any one of the prior embodiments, wherein the scaffold comprises at least one linker unit and at least one nucleic acid agent.

[0679] Embodiment 78. The scaffolding is [ka] or a pharmaceutically acceptable salt thereof, in the formula, Y is -P(R Y )2, -P(OR Y )(N(R Y )2), -P(=O)(ORY )R Y , -P(=S)(OR Y )R Y -P(=O)(SR Y )R Y -P(=S)(SR Y )R Y , -P(=O)(OR Y )2, -P(=S)(OR Y )2, -P(=O)(SR Y )2, -P(=S)(SR Y )2, or a hydroxy protecting group, Each R Y However, independently, they are C1-C6 alkyl groups optionally substituted with H, or one or more halogens or cyano compounds. Z is -P(R Z )2, -P(OR Z )(N(R Z )2), -P(=O)(OR Z )R Z , -P(=S)(OR Z )R Z -P(=O)(SR Z )R Z -P(=S)(SR Z )R Z , -P(=O)(OR Z )2, -P(=S)(OR Z )2, -P(=O)(SR Z )2, -P(=S)(SR Z )2, or a hydroxy protecting group, Each R Z However, independently, they are C1-C6 alkyl groups optionally substituted with H, or one or more halogens or cyano compounds. A scaffold from any one of the preceding embodiments, where n is an integer in the range of approximately 0 to approximately 10.

[0680] Embodiment 79. A scaffold selected from the scaffolds listed in Table S1, which is one of the scaffolds from the preceding embodiments.

[0681] Embodiment 80. The scaffolding is [ka] or a pharmaceutically acceptable salt thereof, in the formula, W is an amino substituent, A scaffold from any one of the preceding embodiments, where n is an integer in the range of approximately 0 to approximately 10.

[0682] Embodiment 81. A scaffold selected from the scaffolds listed in Table S2, which is one of the scaffolds from any of the preceding embodiments.

[0683] Embodiment 82. The conjugate is (linker unit - (ligand) 0-1 ) p -((Nucleic acid agent)-(Linker unit-(Ligand) 0-1 ) s ) r -(Nucleic acid agent) q And in the formula, Each linker unit is independent of other linker units, each nucleic acid agent is independent of other nucleic acid agents, and each ligand is independent of other ligands. Each r is an independent integer in the range of 0 to 10. Each s is an independent integer in the range of 0 to 10. p is an integer in the range of 0 to 10. q is 0 or 1, A conjugate according to any one of the prior embodiments, wherein the conjugate comprises at least one linker unit, at least one nucleic acid agent, and at least one ligand.

[0684] Embodiment 83. A conjugate selected from any one of the preceding embodiments, wherein the conjugate is selected from the conjugates listed in Table C.

[0685] Embodiment 84. A linker unit of formula (I), wherein W is replaced by binding to a ligand, the scaffold or conjugate of any one of the preceding embodiments.

[0686] Embodiment 85. A scaffold or conjugate of any one of the preceding embodiments, wherein the linker unit is of formula (I), where Y and / or Z are replaced by binding to a nucleic acid agent.

[0687] Embodiment 86. A scaffold or conjugate of any one of the preceding embodiments, wherein the ligand comprises a carbohydrate moiety.

[0688] Embodiment 87. A scaffold or conjugate of any one of the preceding embodiments, wherein the carbohydrate portion comprises a monosaccharide, disaccharide, trisaccharide, or tetrasaccharide.

[0689] Embodiment 88. A scaffold or conjugate of any one of the preceding embodiments, wherein the carbohydrate portion comprises galactose or a derivative thereof.

[0690] Embodiment 89. The ligand is [ka] A scaffold or conjugate, including any one of the preceding embodiments.

[0691] Embodiment 90. The ligand is [ka] A scaffold or conjugate, including any one of the preceding embodiments.

[0692] Embodiment 91. The ligand is [ka] A scaffold or conjugate, including any one of the preceding embodiments.

[0693] Embodiment 92. The ligand is [ka] A scaffold or conjugate, including any one of the preceding embodiments.

[0694] Embodiment 93. The ligand is [ka] A scaffold or conjugate, including any one of the preceding embodiments.

[0695] Embodiment 94. The ligand is [ka] A scaffold or conjugate, including any one of the preceding embodiments.

[0696] Embodiment 95. The ligand is [ka] A scaffold or conjugate, including any one of the preceding embodiments.

[0697] Embodiment 96. The ligand is [ka] A scaffold or conjugate, including any one of the preceding embodiments.

[0698] Embodiment 97. The ligand is [ka] A scaffold or conjugate, including any one of the preceding embodiments.

[0699] Embodiment 98. The ligand is [ka] A scaffold or conjugate, including any one of the preceding embodiments.

[0700] Embodiment 99. The ligand is [ka] A scaffold or conjugate, including any one of the preceding embodiments.

[0701] Embodiment 100. The ligand is [ka] A scaffold or conjugate, including any one of the preceding embodiments.

[0702] Embodiment 101. The ligand is [ka] A scaffold or conjugate, including any one of the preceding embodiments.

[0703] Embodiment 102. The ligand is [ka] A scaffold or conjugate, including any one of the preceding embodiments.

[0704] Embodiment 103. The ligand is [ka] A scaffold or conjugate, including any one of the preceding embodiments.

[0705] Embodiment 104. The ligand is [ka] A scaffold or conjugate, including any one of the preceding embodiments.

[0706] Embodiment 105. A scaffold or conjugate of any one of the prior embodiments, wherein the ligand comprises a lipid.

[0707] Embodiment 106. A scaffold or conjugate of any one of the preceding embodiments, wherein the ligand includes a peptide moiety.

[0708] Embodiment 107. A scaffold or conjugate of any one of the preceding embodiments, wherein the ligand includes an antibody moiety.

[0709] Embodiment 108. A scaffold or conjugate of any one of the prior embodiments, wherein the nucleic acid agent comprises an oligonucleotide.

[0710] Embodiment 109. A scaffold or conjugate of any one of the prior embodiments, wherein the nucleic acid agent comprises one or more phosphate groups or one or more analogs of phosphate groups.

[0711] Embodiment 110. A scaffold or conjugate of any one of the preceding embodiments, wherein a linker unit is bound to a nucleic acid agent via a phosphate group or an analogue of a phosphate group in the nucleic acid agent.

[0712] Embodiment 111. A scaffold or conjugate of any one of the prior embodiments, wherein the nucleic acid agent comprises RNA.

[0713] Embodiment 112. A scaffold or conjugate of any one of the preceding embodiments, wherein the oligonucleotide is an siRNA, microRNA, anti-microRNA, microRNA mimetic, anti-miR, antagomir, dsRNA, ssRNA, aptamer, immunostimulatory oligonucleotide, decoy oligonucleotide, splice-modified oligonucleotide, triple-stranded oligonucleotide, G-quadrivalent, or antisense oligonucleotide.

[0714] Embodiment 113. A pharmaceutical composition comprising a compound, scaffold, or conjugate of any one of the prior embodiments.

[0715] Embodiment 114. A method for regulating the expression of a target gene in a subject, comprising administering a conjugate of any one of the prior embodiments to the subject.

[0716] Embodiment 115. A method for delivering a nucleic acid agent, comprising administering it to a conjugate of any one of the prior embodiments.

[0717] Embodiment 116. A method for treating or preventing a disease in a subject requiring treatment or prevention, comprising administering a therapeutically effective amount of one of the preceding embodiments of a conjugate to the subject.

[0718] Embodiment 117. A conjugate of any one of the prior embodiments for regulating the expression of a target gene in a subject.

[0719] Embodiment 118. A conjugate of any one of the prior embodiments for target delivery of a nucleic acid agent.

[0720] Embodiment 119. A conjugate of any one of the prior embodiments for use in a subject requiring treatment or prevention of a disease.

[0721] Embodiment 120. Use of any one of the preceding embodiments of a conjugate in the manufacture of a pharmaceutical product for modulating the expression of a target gene in a subject.

[0722] Embodiment 121. Use of one of the conjugates from the prior embodiments in the manufacture of a pharmaceutical product for target delivery of a nucleic acid agent.

[0723] Embodiment 122. Use of any one of the preceding embodiments in the manufacture of a pharmaceutical product for a subject requiring treatment or prevention of a disease.

[0724] Embodiment 123. Any one of the methods, conjugates, or uses of the prior embodiments, wherein the subject is a human. [Examples]

[0725] Example 1. Synthesis of 1'-Debase-Alpha-C-alkyl-GalNAc. [ka] Synthesis of (2R,3R,4S,5R)-2-(acetoxymethyl)-5-allyltetrahydrofuran-3,4-diyldiacetate (1-2). To a solution of compound 1-1 (50.0 g, 157.1 mmol) and compound 1a (52.1 g, 455.58 mmol) in MeCN (500 mL), TMSOTf (41.9 g, 188.52 mmol) was added at 0°C, and the mixture was stirred at 15°C for 2 hours. The mixture was then quenched with aqueous NaHCO3 (500 mL) and extracted with dimethyl (3 × 5 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated under vacuum. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 5 / 1 to 1 / 1) to obtain compound 1-2 (45.6 g, yield 96.7%) as yellow oil. 1 H NMR:400MHz,DMSO-d6,δ5.75-5.67(m,1H),5.31-5.30(m,1H),5.29-5.22(m,1H),5.10(d,J=1.6Hz,1H),5.06- 5.01(m,1H),4.25-4.16(m,2H),4.09-4.06(m,2H),2.50-2.24(m,2H),2.09(s,3H),2.03(s,3H),1.98(s,3H).

[0726] Synthesis of (2R,3R,4S,5R)-2-allyl-5-(hydroxymethyl)tetrahydrofuran-3,4-diol (1-3). To a solution of compound 1-2 (45.6 g, 151.85 mol) in MeOH (456 mL), NaOMe (2.73 g, 15.18 mmol, 30% purity) was added at 0°C. The mixture was stirred at 15°C for 1 hour and neutralized with AcOH (0.1 mL). The mixture was concentrated under vacuum to obtain compound 1-3 (32.1 g, crude) as a yellow oil, which was used in the next step without further purification.

[0727] Synthesis of (6aR,8R,9S,9aS)-8-allyl-2,2,4,4-tetraisopropyltetrahydro-6H-flu[3,2-f][1,3,5,2,4]-trioxadisylosin-9-ol(1-4). To a solution of compounds 1-3 (26.5 g, 151.84 mmol) in Py(265 mL), TIPSCl(52.7 g, 167.03 mmol) was added at 0°C. The mixture was stirred at 25°C for 16 hours, quenched with 20 mL of MeOH, and concentrated under vacuum. The residue was then dissolved in Depositphotos(300 mL), washed with citric acid aqueous solution(300 mL x 2) and brine(300 mL), dried over anhydrous Na2SO4, filtered, and concentrated under vacuum. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 20 / 1 to 1 / 1) to obtain compounds 1-4 (48.3 g, yield 76.3%) as yellow oil. 1 H NMR:400MHz,DMSO-d6,δ5.82-5.73(m,1H),5.10-4.98(m,2H),4.71(d,J=4.0Hz,1H),4.23- 4.20(m,1H),3.94-3.89(m,1H),3.82-3.74(m,4H),2.36-2.20(m,2H),1.04-0.95(m,29H).

[0728] Synthesis of (6aR,8R,9S,9aR)-8-allyl-2,2,4,4-tetraisopropyl-9-methoxytetrahydro-6H-flu[3,2-f][1,3,5,2,4]trioxadisylosine (1-5). To a solution of compounds 1-4 (19.9 g, 47.76 mmol) in DMF (199 mL), MeI (13.6 g, 95.51 mmol) was added at 0°C, followed by NaH (2.9 g, 71.63 mmol) at 0°C. The mixture was stirred at 0°C for 0.5 hours, quenched with aqueous NH4Cl solution (400 mL), and extracted with ELISA (400 mL x 2). The organic layer was washed with brine (400 mL), dried over Na2SO4, filtered, and concentrated under vacuum. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 20 / 1 to 3 / 1) to obtain compounds 1-5 (35.0 g, yield 85.1%) as yellow oil. 1H NMR:400MHz,DMSO-d6,δ5.78-5.68(m,1H),5.10-5.00(m,2H),4.35-4.32(m, 1H), 3.97-3.80 (m, 5H), 3.50 (s, 3H), 2.31-2.17 (m, 2H), 1.15-0.91 (m, 33H).

[0729] Synthesis of 3-((6aR,8R,9S,9aR)-2,2,4,4-tetraisopropyl-9-methoxytetrahydro-6H-flu[3,2-f][1,3,5,2,4]trioxadisylosin-8-yl)propan-1-ol (1-6). To a solution of compounds 1-5 in THF (163.5 mL), 9-BBN (0.5 M, 151.8 mL, 75.92 mmol) was added and the mixture was stirred at 15°C for 2 hours. Then, NaBO3·4(H2O) (35.0 g, 227.76 mmol) and H2O (57.0 g, 3.17 mol) were added and the mixture was stirred at 15°C for 2 hours. The reaction mixture was washed with brine (400 mL) and extracted with ethyl acetate (400 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated under vacuum. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 10 / 1 to 0 / 1) to obtain compounds 1-6 (35 g, yield 96.0%) as yellow oil. 1 H NMR:400MHz,DMSO-d6,δ4.37(t,J=5.0Hz,1H),4.34-4.31(m,1H),3.82-3.80(m,3H),3. 68-3.66(m,2H),3.50(s,3H),3.40-3.33(m,2H),1.55-1.43(m,5H),1.17-0.90(m,30H).

[0730] Synthesis of 3-(6aR,8R,9S,9aR)-2,2,4,4-tetraisopropyl-9-methoxytetrahydro-6H-flu[3,2-f][1,3,5,2,4]trioxadisylosin-8-yl)propylmethanesulfonate (I-7). To a solution of compounds 1-6 in DCM (350 mL), TEA (15.8 g, 155.99 mmol) was added. The mixture was then cooled to 0°C, treated with MsCl (10.8 g, 93.84 mmol) at 0°C, and stirred at 15°C for 1 hour. The reaction mixture was poured into an aqueous solution of NaHCO3 (400 mL), extracted with DCM (400 mL), and washed with brine (400 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated under vacuum. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 5 / 1 to 0 / 1) to obtain compounds 1-7 (32.5 g, yield 79.1%) as colorless oil. 1 H NMR:400MHz DMSO-d6, δ4.32-4.31(m,1H),4.21-4.17(m,2H),3.83-3.72(m,5H),3.71(s,3H),3.15(s,3H),1.68-1.52(m,4H),1.17-0.85(m,29H).

[0731] Synthesis of (6aR,8R,9S,9aR)-8-(3-azidopropyl)-2,2,4,4-tetraisopropyl-9-methoxytetrahydro-6H-flu[3,2-f][1,3,5,2,4]trioxadisylosine (1-8). To a solution of compound 1-7 (32.5 g, 61.69 mmol) in DMF (325 mL), NaN3 (8.0 g, 123.38 mmol) was added at 15°C, and the mixture was then stirred at 50°C for 1 hour. The reaction mixture was then adjusted to pH ≥ 9, diluted with ELISA (500 mL), and washed with aqueous NaHCO3 solution (500 mL x 2) and brine (500 mL). The organic phase was dried over anhydrous Na2SO4, filtered, and concentrated under vacuum to obtain compound 1-8 (28.4 g, crude) as a yellow oil, which was used in the next step without further purification.

[0732] Synthesis of (2R,3R,4R,5R)-5-(3-azidopropyl)-2-(hydroxymethyl)-4-methoxytetrahydrofuran-3-ol (I-9). To a solution of compound 1-8 (28.4 g, 59.95 mmol) in MeOH (284 mL), NH4F (22.2 g, 599.47 mmol) was added at 15°C and the mixture was stirred at 60°C for 2 hours. The mixture was then concentrated under vacuum and filtered. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 5 / 1 to 0 / 1) to obtain compound 1-9 (9.5 g, yield 68.3%) as a colorless oil. 1 H NMR:400MHz,DMSO-d6,δ4.85(d,J=6.8Hz,1H),4.58(t,J=5.8Hz,1H),4.03-4.00(m,1H), 3.85-3.52(m,1H),3.60-3.52(m,3H),3.49(s,3H),3.42-3.31(m,4H),1.61-1.17(m,4H).

[0733] Synthesis of (2R,3R,4R,5R)-5-(3-azidopropyl)-2-((bis(4-methoxyphenyl)(phenyl)-methoxy)methyl)-4-methoxytetrahydrofuran-3-ol (1-10). To a solution of compound 1-9 (9.5 g, 40.95 mmol) in Py (95 mL), DMTrCl (15.3 g, 45.05 mmol) was added at 15°C and the mixture was stirred for 1 hour. The reaction mixture was dissolved in ELISA (100 mL), washed with aqueous citric acid solution (100 mL x 2) and brine (100 mL), dried over anhydrous Na2SO4, filtered, and concentrated under vacuum. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 10 / 1 to 3 / 1, 0.1% TEA) to obtain compound 1-10 (21.5 g, yield 98.4%) as yellow oil. 1H NMR:400MHz,DMSO-d6,δ7.42(d,J=7.6Hz,2H),7.32-7.19(m,7H),8.05(s,1H),6.87(d,J=8.4Hz,4H),4.92(d,J=7.2Hz,1H),4.08 -4.06(m,1H),3.93(s,1H),3.80(s,1H),3.73(s,6H),3.55-3.53(m,1H),3.45-3.34(m,5H),3.06-2.94(m,2H),1.73-1.17(m,4H).

[0734] Synthesis of (2R,3R,4R,5R)-5-(3-aminopropyl)-2-((bis(4-methoxyphenyl)(phenyl)-methoxy)methyl)-4-methoxytetrahydrofuran-3-ol (1-11). To a solution of compound 1-10 (10.8 g, 20.15 mmol) in THF (108 mL), Pd / C (4.3 g, 10% on carbon) was added and the mixture was stirred for 1 hour under H2 (15 psi). The mixture was filtered and concentrated under vacuum to obtain compound 1-11 (19.5 g, crude) as a white solid, which was used directly in the next step.

[0735] Synthesis of (2R,3R,4R,5R,6R)-5-acetamido-2-(acetoxymethyl)-6-((5-((3-((2R,3R,4R,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-hydroxy-3-methoxytetrahydrofuran-2-yl)propyl)amino)-5-oxopentyl)oxy)tetrahydro-2H-pyran-3,4-diyldiacetate (1-12). To a solution of compounds 1-11 (10.8 g, 21.18 mmol) and compound 10 (9.5 g, 21.18 mmol) in DMF (108 mL), HCTU (13.1 g, 31.77 mmol) and NMM (6.4 g, 63.53 mmol) were added at 15°C. The mixture was stirred at 15°C for 1 hour. Next, the reaction mixture was quenched with an aqueous NaHCO3 solution and extracted with dimethyl. The organic layer was dried over sodium sulfate, filtered, and concentrated under vacuum. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 10 / 1 to 0 / 1, 0.1% TEA) to obtain compounds 1-12 (23.5 g, yield 59.2%) as yellow oil. 1 H NMR:400MHz,DMSO-d6,δ7.81-7.77(m,2H),7.40(d,J=7.6Hz,2H),7.31-7.20(m,8H),6.86(d,J=8.8Hz,2H),5.21(s 1H),4.98-4.95(m,1H),4.87(d,J=7.2Hz,1H),4.48(d,J=8.4Hz,1H),3.88-3.72(m,12H),3.51-3.3 2(m,5H),3.07-3.04(m,5H),2.09(s,6H),1.98(s,5H),1.88(s,3H),1.77(s,3H),1.54-1.17(m,9H).

[0736] Synthesis of (2R,3R,4R,5R,6R)-5-acetamido-2-(acetoxymethyl)-6-((5-((3-((2R,3S,4R,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-(((2-cyanoethoxy)(diisopropylamino)phosphanyl)oxy)-3-methoxytetrahydrofuran-2-yl)propyl)amino)-5-oxopentyl)oxy)tetrahydro-2H-pyran-3,4-diyldiacetate (GalNAc 1a). To a solution of compounds 1-12 (11.1 g, 11.85 mmol) in DCM (110 mL), DCI (1.5 g, 13.03 mmol), NMI (1.5 g, 17.77 mmol), and compound a (7.1 g, 23.69 mmol) were added at 15°C. The mixture was stirred at 15°C for 1 hour, then quenched with NaHCO3 (100 mL), and extracted with DCM (100 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated under vacuum. The mixture was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 3 / 1 to 0 / 1, 0.1% TEA) to obtain GalNAc 1a (9.8 g, yield 66.7%) as a white solid. 1 H NMR:400MHz,CD3CN,δ7.45(s,2H),7.35-7.31(m,7H),6.87-6.84(m,5H),6.5 0-6.45(m,2H),5.27(d,J=3.2Hz,1H),5.01-4.97(m,1H),4.51-4.49(m,1H), 4.38-4.08(m,1H),4.07-3.93(m,7H),3.78-3.76(m,10H),3.65(s,1H),3.52 -3.20(m,11H),2.64-1.54(m,30H),1.13-1.10(m,9H),0.94(d,J=6.8Hz,3H).

[0737] Example 2.1' Synthesis of -Debase-Beta-C-alkyl-GalNAc. [ka] Synthesis of (3aR,6R,6aR)-6-(hydroxymethyl)-2,2-dimethyltetrahydroflo[3,4-d][1,3]dioxol-4-ol(2-2). To a stirred solution of D-ribofuranside(2-1)(50g, 333.04 mmol, 1 equivalent) in acetone(500mL), H2SO4(1.5mL, 28.14 mmol, 0.08 equivalents) was added dropwise at room temperature under an Ar atmosphere. The reaction mixture was stirred at room temperature for 12 hours. The resulting mixture was neutralized to pH 7 with saturated NaHCO3 aqueous solution and concentrated to remove most of the acetone (approximately 400mL). 300mL of water was added to the mixture, and the aqueous layer was extracted with EA(2×200mL). The combined organic layers were washed with brine(2×100mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluted with 3% MeOH in DCM to obtain (3aR,6R,6aR)-6-(hydroxymethyl)-2,2-dimethyltetrahydrofl[3,4-d][1,3]dioxol-4-ol (51 g, yield 80.5%) as a yellow oil. 1 ¹H NMR (300MHz, chloroform-d): δ 5.43 (s, 1H), 4.84 (d, J=6.0Hz, 1H), 4.59 (d, J=6.0Hz, 1H), 4.45-4.39 (m, 1H), 3.74 (t, J=3.0Hz, 2H), 1.50 (s, 3H), 1.34 (s, 3H).

[0738] Synthesis of [(3aR,4R,6aR)-6-(acetyloxy)-2,2-dimethyl-tetrahydrofluoro[3,4-d][1,3]dioxol-4-yl]methylacetate (2-3). To a stirred solution of (3aR,6R,6aR)-6-(hydroxymethyl)-2,2-dimethyl-tetrahydrofluoro[3,4-d][1,3]dioxol-4-ol (50 g, 262.88 mmol, 1 equivalent) in pyridine (200 mL), Ac2O (107.35 g, 1051.55 mmol, 4 equivalents) was added dropwise at room temperature under an Ar atmosphere. The reaction mixture was stirred for 4 hours. The resulting mixture was extracted with ethyl acetate (2 × 200 mL). The combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluted with 30% PE in EA to obtain [(3aR,4R,6aR)-6-(acetyloxy)-2,2-dimethyltetrahydrofluoro[3,4-d][1,3]dioxol-4-yl]methylacetate (55 g, yield 76.2%) as a yellow oil. 1 H NMR(400MHz,DMSO-d6)δ6.00(s,1H),4.87-4.74(m,2H),4.40-4.33(m,1H),4.15-4.01(m,2H),2.05(s,3H),2.02(s,3H),1.42(s,3H),1.29(s,3H).

[0739] Synthesis of [(3aR,4R,6S,6aS)-2,2-dimethyl-6-(propa-2-en-1-yl)-tetrahydrofluoro[3,4-d][1,3]dioxol-4-yl]methylacetate (2-4). To a stirred solution of [(3aR,4R,6aR)-6-(acetyloxy)-2,2-dimethyl-tetrahydrofluoro[3,4-d][1,3]dioxol-4-yl]methylacetate (50 g, 182.31 mmol, 1 equivalent) and ZnBr2 (102.64 g, 455.75 mmol, 2.5 equivalents) in nitromethane (1 L), trimethyl(propa-2-en-1-yl)silane (93.74 g, 820.36 mmol, 4.5 equivalents) was added dropwise at room temperature under an Ar atmosphere. The resulting mixture was stirred at room temperature under an Ar atmosphere for 1 hour. The resulting mixture was diluted with 200 mL of saturated NaHCO3 aqueous solution, and the precipitated solid was filtered. The residue was removed and washed with DCM (3 × 50 mL). 300 mL of water was added to the filtrate, and the aqueous layer was re-extracted with DCM (3 × 300 mL). The combined organic layers were collected, washed with brine (150 mL), dried over anhydrous Na2SO4, and concentrated under vacuum to obtain the crude product. The crude product was then purified by silica gel column chromatography eluting with 40% EA in PE to obtain [(3aR,4R,6S,6aS)-2,2-dimethyl-6-(propa-2-en-1-yl)-tetrahydrofluoro[3,4-d][1,3]dioxol-4-yl]methylacetate (36 g, yield 77.1%) as a yellow oil. 1 ¹H NMR (300MHz, chloroform-d) δ 5.93-5.74 (m,1H), 5.25-5.08 (m,2H), 4.53-4.46 (m,1H), 4.44-4.37 (m,1H), 4.34-4.24 (m,1H), 4.18-4.07 (m,2H), 4.05-3.98 (m,1H), 2.45-2.36 (m,2H), 2.11 (s,3H), 1.55 (s,3H), 1.36 (s,3H).

[0740] Synthesis of [(3aR,4R,6S,6aS)-2,2-dimethyl-6-(propa-2-en-1-yl)-tetrahydrofluoro[3,4-d][1,3]dioxol-4-yl]methanol (2-5). To a stirred solution of [(3aR,4R,6S,6aS)]-2,2-dimethyl-6-(propa-2-en-1-yl)-tetrahydrofluoro[3,4-d][1,3]dioxol-4-yl]methylacetate (36 g, 140.46 mmol, 1 equivalent) in MeOH (450 mL), 30% sodium methylate (5 mol / L, 33.7 mL, 1.2 equivalents) in MeOH solution was added dropwise at 0°C under an Ar atmosphere. The resulting mixture was warmed to room temperature and stirred for 1 hour. The mixture was neutralized with NH4Cl. The precipitated solid was removed by filtration and washed with MeOH (3 × 50 mL). The resulting mixture was concentrated under reduced pressure. The mixture was reduced and separated with ethyl acetate (250 mL) / water (200 mL). The aqueous layer was re-extracted with ethyl acetate (2 × 10 mL). The combined organic layer was collected, washed with brine (100 mL), dried over anhydrous Na₂SO₄, and concentrated under vacuum to obtain a yellow syrup. The residue was then purified by silica gel column chromatography eluted with 50% ethyl acetate in PE to obtain [(3aR,4R,6S,6aS)-2,2-dimethyl-6-(propa-2-en-1-yl)-tetrahydrofluoro[3,4-d][1,3]dioxol-4-yl]methanol (21 g, yield 69.7%) as a yellow oil. 1 ¹H NMR (400MHz, chloroform-d) δ 5.89-5.77 (m,1H), 5.24-5.06 (m,2H), 4.64-4.54 (m,1H), 4.41-4.33 (m,1H), 4.06-3.93 (m,2H), 3.86-3.79 (m,1H), 3.70-3.64 (m,1H), 2.45-2.36 (m,2H), 1.54 (s,3H), 1.34 (s,3H).

[0741] Synthesis of (2R,3S,4R,5S)-2-(hydroxymethyl)-5-(propa-2-en-1-yl)oxolan-3,4-diol (2-6). In a stirred solution of [(3aR,4R,6S,6aS)-2,2-dimethyl-6-(propa-2-en-1-yl)-tetrahydrofluor[3,4-d][1,3]dioxol-4-yl]methanol (21 g, 98.01 mmol, 1 equivalent) in EtOH (120 mL), HCl (9.8 mL, 0.1 equivalent) of M was added under an Ar atmosphere at 0°C. The resulting mixture was stirred under an Ar atmosphere at room temperature for 12 hours. The mixture was neutralized with an aqueous Na2CO3 solution. The precipitated solid was removed by filtration and washed with MeOH (3 × 30 mL). The resulting mixture was concentrated under reduced pressure to obtain a yellow residue, which was further purified by silica gel column chromatography eluted with 10% MeOH in DCM to obtain (2R,3S,4R,5S)-2-(hydroxymethyl)-5-(propa-2-en-1-yl)oxolan-3,4-diol (13 g, yield 76.1%) as a yellow oil. 1 H NMR(400MHz,DMSO-d6)δ5.89-5.76(m,1H),5.14-4.95(m,2H),4.69(d,J=1.6Hz,1H),4.67(d,J=2.2Hz,1H),4.62-4.56(m,1H),3.7 5-3.69(m,1H),3.65-3.57(m,2H),3.54-3.50(m,1H),3.46-3.38(m,1H),3.39-3.35(m,1H),2.33-2.25(m,1H),2.23-2.09(m,1H).

[0742] Synthesis of (4aR,6S,7S,7aS)-2,2-di-tert-butyl-6-(propa-2-en-1-yl)-tetrahydro-4H-flu[3,2-d][1,3,2]dioxacillin-7-ol (2-7). To a stirred solution of (2R,3S,4R,5S)-2-(hydroxymethyl)-5-(propa-2-en-1-yl)oxolan-3,4-diol (13 g, 74.62 mmol, 1 equivalent) in pyridine (150 mL), di-tert-butyl[(trifluoromethane)sulfonyloxy]silyltrifluoromethanesulfonate (36.16 g, 82.09 mmol, 1.1 equivalent) was added dropwise at 0°C under an Ar atmosphere. The resulting mixture was stirred at 0°C under an Ar atmosphere for 15 minutes. The reaction mixture was concentrated and then separated with DCM (100 mL) and cold water (100 mL). The organic layer was collected, washed with saturated NaHCO3 (2 × 50 mL) and brine (50 mL), dried over anhydrous Na2SO4, filtered, and concentrated under vacuum to obtain a yellow syrup. The crude product was further purified by silica gel column chromatography eluting with 15% PE in EA to obtain (4aR,6S,7S,7aS)-2,2-di-tert-butyl-6-(propa-2-en-1-yl)-tetrahydro-4H-fluoro[3,2-d][1,3,2]dioxacillin-7-ol (15 g, yield 63.9%) as a yellow oil. 1 H NMR(400MHz,DMSO-d6)δ5.81-5.72(m,1H),5.14-5.02(m,2H),4.99(d,J=3.6Hz,1H),4.31-4 .24(m,1H),3.91-3.85(m,1H),3.84-3.72(m,3H),3.71-3.64(m,1H),2.27-2.21(m,2H),1.03 -0.96(m,18H).

[0743] Synthesis of (4aR,6S,7S,7aR)-2,2-di-tert-butyl-7-methoxy-6-(propa-2-en-1-yl)-tetrahydro-4H-fluoro[3,2-d][1,3,2]dioxacillin (2-8). To a solution of (4aR,6S,7S,7aS)-2,2-di-tert-butyl-6-(propa-2-en-1-yl)-tetrahydro-4H-fluoro[3,2-d][1,3,2]dioxacillin-7-ol (15 g, 47.69 mmol, 1 equivalent) in THF (200 mL), sodium hydride (60% in oil, 2.86 g, 71.54 mmol, 1.5 equivalents) was added at 0°C. The mixture was stirred for 30 minutes. MeI (10.15 g, 71.54 mmol, 1.5 equivalents) was added, and the mixture was then warmed to room temperature and stirred for a further 2 hours. The reaction mixture was quenched at 0°C by adding 150 mL of saturated NH4Cl aqueous solution. The aqueous layer was re-extracted with EA (3 × 100 mL). The combined organic layers were collected, washed with brine (100 mL), dried over anhydrous Na2SO4, and concentrated under vacuum to obtain a yellow syrup. The residue was then purified by silica gel column chromatography eluted with 8% EA in PE to obtain (4aR,6S,7S,7aR)-2,2-di-tert-butyl-7-methoxy-6-(propa-2-en-1-yl)-tetrahydro-4H-fluoro[3,2-d][1,3,2]dioxacillin (10 g, yield 63.8%) as a yellow oil. 1 ¹H NMR (300 MHz, chloroform-d) δ 5.85-5.71 (m, 1H), 5.20-5.06 (m, 2H), 4.44-4.34 (m, 1H), 4.02-3.75 (m, 4H), 3.59-3.49 (m, 4H), 2.46-2.18 (m, 2H), 1.06-0.99 (m, 18H).

[0744] Synthesis of 3-[(4aR,6S,7S,7aR)-2,2-di-tert-butyl-7-methoxytetrahydro-4H-fluoro[3,2-d][1,3,2]dioxacillin-6-yl]propan-1-ol (2-9). To a stirred solution of (4aR,6S,7S,7aR)-2,2-di-tert-butyl-7-methoxy-6-(propa-2-en-1-yl)-tetrahydro-4H-fluoro[3,2-d][1,3,2]dioxacillin (10 g, 30.43 mmol, 1 equivalent) in THF (150 mL), 1 M BH3 (91 mL, 91.31 mmol, 3 equivalents) in THF was added dropwise at 0°C under an Ar atmosphere. The resulting mixture was stirred at 0°C under an Ar atmosphere for 3 hours. The reaction mixture was quenched at 0°C with 300 mL of 3 M NaOH aqueous solution, followed by the addition of 300 mL of 30% H2O2 solution. The reaction mixture was warmed to room temperature and stirred for a further 1.5 hours. The resulting mixture was extracted with DCM (2 × 300 mL). The combined organic layer was collected, washed with brine (200 mL), dried over anhydrous Na2SO4, and concentrated under vacuum to obtain a yellow syrup. The residue was then purified by silica gel column chromatography eluted with 35% EA in PE to obtain 3-[(4aR,6S,7S,7aR)-2,2-di-tert-butyl-7-methoxytetrahydro-4H-fluoro[3,2-d][1,3,2]dioxacillin-6-yl]propan-1-ol (8 g, yield 75.8%) as a yellow oil. 1 ¹H NMR (400MHz, chloroform-d) δ 4.40-4.35 (m,1H), 3.96-3.78 (m,4H), 3.70-3.63 (m,2H), 3.57-3.50 (m,4H), 1.79-1.54 (m,4H), 1.06-1.01 (m,18H).

[0745] Synthesis of (4aR,6S,7S,7aR)-6-(3-azidopropyl)-2,2-di-tert-butyl-7-methoxytetrahydro-4H-fluoro[3,2-d][1,3,2]dioxacillin (2-10). DPPA (8.26 g, 30.01 mmol, 1.3 equivalents) was added dropwise at 0°C under an Ar atmosphere to a stirred solution of 3-[(4aR,6S,7S,7aR)-2,2-di-tert-butyl-7-methoxytetrahydro-4H-fluoro[3,2-d][1,3,2]dioxacillin-6-yl]propan-1-ol (8 g, 23.08 mmol, 1 equivalent) and DBU (5.27 g, 34.62 mmol, 1.5 equivalents) in toluene (100 mL). The resulting mixture was heated to 110°C and stirred for 6 hours. 150 mL of water was added, and the aqueous layer was extracted with EA (3 × 100 mL). The combined organic layers were collected, washed with brine (120 mL), dried over anhydrous Na₂SO₄, and concentrated under vacuum to obtain a yellow syrup. The residue was then purified by silica gel column chromatography eluted with 20% EA in PE to obtain (4aR,6S,7S,7aR)-6-(3-azidopropyl)-2,2-di-tert-butyl-7-methoxytetrahydro-4H-fluoro[3,2-d][1,3,2]dioxacillin (6.2 g, yield 72.2%) as a yellow oil. 1 ¹H NMR (400MHz, chloroform-d) δ 4.39-4.34 (m,1H), 3.95-3.74 (m,4H), 3.55 (s,3H), 3.52-3.49 (m,1H), 3.35-3.29 (m,2H), 1.73-1.57 (m,4H), 1.08-1.01 (m,18H).

[0746] Synthesis of 3-[(4aR,6S,7S,7aR)-2,2-di-tert-butyl-7-methoxytetrahydro-4H-fluoro[3,2-d][1,3,2]dioxacillin-6-yl]propan-1-amine (2-11). To a stirred solution of (4aR,6S,7S,7aR)-6-(3-azidopropyl)-2,2-di-tert-butyl-7-methoxytetrahydro-4H-fluoro[3,2-d][1,3,2]dioxacillin (4 g, 10.76 mmol, 1 equivalent) in THF (50 mL) and water (5 mL), trimethylphosphan (2.46 g, 32.29 mmol, 3 equivalents) was added dropwise at 0°C under an Ar atmosphere. The resulting mixture was stirred at room temperature under an Ar atmosphere for 3 hours. The resulting mixture was concentrated under reduced pressure to obtain a crude product, which was further purified by silica gel column chromatography eluting with 10% MeOH in DCM to obtain 3-[(4aR,6S,7S,7aR)-2,2-di-tert-butyl-7-methoxytetrahydro-4H-fluoro[3,2-d][1,3,2]dioxacillin-6-yl]propan-1-amine (3.25 g, yield 90.0%) as a yellow oil. 1 ¹H NMR (400MHz, chloroform-d) δ 4.39-4.35 (m,1H), 3.96-3.76 (m,4H), 3.57-3.48 (m,4H), 2.75-2.69 (m,2H), 1.64-1.47 (m,4H), 1.07-1.01 (m,18H).

[0747] Synthesis of [(2R,3R,4R,5R,6R)-6-[4-({3-[(4aR,6S,7S,7aR)-2,2-di-tert-butyl-7-methoxytetrahydro-4H-fluoro[3,2-d][1,3,2]dioxacillin-6-yl]propyl}carbamoyl)butoxy]-3,4-bis(acetyloxy)-5-acetamidooxan-2-yl]methylacetate (2-12). DCM (30 mL) contains 3-[(4aR,6S,7S,7aR)-2,2-di-tert-butyl-7-methoxytetrahydro-4H-fluoro[3,2-d][1,3,2]dioxacillin-6-yl]propan-1-amine (900 mg, 2.60 mmol, 1 equivalent), 5-{[(2R,3R,4R,5R,6R)-4,5-bis(acetyloxy)-6-[(acetyloxy)methyl ]-3-acetamidooxan-2-yl]oxypentanoic acid (1.17 g, 2.60 mmol, 1 equivalent), HOBT (422.32 mg, 3.12 mmol, 1.2 equivalents), and EDC-HCl (848.79 mg, 4.42 mmol, 1.7 equivalents) were stirred together. 2,4,6-trimethylpyridine (946.84 mg, 7.81 mmol, 3 equivalents) was added dropwise at 0°C under an Ar atmosphere. The resulting mixture was warmed to room temperature and stirred for 16 hours. 30 mL of water was added, and the aqueous layer was re-extracted with DCM (3 × 30 mL). The combined organic layer was collected, washed with brine (30 mL), dried over anhydrous Na₂SO₄, and concentrated under vacuum to obtain the crude product. Next, the crude product was purified by silica gel column chromatography eluting with 5% MeOH in DCM to obtain [(2R,3R,4R,5R,6R)-6-[4-({3-[(4aR,6S,7S,7aR)-2,2-di-tert-butyl-7-methoxytetrahydro-4H-fluoro[3,2-d][1,3,2]dioxacillin-6-yl]propyl}carbamoyl)butoxy]-3,4-bis(acetyloxy)-5-acetamidooxan-2-yl]methylacetate (1.05 g, yield 52.1%) as a white solid. MS ESI (m / z) = 775.50 [M+H] + . 1H NMR(400MHz,クロロホルム-d)δ6.03-5.99(m,2H),5.38 -5.34(m,1H),5.21-5.15(m,1H),4.60(d,J=8.4Hz,1H),4.40-4.33(m,1H),4.21-4.06(m,3H),3.97-3.75(m,6H),3.58-3.48(m,5H),3.33-3.21(m,2H),2.27 -2.11(m,5H),2.05(s,3H),2.01(s,3H),1.96(s,3H),1.85-1.76(m,1H),1.68-1.53(m,7H),1.09-0.99(m,18H)。

[0748] Synthesis of [(2R,3R,4R,5R,6R)-3,4-bis(acetyloxy)-5-acetamido-6-[4-({3-[(2S,3R,4R,5R)-4-hydroxy-5-(hydroxymethyl)-3-methoxyoxolan-2-yl]propyl}carbamoyl)butoxy]oxan-2-yl]methylacetate (2-13). To a stirred solution of [(2R,3R,4R,5R,6R)-6-[4-({3-[(4aR,6S,7S,7aR)-2,2-di-tert-butyl-7-methoxytetrahydro-4H-fluoro[3,2-d][1,3,2]dioxacillin-6-yl]propyl}carbamoyl)butoxy]-3,4-bis(acetyloxy)-5-acetamidooxan-2-yl]methylacetate (1 g, 1.29 mmol, 1 equivalent) in DCM (15 mL), a solution of 65% HF-pyridine (0.23 mL, 2.58 mmol, 2 equivalents) in pyridine (15 mL) was slowly added at 0°C under an Ar atmosphere. The resulting mixture was stirred for 1 hour. The resulting mixture was concentrated under reduced pressure to obtain the crude product, which was further purified by silica gel column chromatography eluting with 15% MeOH in DCM to obtain [(2R,3R,4R,5R,6R)-3,4-bis(acetyloxy)-5-acetamido-6-[4-({3-[(2S,3R,4R,5R)-4-hydroxy-5-(hydroxymethyl)-3-methoxyoxolan-2-yl]propyl}carbamoyl)butoxin]oxan-2-yl]methylacetate (618 mg, yield 75.4%) as a white solid. MS ESI (m / z) = 635.20 [M+H] + . 1 H NMR(300MHz,chloroform-d)δ6.59-6.28(m,2H),5.36(d,J=3.3Hz,1H),5.22-5.14(m ,1H),4.61(d,J=8.1Hz,1H),4.24-4.05(m,4H),3.98-3.78(m,5H),3.73-3.63(m ,1H),3.57-3.51(m,1H),3.47-3.38(m,5H),3.33-3.19(m,1H),2.34-2.12(m,9H ),2.05(s,3H),2.01(s,3H),1.98(s,3H),1.83-1.76(m,1H),1.71-1.54(m,7H).

[0749] Synthesis of (2R,3R,4R,5R,6R)-3,4-bis(acetyloxy)-6-[4-({3-[(2S,3R,4R,5R)-5-{[bis(4-methoxyphenyl)(phenyl)methoxy]methyl}-4-hydroxy-3-methoxyoxolan-2-yl]propyl}-carbamoyl)butoxy]-5-acetamidooxan-2-yl]methylacetate (2-14). A mixture of [(2R,3R,4R,5R,6R)-3,4-bis(acetyloxy)-5-acetamido-6-[4-({3-[(2S,3R,4R,5R)-4-hydroxy-5-(hydroxymethyl)-3-methoxyoxolan-2-yl]propyl}carbamoyl)butoxy]oxan-2-yl]methyl acetate (600 mg, 0.94 mmol, 1.00 equivalent) and DMAP (11.55 mg, 0.09 mmol, 0.1 equivalent) was co-evaporated with dried pyridine (3 × 5 mL) and then redissolved in pyridine (10 mL) under an Ar atmosphere. To the mixture, Et3N (143.49 mg, 1.41 mmol, 1.5 equivalents) was added dropwise, followed by the addition of 1-[chloro(4-methoxyphenyl)benzyl]-4-methoxybenzene (480.47 mg, 1.41 mmol, 1.5 equivalents) in 5 mL of pyridine (10 mL). The reaction mixture was stirred overnight at room temperature. The resulting mixture was liquid-liquid-diluted with EA (30 mL) / water (30 mL). The aqueous layer was re-extracted with EA (2 × 20 mL). The combined organic layers were collected, washed with brine (10 mL), dried over anhydrous Na2SO4, and concentrated under vacuum to obtain the crude product. The residue was purified by reverse-phase flash chromatography under the following conditions: column, C18 silica gel, mobile phase, ACN in water, gradient from 5% to 95% over 35 minutes, detector, UV 254 nm. A fresh solution of the pure product recovered from the mobile phase was concentrated under reduced pressure to obtain [(2R,3R,4R,5R,6R)-3,4-bis(acetyloxy)-6-[4-({3-[(2S,3R,4R,5R)-5-{[bis(4-methoxyphenyl)(phenyl)methoxy]methyl}-4-hydroxy-3-methoxyoxolan-2-yl]propyl}carbamoyl)butoxy]-5-acetamidooxan-2-yl]methyl acetate (580 mg, yield 65.4%) as a white solid. MS ESI (m / z) = 935.40 [MH] -。 1 H NMR(300MHz,アセトニトリル-d3)δ7.55-7.44(m,2H),7.39-7.22(m,7H),6.95-6.87(m,4H),6.49(d,J=9.1Hz,2H),5.32-5.29(m,1H),5.06-4.98(m,1H),4.52(d,J=8.4Hz,1H),4.17-4.10(m,1H),4.08-3.92(m,4H),3.84-3.77(m,8H),3.53-3.38(m,5H),3.24-3.16(m,3H),3.10-2.96(m,2H),2.19(s,2H),2.12(s,3H),2.01(s,3H),1.94(s,3H),1.85(s,3H),1.72-1.47(m,8H)。

[0750] Synthesis of [(2R,3R,4R,5R,6R)-3,4-bis(acetyloxy)-6-[4-({3-[(2S,3S,4R,5R)-5-{[bis(4-methoxyphenyl)(phenyl)methoxy]methyl}-4-{[(2-cyanoethoxy)(diisopropylamino)-phosphanyl]oxy}-3-methoxyoxolan-2-yl]propyl}carbamoyl)butoxy]-5-acetamidooxan-2-yl]methyl acetate (GalNAc 1b). A portion (550 mg, 0.58 mmol, 1.00 equivalent) of [(2R,3R,4R,5R,6R)-3,4-bis(acetyloxy)-6-[4-({3-[(2S,3R,4R,5R)-5-{[bis(4-methoxyphenyl)(phenyl)methoxy]methyl}-4-hydroxy-3-methoxyoxolan-2-yl]propyl}carbamoyl)butoxy]-5-acetamidooxan-2-yl]methyl acetate was co-evaporated with dry MeCN (3 × 10 mL), then redissolved in DCM (10 mL), marked as Solution A, and protected with Ar before use. 3-([bis[(propan-2-yl)amino]phosphanyl]oxy)propanenitrile (265.37 mg, 0.88 mmol, 1.5 equivalents) was co-evaporated with dry MeCN (3 × 10 mL), then redissolved in DCM (10 mL), and marked as solution B. 1H-imidazole-4,5-dicarbonitrile (55.45 mg, 0.47 mmol, 0.8 equivalents) was added to solution B, followed by the addition of solution A at ambient temperature. The resulting mixture was filled with argon and stirred at room temperature for 1 hour. After the reaction was complete, the mixture was diluted with DCM (60 mL) and washed with saturated NaHCO3 (50 mL × 2) and brine (50 mL), respectively. The combined organic layers were dried over anhydrous Na2SO4 and concentrated. The filtrate was concentrated under vacuum. The residue was purified by reverse-phase flash chromatography under the following conditions: column, C18 silica gel, mobile phase, ACN in water, gradient from 5% to 95% over 40 minutes, detector: UV254nm.The product-containing fractions were combined and rotated under vacuum to obtain [(2R,3R,4R,5R,6R]-3,4-bis(acetyloxy)-6-[4-({3-[(2S,3S,4R,5R)-5-{[bis(4-methoxyphenyl)(phenyl)methoxy]methyl}-4-{[(2-cyanoethoxy)-(diisopropylamino)phosphanyl]oxy}-3-methoxyoxolan-2-yl]propyl}carbamoyl)-butoxyl]-5-acetamidooxan-2-yl]methyl acetate (406 mg, yield 60.8%) as a white solid. MS ESI (m / z) = 1137.70 [M+H]. + . 1 ¹H NMR (400MHz, acetonitrile-d3) δ 7.54-7.45 (m, 2H), 7.43-7.31 (m, 6H), 7.29-7.20 (m, 1H), 6.92-6.86 (m, 4H), 6.52-6.45 (m, 2H), 5.31-5.28 (m, 1H), 5.04-4.99 (m, 1H), 4.53 (d, J=8.4Hz, 1H), 4.29-4.21 (m, 1H), 4.18-3.93 (m, 6H), 3.88- 3.74(m,9H),3.66-3.44(m,5H),3.42-3.36(m,3H),3.27-3.15(m,3H),3.05-2.97(m,1H),2.69-2.63(m,1H),2.15 -2.07(m,5H),2.01(s,3H),1.94(s,3H),1.85(s,3H),1.73-1.49(m,8H),1.21-1.11(m,8H),1.02(d,J=6.8Hz,4H).

[0751] Preparation of conjugate C-1. The sense and antisense chains of C-1 were generated by solid-phase synthesis and then annealed to obtain a C-1 double chain. S1-1 and 2'-modified nucleoside phosphoramidites such as 2'-F or 2'-OMe were used for oligonucleotide synthesis. Synthesis was carried out on a solid support in the 3' to 5' direction using standard oligonucleotide synthesis procedures. Generally, the coupling time was 300 seconds using 5-ethylthio-1H-tetrazole (ETT) as an activator. The resulting phosphite triesters were oxidized with iodine in the presence of pyridine and water. The phosphorothioate bond was generated using a solution of 3-[(dimethylaminomethylene)amino]-3H-1,2,4-dithiazol-5-thione (DDTT). The synthesized oligonucleotides were then deprotected, cleaved from the solid support, and purified by SAX-HPLC. The pure fractions were combined, concentrated, desalted, and freeze-dried to obtain the sense and antisense chains of C-1. The sense and antisense chains were redissolved in water, and their concentrations were determined by OD. Based on their concentrations, the two single strands were annealed to obtain double-stranded C-1 with >95% purity. Conjugates C-2, C-3, and C-4 were prepared using the same procedure as above to produce C-1.

[0752] Example 3. mRNA knockdown activity of a double-stranded siRNA conjugated with target gene 2 by GalNAc G1b. The gene silencing activity was tested using the siRNA double strands listed in Table 1. These siRNA double strands were conjugated with either GalNAc GC3 (Glen Research, catalog no. 10-1974) or GalNAc G1b for hepatic delivery to target gene 2. As shown in Figure 1, GalNAc G1b provided better delivery efficiency and knockdown activity than GalNAc GC3.

[0753] CD-1 female mice were subcutaneously administered 0.5 mg / kg of siRNA double-stranded conjugated with GalNAc. The control group was administered phosphate-buffered saline (PBS). Four days after treatment, the animals were then hydrodynamically injected (HDI) into the tail vein with 20 μg of target gene 2 in pcDNA3.1(+). The mice were sacrificed one day after treatment. Liver tissue was collected and stored overnight in RNAlater® at 4°C, then transferred to -80°C after RNAlater removal for mRNA analysis. The decrease in target mRNA was measured by qPCR using a CFX384 TOUCH® Real-Time PCR Detection System (BioRad Laboratories, Inc., Hercules, CA). All samples were normalized to PBS-treated control animals and plotted using GraphPad Prism software (GraphPad Software Inc., La Jolla, CA). [Table 5] The lowercase letters "f" and "m" indicate 2'-deoxy-2'-fluoro(2'-F) and 2'-O-methyl(2'-OMe) sugar modifications to adenosine, cytidine, guanosine, and uridine, respectively. The letter "s" indicates a phosphorothioate (PS) bond, EP indicates an ethylphosphonate modification at the 5' end, and GC3 and G1b indicate GalNAc structures as shown below: [ka]

[0754] Example 4. mRNA knockdown activity of a double-stranded siRNA conjugated to target gene 1 by GalNAc G1b. The gene silencing activity was tested using the siRNA double strands listed in Table 2. These siRNA double strands were conjugated with either GalNAc L96 or GalNAc G1b for hepatic delivery to target gene 1. As shown in Figure 2, GalNAc G1b provides better delivery efficiency and KD activity than GalNAc L96.

[0755] CD-1 female mice were subcutaneously administered 0.5 mg / kg of siRNA double-stranded conjugated with GalNAc. The control group was administered phosphate-buffered saline (PBS). Four days after treatment, the animals were then hydrodynamically injected (HDI) into the tail vein with 10 μg of target gene 1 in pcDNA3.1(+). The mice were sacrificed one day after treatment. Liver tissue was collected and stored overnight in RNAlater® at 4°C, then transferred to -80°C after RNAlater removal for mRNA analysis. The decrease in target mRNA was measured by qPCR using a CFX384 TOUCH® Real-Time PCR Detection System (BioRad Laboratories, Inc., Hercules, CA). All samples were normalized to PBS-treated control animals and plotted using GraphPad Prism software (GraphPad Software Inc., La Jolla, CA). [Table 6] The lowercase letters "f" and "m" indicate 2'-deoxy-2'-fluoro(2'-F) and 2'-O-methyl(2'-OMe) sugar modifications to adenosine, cytidine, guanosine, and uridine, respectively. The letter "s" indicates a phosphorothioate (PS) bond, EP indicates an ethylphosphonate modification at the 5' terminus, and L96 and G1b indicate GalNAc structures as shown below: [ka]

[0756] Equal portions Details of one or more embodiments of this disclosure are described in the accompanying specification above. Any methods and materials similar or equivalent to those described herein may be used in the practice or testing of this disclosure, but preferred methods and materials are described herein. Other features, purposes, and advantages of this disclosure will become apparent from this specification and the claims. In this specification and the accompanying claims, the singular form includes multiple subjects unless the context makes it obvious otherwise. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this disclosure belongs. All patents and publications referenced herein are incorporated by reference.

[0757] The foregoing description is provided for illustrative purposes only and is not intended to limit this disclosure to the exact form disclosed, but rather to be limited by the claims appended to this specification.

Claims

1. A compound of formula (I) or (II), 【Chemistry 1】 or a pharmaceutically acceptable salt thereof, in the formula, W is replaced by H, and C is optionally replaced by one or more halogens. １ ~C ６ Alkyl or amino substituent, X is H, halogen, or - OR Ｘ And, R Ｘ is H, C １ ~C ６ alkyl, or -(C １ ~C ６ alkyl)-(C ６ ~C １０ aryl), and the C １ ~C ６ alkyl or -(C １ ~C ６ alkyl)-(C ６ ~C １０ aryl) is optionally substituted with one or more R Ｘａ s, Each R Ｘａ However, independently, halogen, C １ ~C ６ Alkyl, or -O-(C １ ~C ６ Alkyl) and the above C １ ~C ６ Alkyl or -O-(C １ ~C ６ The alkyl group is optionally substituted with one or more halogens. Y is replaced by H, or C is optionally replaced by one or more halogens. １ ~C ６ Alkyl, -P(R) Ｙ ) ２ , -P(OR Ｙ ) (N(R Ｙ ) ２ ), -P(=O)(OR Ｙ ) R Ｙ , -P(=S)(OR Ｙ ) R Ｙ , -P(=O)(SR Ｙ ) R Ｙ , -P(=S)(SR Ｙ ) R Ｙ , -P(=O)(OR Ｙ ) ２ , -P(=S)(OR Ｙ ) ２ , -P(=O)(SR Ｙ ) ２ , -P(=S)(SR Ｙ ) ２ , or a hydroxy protecting group, Each R Ｙ However, independently, C is optionally substituted with H, or one or more halogens or cyanoacrylates. １ ~C ６ It is alkyl, Z is optionally replaced with H or one or more halogens. １ ~C ６ Alkyl, -P(R) Ｚ ) ２ , -P(OR Ｚ ) (N(R Ｚ ) ２ ), -P(=O)(OR Ｚ ) R Ｚ , -P(=S)(OR Ｚ ) R Ｚ , -P(=O)(SR Ｚ ) R Ｚ , -P(=S)(SR Ｚ ) R Ｚ , -P(=O)(OR Ｚ ) ２ , -P(=S)(OR Ｚ ) ２ , -P(=O)(SR Ｚ ) ２ , -P(=S)(SR Ｚ ) ２ , or a hydroxy protecting group, Each R Ｚ However, independently, C is optionally substituted with H, or one or more halogens or cyanoacrylates. １ ~C ６ Is it alkyl? Alternatively, Y and Z in formula (I) together become -Si(R Ｌ ) ２ -O-Si(R Ｌ ) ２ - forms, each R Ｌ However, independently, H or C １ ~C ６ It is alkyl, Each R ａ However, independently, C is substituted with H, halogen, or one or more halogens of any choice. １ ~C ６ Alkyl or two R on two adjacent carbon atoms ａ However, together with the two adjacent carbon atoms, they form a double bond. Each R ｂ is independently H, halogen, or C optionally substituted with one or more halogens １ to C ６ alkyl, R １ However, C is optionally replaced with H, halogen, or one or more halogens. １ ~C ６ It is alkyl, R ２ is H, halogen, or C optionally substituted with one or more halogens １ ~C ６ alkyl, R ３ However, C is optionally replaced with H, halogen, or one or more halogens. １ ~C ６ It is alkyl, R ４ However, C is optionally replaced with H, halogen, or one or more halogens. １ ~C ６ It is alkyl, Each R ５ However, independently, C is substituted with H, halogen, or one or more halogens of any choice. １ ~C ６ It is alkyl, A compound in which n is an integer in the range of approximately 0 to approximately 10.

2. A scaffold or a pharmaceutically acceptable salt thereof, wherein the scaffold is (i) ligand, and (ii) A linker unit, wherein the linker unit is 【Chemistry 2】 It includes linker units, In the formula, R １ , R ２ , R ３ , R ４ , R ５ X, Y, Z, R ａ , R ｂ A scaffold or a pharmaceutically acceptable salt thereof, wherein n is as defined in claim 1, and # indicates binding to the ligand.

3. A scaffold or a pharmaceutically acceptable salt thereof, wherein the scaffold is (i) one or more nucleic acid agents, and (ii) One or more linker units, where each linker unit is independent, 【Transformation 3】 It includes one or more linker units, In the formula, the variable element R １ , R ２ , R ３ , R ４ , R ５ , W, X, Y, Z, R ａ , R ｂ A scaffold or a pharmaceutically acceptable salt thereof, wherein n is as defined in claim 1, and ## indicates binding to the nucleic acid agent.

4. A conjugate or a pharmaceutically acceptable salt thereof, wherein the conjugate is (i) One or more nucleic acid agents, (ii) one or more ligands, and (iii) One or more linker units, where each linker unit is independent, 【Chemistry 4】 It includes one or more linker units, In the formula, the variable element R １ , R ２ , R ３ , R ４ , R ５ X, Y, Z, R ａ , R ｂ A conjugate or a pharmaceutically acceptable salt thereof, wherein n is as described in claim 1, where # indicates binding to the ligand and ## indicates binding to the nucleic acid agent.

5. A compound, scaffold, or conjugate according to any one of the prior claims, wherein W is H.

6. W is replaced by C with one or more halogens of any choice. １ ~C ６ A compound, scaffold, or conjugate according to any one of the prior claims, wherein the compound is alkyl.

7. A compound, scaffold, or conjugate according to any one of the prior claims, wherein W is an amino substituent.

8. A compound, scaffold, or conjugate according to any one of the prior claims, wherein W is fluorenylmethyloxycarbonyl (Fmoc), tert-butyloxycarbonyl (BOC), benzyloxycarbonyl (Cbz), optionally substituted acyl, trifluoroacetyl (TFA), benzyl, triphenylmethyl (Tr), 4,4'-dimethoxytrityl (DMTr), or toluenesulfonyl (Ts).

9. A compound, scaffold, or conjugate according to any one of the prior claims, wherein X is H.

10. A compound, scaffold, or conjugate according to any one of the prior claims, wherein X is a halogen.

11. X is - OR Ｘ The compound, scaffold, or conjugate described in any one of the prior claims.

12. A compound, scaffold, or conjugate according to any one of the prior claims, wherein Y is H.

13. Y is replaced by one or more halogens of choice in C １ ~C ６ A compound, scaffold, or conjugate according to any one of the prior claims, wherein the compound is alkyl.

14. Y is -P(R Ｙ ) ２ , -P(OR Ｙ ) (N(R Ｙ ) ２ ), -P(=O)(OR Ｙ ) R Ｙ , -P(=S)(OR Ｙ ) R Ｙ , -P(=O)(SR Ｙ ) R Ｙ , -P(=S)(SR Ｙ ) R Ｙ , -P(=O)(OR Ｙ ) ２ , -P(=S)(OR Ｙ ) ２ , -P(=O)(SR Ｙ ) ２ , -P(=S)(SR Ｙ ) ２ The compound, scaffold, or conjugate described in any one of the prior claims.

15. A compound, scaffold, or conjugate according to any one of the prior claims, wherein Y is a hydroxy protecting group.

16. A compound, scaffold, or conjugate according to any one of the prior claims, wherein Z is H.

17. Z is replaced by C with one or more halogens of any choice. １ ~C ６ A compound, scaffold, or conjugate according to any one of the prior claims, wherein the compound is alkyl.

18. Z is -P(R Ｚ ) ２ , -P(OR Ｚ ) (N(R Ｚ ) ２ ), -P(=O)(OR Ｚ ) R Ｚ , -P(=S)(OR Ｚ ) R Ｚ , -P(=O)(SR Ｚ ) R Ｚ , -P(=S)(SR Ｚ ) R Ｚ , -P(=O)(OR Ｚ ) ２ , -P(=S)(OR Ｚ ) ２ , -P(=O)(SR Ｚ ) ２ , -P(=S)(SR Ｚ ) ２ The compound, scaffold, or conjugate described in any one of the prior claims.

19. A compound, scaffold, or conjugate according to any one of the prior claims, wherein Z is a hydroxy protecting group.

20. In equation (I), Y and Z together become -Si(R Ｌ ) ２ -O-Si(R Ｌ ) ２ A compound, scaffold, or conjugate according to any one of the prior claims, which forms a compound, scaffold, or conjugate.

21. The compound is of formula (I'-1), (I'-2), (II'-1), or (II'-2): 【Transformation 5】 things, The compound according to any one of the prior claims, or a pharmaceutically acceptable salt thereof.

22. The compound is of formula (I-A), (II-A), (I-A'-1), (I-A'-2), (II-A'-1), or (II-A'-2): 【Transformation 6】 things, The compound according to any one of the prior claims, or a pharmaceutically acceptable salt thereof.

23. The aforementioned compound is of formula (I-B), (II-B), (I-B'-1), (I-B'-2), (II-B'-1), or (II-B'-2): 【Transformation 7】 things, The compound according to any one of the prior claims, or a pharmaceutically acceptable salt thereof.

24. The compound according to any one of the prior claims, wherein the compound is selected from the compounds listed in Table L and their pharmaceutically acceptable salts.

25. The aforementioned scaffolding (in linker units) ｐ - ((Nucleic acid agent) - (Linker unit) ｓ ) ｒ - (Nucleic acid agent) ｑ And, Each linker unit is independent of other linker units, and each nucleic acid agent is independent of other nucleic acid agents. Each r is an independent integer in the range of 0 to 10. Each s is an independent integer in the range of 0 to 10. p is an integer in the range of 0 to 10. q is 0 or 1, The scaffold according to any one of the prior claims, wherein the scaffold comprises at least one linker unit and at least one nucleic acid agent.

26. The aforementioned scaffolding, 【Transformation 8】 or a pharmaceutically acceptable salt thereof, in the formula, Y is -P(R Ｙ ) ２ , -P(OR Ｙ ) (N(R Ｙ ) ２ ), -P(=O)(OR Ｙ ) R Ｙ , -P(=S)(OR Ｙ ) R Ｙ , -P(=O)(SR Ｙ ) R Ｙ , -P(=S)(SR Ｙ ) R Ｙ , -P(=O)(OR Ｙ ) ２ , -P(=S)(OR Ｙ ) ２ , -P(=O)(SR Ｙ ) ２ , -P(=S)(SR Ｙ ) ２ , or a hydroxy protecting group, Each R Ｙ However, independently, C is optionally substituted with H, or one or more halogens or cyanoacrylates. １ ~C ６ It is alkyl, Z is -P(R Ｚ ) ２ , -P(OR Ｚ ) (N(R Ｚ ) ２ ), -P(=O)(OR Ｚ ) R Ｚ , -P(=S)(OR Ｚ ) R Ｚ , -P(=O)(SR Ｚ ) R Ｚ , -P(=S)(SR Ｚ ) R Ｚ , -P(=O)(OR Ｚ ) ２ , -P(=S)(OR Ｚ ) ２ , -P(=O)(SR Ｚ ) ２ , -P(=S)(SR Ｚ ) ２ , or a hydroxy protecting group, Each R Ｚ However, independently, C is optionally substituted with H, or one or more halogens or cyanoacrylates. １ ~C ６ It is alkyl, A scaffold according to any one of the prior claims, wherein n is an integer in the range of approximately 0 to approximately 10.

27. The scaffolding described above is selected from the scaffolding in Table S1, as described in any one of the prior claims.

28. The aforementioned scaffolding, 【Chemistry 9】 or a pharmaceutically acceptable salt thereof, in the formula, W is an amino substituent, A scaffold according to any one of the prior claims, wherein n is an integer in the range of approximately 0 to approximately 10.

29. The scaffolding described above is selected from the scaffolding in Table S2, as described in any one of the prior claims.

30. The aforementioned conjugate is (linker unit - (ligand) ０－１ ) ｐ - ((Nucleic acid agent) - (Linker unit - (Ligand) ０－１ ) ｓ ) ｒ - (Nucleic acid agent) ｑ And in the formula, Each linker unit is independent of other linker units, each nucleic acid agent is independent of other nucleic acid agents, and each ligand is independent of other ligands. Each r is an independent integer in the range of 0 to 10. Each s is an independent integer in the range of 0 to 10. p is an integer in the range of 0 to 10. q is 0 or 1, The conjugate according to any one of the prior claims, wherein the conjugate comprises at least one linker unit, at least one nucleic acid agent, and at least one ligand.

31. The conjugate according to any one of the prior claims, wherein the conjugate is selected from the conjugates in Table C.

32. The ligand is 【Chemistry 10】 A scaffold or conjugate according to any one of the prior claims, including the scaffold or conjugate described in any one of the prior claims.

33. The ligand is 【Chemistry 11】 A scaffold or conjugate according to any one of the prior claims, including the scaffold or conjugate described in any one of the prior claims.

34. The scaffold or conjugate according to any one of the prior claims, wherein the ligand comprises a lipid, a peptide, or an antibody.

35. The scaffold or conjugate according to any one of the prior claims, wherein the nucleic acid agent comprises an oligonucleotide.

36. A pharmaceutical composition comprising a compound, scaffold, or conjugate as described in any one of the prior claims.

37. A method for performing the regulation of the expression of a target gene in a subject requiring the delivery of a nucleic acid agent, or in a subject requiring the treatment or prevention of a disease, comprising administering a therapeutically effective amount of the conjugate described in any one of the prior claims to the subject.

38. A conjugate according to any one of the prior claims, for use in subjects requiring regulation of target gene expression, for use in subjects requiring delivery of nucleic acid agents, or for use in subjects requiring treatment or prevention of disease.

39. Use of the conjugate described in any one of the prior claims in the manufacture of a pharmaceutical product for which regulation of target gene expression is required, for which delivery of nucleic acid agents is required, or for which treatment or prevention of disease is required.

Images